,永雄,Stella,Datetime,Media,Title with link,Title,Desc,Link
0,,,2021/11/3 19:41,MedCity,CMS extends telehealth coverage for behavioral health in 2022 physician fee schedule,CMS extends telehealth coverage for behavioral health in 2022 physician fee schedule,"The Centers for Medicare and Medicaid Services dropped its physician fee schedule for next year. It would bolster coverage of telehealth visits for behavioral health and vaccine payments, but would also reduce the conversion factor used to calculate fee-for-service payments. ",https://medcitynews.com/2021/11/cms-extends-telehealth-coverage-for-behavioral-health-in-2022-physician-fee-schedule/
1,,,2021/11/3 18:34,MedCity,"ALS drugmaker steps up with FDA filing, but yet another biotech stumbles in clinic","ALS drugmaker steps up with FDA filing, but yet another biotech stumbles in clinic","Amylyx Pharmaceuticals has submitted its amyotrophic lateral sclerosis (ALS) drug for FDA review based on positive Phase 2 data after discussions with the agency over the summer. Meanwhile, a Clene Nanomedicine ALS drug failed its Phase 2 study, but the biotech points to encouraging results in a subgroup of patients.",https://medcitynews.com/2021/11/als-drugmaker-steps-up-with-fda-filing-but-yet-another-biotech-stumbles-in-clinic/
2,,,2021/11/3 16:41,MedCity,Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients,Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients,"Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics in response to emailed questions from MedCity News.",https://medcitynews.com/2021/11/pilar-biosciences-seeks-to-make-precision-medicine-a-first-line-therapy-for-cancer-patients/
3,,,2021/11/3 16:11,MedCity,Kaia adds in-person physical therapy through partnership,Kaia adds in-person physical therapy through partnership,"The digital health company recently struck a partnership with Luna On-Demand Physical Therapy to offer in-person physical therapy services, in addition to its virtual programs for musculoskeletal care. Users in markets where Luna is available can schedule an in-home visit with the same physical therapists over time. ",https://medcitynews.com/2021/11/kaia-adds-in-person-physical-therapy-through-partnership/
4,,,2021/11/3 14:17,MedCity,Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer,Shoreline Biosciences secures $140M for off-the-shelf NK cell therapies for cancer,"Gilead Sciences and BeiGene, which started research alliances with Shoreline Biosciences earlier this year, are among the investors in the biotech’s latest financing. The preclinical-stage company technology develops cell therapies for cancer by using natural killer cells.",https://medcitynews.com/2021/11/shoreline-biosciences-secures-140m-for-off-the-shelf-nk-cell-therapies-for-cancer/
5,,,2021/11/2 09:15,Biotech,Why public health lab workers are fleeing the field,Why public health lab workers are fleeing the field,"Across California, public health departments are losing experienced staffers to retirement, exhaustion, partisan politics and higher-paying jobs.",https://www.fiercebiotech.com/medtech/labs-no-one-to-run-them-why-public-health-workers-are-fleeing-field
6,,,2021/11/2 08:30,Biotech,Pfizer sells midphase inflammatory drugs to mystery startup,Pfizer sells midphase inflammatory drugs to mystery startup,"Having studied its lead TYK2 inhibitor in a raft of diseases, Pfizer is offloading the portfolio to a new company in return for a 25% stake.",https://www.fiercebiotech.com/biotech/pfizer-sells-midphase-inflammatory-drugs-to-mystery-startup-exiting-race-against-bristol
7,,,2021/11/2 08:00,Biotech,"BMS tops AbbVie-backed Nitrase's $45M series A, snags Nurix exec","BMS tops AbbVie-backed Nitrase's $45M series A, snags Nurix exec","Not a U.K. gaming company: Nitrome rebrands to Nitrase to mirror its new enzymes, adds BMS as investor and snags new CEO to ink pharma collaborations.",https://www.fiercebiotech.com/biotech/abbvie-backed-nitrome-adds-bms-as-investor-snags-nurix-cbo-as-ceo-and-rebrands-to-nitrase
8,,,2021/11/2 07:30,MedCity,Remote service: The new paradigm for biopharma manufacturing,Remote service: The new paradigm for biopharma manufacturing,Microsoft seeks to change the way pharma industry companies use technology to navigate human resource challenges and restore confidence in drug development supply chains.,https://medcitynews.com/2021/11/remote-service-the-new-paradigm-for-biopharma-manufacturing/
9,,,2021/11/2 05:00,Biotech,Novartis inks protein degrader deal with new British startup,Novartis inks protein degrader deal with new British startup,"By putting up $24 million and committing to $1.3 billion in biobucks, Novartis has secured the chance to option candidates against up to four targets.",https://www.fiercebiotech.com/biotech/novartis-makes-protein-degrader-play-inking-deal-new-british-startup-to-access-fruits-novel
10,,,2021/11/2 04:34,Biotech,"FDA delays Legend, Janssen-partnered CAR-T cilta-cel","FDA delays Legend, Janssen-partnered CAR-T cilta-cel",Legend Biotech and Johnson & Johnson have been hit by an FDA delay for their cell therapy blood cancer hopeful ciltacabtagene autoleucel.,https://www.fiercebiotech.com/biotech/legend-s-status-put-hold-as-fda-delays-janssen-partnered-car-t-decision
11,,,2021/11/2 03:00,Biotech,The top 10 highest-paid medtech CEOs,The top 10 highest-paid medtech CEOs,"The COVID-19 pandemic presented a once-in-a-generation challenge for the medtech industry, and many of the CEOs on this list met it head-on.",https://www.fiercebiotech.com/special-report/top-10-highest-paid-medtech-ceos
12,,,2021/11/2 14:00,MedCity,Rx for clinical trials moving forward: 4 key success factors,Rx for clinical trials moving forward: 4 key success factors,Covid-19 protocols may make re-opening or starting clinical trials seem like a daunting responsibility. Consider these four factors for a successful return to research.,https://medcitynews.com/2021/11/rx-for-clinical-trials-moving-forward-4-key-success-factors/
13,,,2021/11/2 11:00,Biotech,"Aldeyra dry eye drug helps with redness, misses secondary goals","Aldeyra dry eye drug helps with redness, misses secondary goals",Aldeyra Therapeutics’ dry eye drug helped relieve ocular redness but merely “approached statistical significance” on a secondary endpoint of wetness.,https://www.fiercebiotech.com/biotech/aldeyra-s-dry-eye-drug-helps-redness-but-misses-other-phase-2-goals-important-measures
14,,,2021/11/2 10:20,Biotech,Cambridge Epigenetix lines up $88M for genetic sequencing tech,Cambridge Epigenetix lines up $88M for genetic sequencing tech,"With the additional funds, the University of Cambridge spinout will accelerate the commercialization of its sequencing platform.",https://www.fiercebiotech.com/medtech/gv-backed-cambridge-epigenetix-lines-up-88m-to-roll-out-genetic-sequencing-technology
15,,,2021/11/1 09:40,Biotech,How differences in T cells govern I-O resistance in NSCLC,How differences in T cells govern I-O resistance in NSCLC,"T cells that become dysfunctional because of changes in gene expression were reactivated with cytokines in mouse models of NSCLC, an MIT team said.",https://www.fiercebiotech.com/research/mit-team-uncovers-differences-t-cells-drive-immuno-oncology-resistance-lung-cancer
16,,,2021/11/1 09:30,Biotech,Lengo's hiring spree shows continues with Pfizer vet hire,Lengo's hiring spree shows continues with Pfizer vet hire,"Lengo Therapeutics has named a slate of new hires in recent months and is back at it again, nabbing Turning Point’s Brion Murray, Ph.D.",https://www.fiercebiotech.com/biotech/lengo-s-hiring-spree-shows-no-signs-slowing-as-it-hires-pfizer-veteran-murray-as-vp
17,,,2021/11/1 09:05,Biotech,Ex-Moderna CMO Zaks takes venture partner post at OrbiMed,Ex-Moderna CMO Zaks takes venture partner post at OrbiMed,"Weeks after leaving Moderna, Zaks has taken up a venture partner post at OrbiMed—where he is joined by another storied biopharma executive.",https://www.fiercebiotech.com/biotech/zaks-fresh-from-making-millions-at-moderna-takes-venture-partner-post-at-orbimed
18,,,2021/11/1 08:45,Biotech,"Gilead bought his last biotech. Now, Helin has a new startup","Gilead bought his last biotech. Now, Helin has a new startup",The founder of a biotech bought by Gilead has birthed another startup.,https://www.fiercebiotech.com/biotech/gilead-bought-his-last-biotech-now-helin-back-another-cancer-startup
19,,,2021/11/1 08:00,Biotech,Intranasals in Clinic Now Positioned for $71 Billion Market,Intranasals in Clinic Now Positioned for $71 Billion Market,Australia’s Avance Clinical: how intranasal biotechs can expedite trials with rapid approval processes - including no IND and a 43.5% incentive rebate,https://www.fiercebiotech.com/sponsored/intranasals-clinic-now-positioned-for-71-billion-nasal-delivery-market
20,,,2021/11/1 08:00,Biotech,Merck inks $525M biobucks pact for Synthekine's cytokine target,Merck inks $525M biobucks pact for Synthekine's cytokine target,Preclinical biotech Synthekine inks its first pharma collaborator in $525 million biobucks pact with Merck for cytokine target in autoimmune disease.,https://www.fiercebiotech.com/biotech/as-covid-takes-center-stage-at-merck-pharma-signs-525m-biobucks-pact-synthekine-for
21,,,2021/11/1 08:00,Biotech,A New Reference Model for Clinical Trial Recruitment,A New Reference Model for Clinical Trial Recruitment,Rare diseases demand a modern approach grounded in uncovering medically-eligible patients with the highest propensity for enrollment and retention.,https://www.fiercebiotech.com/sponsored/a-new-reference-model-for-clinical-trial-recruitment-enrollment-and-retention-success
22,,,2021/11/1 19:59,MedCity,Teladoc plans to fend off competitors by building a full suite of products,Teladoc plans to fend off competitors by building a full suite of products,"As more companies spin up their own telehealth products, Teladoc CEO Jason Gorevic said the company continues to acquire and retain customers by having a full suite of solutions. He expects that point solutions will have a harder time going forward. ",https://medcitynews.com/2021/11/teladoc-plans-to-fend-off-competitors-by-building-a-full-suite-of-products/
23,,,2021/11/1 07:15,Biotech,BD inks BARDA contract to develop tests for COVID’s long future,BD inks BARDA contract to develop tests for COVID’s long future,The goal is to provide COVID tests that simultaneously screen for the flu and other infectious diseases from a single sample.,https://www.fiercebiotech.com/medtech/bd-inks-barda-contract-to-develop-covid-tests-for-long-future-pandemic
24,,,2021/11/1 07:10,Biotech,Detect nets FDA green light for home-based molecular COVID test,Detect nets FDA green light for home-based molecular COVID test,The company’s molecular diagnostic received an emergency authorization allowing it to be sold at retail stores over-the-counter.,https://www.fiercebiotech.com/medtech/detect-nets-fda-green-light-to-bring-routine-molecular-covid-testing-to-home
25,,,2021/11/1 17:25,MedCity,"New CMS incentives look to close equity gap in home dialysis, kidney transplants ","New CMS incentives look to close equity gap in home dialysis, kidney transplants ",The agency issued a final rule on Friday that would update payment rates for dialysis. It includes a payment model that would incentivize healthcare providers to decrease disparities for in-home dialysis rates and transplant rates among low-income patients. ,https://medcitynews.com/2021/11/new-cms-incentives-look-to-close-equity-gap-in-home-dialysis-kidney-transplants/
26,,,2021/11/1 16:38,MedCity,A new California law aims to strengthen access to mental health services,A new California law aims to strengthen access to mental health services,"A California law signed Oct. 8 by Gov. Gavin Newsom requires that mental health and substance abuse patients be offered return appointments no more than 10 days after a previous session, unless their provider OKs less frequent visits.",https://medcitynews.com/2021/11/a-new-california-law-aims-to-strengthen-access-to-mental-health-services/
27,,,2021/11/1 15:10,Biotech,TriNetX hires Harvard professor as chief scientific officer,TriNetX hires Harvard professor as chief scientific officer,Jeffrey Brown will move down the block from his office at Harvard Medical School to be the chief scientific officer of TriNetX.,https://www.fiercebiotech.com/cro/trials-network-provider-life-sciences-data-company-trinetx-snags-harvard-prof-as-chief
28,,,2021/11/1 14:00,MedCity,Strategies for managing opioid use in elderly patients,Strategies for managing opioid use in elderly patients,Clinicians must be aware that coordination of care is one of the key factors to combat opioid epidemic and stop overuse of more powerful and dangerous medications.,https://medcitynews.com/2021/11/strategies-for-managing-opioid-use-in-elderly-patients/
29,,,2021/11/1 13:16,MedCity,MedCity News adds publisher to accelerate growth,MedCity News adds publisher to accelerate growth,"Breaking Media Inc. has announced Ken Montgomery as Publisher for MedCity News, the leading online news source for innovation in the healthcare industry. ",https://medcitynews.com/2021/11/medcity-news-adds-publisher-to-accelerate-growth/
30,,,2021/11/1 11:52,Biotech,Boehringer joins $20M series A for Alzheimer's test maker Optina,Boehringer joins $20M series A for Alzheimer's test maker Optina,Optina will continue to develop its Retinal Deep Phenotyping platform and accelerate clinical trials of its first Alzheimer’s diagnostic.,https://www.fiercebiotech.com/medtech/optina-diagnostics-nabs-boehringer-s-support-20m-vc-round-for-retina-based-alzheimer-s-test
31,,,2021/11/1 11:14,Biotech,"Mirati KRAS concerns as key adagrasib lead, COO suddenly exit","Mirati KRAS concerns as key adagrasib lead, COO suddenly exit",Mirati's new CEO has shown the biotech's chief medical and operating officers the exit as the biotech searches for a CFO to lead commercialization.,https://www.fiercebiotech.com/biotech/kras-race-against-amgen-mirati-cmo-and-coo-shown-exit-ahead-fda-drug-approval-request
32,,,2021/11/1 10:22,Biotech,Inovio falls victim to AstraZeneca's 'usual pipeline pruning',Inovio falls victim to AstraZeneca's 'usual pipeline pruning',AstraZeneca is wielding the ax to a bloated pipeline and Inovio has found itself the latest victim. ,https://www.fiercebiotech.com/biotech/inovio-falls-victim-to-astrazeneca-s-usual-pipeline-pruning-as-human-papillomavirus-cancer
33,,,2021/11/1 10:10,Biotech,Zimmer Biomet recalls Rosa One robotic neurosurgery platform,Zimmer Biomet recalls Rosa One robotic neurosurgery platform,"According to the FDA, an error in the latest version of the Rosa One software could cause instruments to be incorrectly placed during neurosurgery.",https://www.fiercebiotech.com/medtech/zimmer-biomet-issues-class-i-recall-rosa-one-robotic-neurosurgery-platform-due-to-software
34,,,2021/11/1 10:00,Biotech,"LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra","LianBio inks $325M IPO for pipeline with BMS, BridgeBio, Lyra","LianBio raised $325 million in its IPO for a pipeline stacked with partners BMS, BridgeBio, Tarsus, Lyra, Landos, Nanobiotix and ReViral.",https://www.fiercebiotech.com/biotech/lianbio-snags-325m-ipo-slightly-bigger-than-multi-partnered-biotech-s-2020-series-a
35,,,2021/11/1 10:00,MedCity,"Transforming medical device training, adoption, and sales with remote case observation","Transforming medical device training, adoption, and sales with remote case observation","Hospitals need to keep patient safety and operational efficiency at the forefront. By minimizing the number of individuals entering the OR, RCO provides immediate operational and safety improvements.",https://medcitynews.com/2021/11/transforming-medical-device-training-adoption-and-sales-with-remote-case-observation/
36,,,2021/10/31 14:00,MedCity,5 ways health plans are addressing health equity,5 ways health plans are addressing health equity,Medicare and Medicaid plans that invest in effectively addressing these five health equity issues can create a win-win situation that both improves member satisfaction and retention,https://medcitynews.com/2021/10/5-ways-health-plans-are-addressing-health-equity/
37,,,2021/10/29 09:30,Biotech,Alnylam CEO to pass baton to president by 2022—Chutes & Ladders,Alnylam CEO to pass baton to president by 2022—Chutes & Ladders,Alynlam CEO Maraganore to leave by 2022 as President Greenstreet steps into role. Medivir taps fourth CEO in two years. Aadi snags Immunomedics CMO.,https://www.fiercebiotech.com/biotech/chutes-ladders-medivir-poaches-astrazeneca-veteran-to-be-fourth-ceo-past-2-years
38,,,2021/10/29 09:29,Biotech,DNA Script tallies $165M to help launch its desktop DNA printer,DNA Script tallies $165M to help launch its desktop DNA printer,"Using four specially prepared genetic “inks”—G, A, T and C—the strings of genetic code are assembled letter by letter.",https://www.fiercebiotech.com/medtech/dna-script-tallies-up-165m-to-help-launch-its-desktop-dna-printer
39,,,2021/10/29 08:50,Biotech,Signet Therapeutics gets a $10M top-up for next-gen cancer bets,Signet Therapeutics gets a $10M top-up for next-gen cancer bets,Little U.S.-China startup Signet Therapeutics has bagged a second seed round worth around $10 million as plots a path to the clinic.,https://www.fiercebiotech.com/biotech/signet-therapeutics-gets-a-10m-top-up-for-next-gen-cancer-bets
40,,,2021/10/29 07:45,Biotech,Daiichi jettisons ADC after flunking early solid tumor test,Daiichi jettisons ADC after flunking early solid tumor test,"Daiichi's ADC team has hit a rare bump in the road, dumping a gastrointestinal stromal tumor candidate after seeing “no clear responses” in phase 1.",https://www.fiercebiotech.com/biotech/daiichi-jettisons-adc-after-flunking-early-solid-tumor-test
41,,,2021/10/29 07:30,Biotech,Gilead taps brakes on $4.9B bet after rival's failure,Gilead taps brakes on $4.9B bet after rival's failure,"Weeks after Takeda’s rival drug flunked a pivotal trial, Gilead has delayed data from a phase 1b study designed to support accelerated approval.",https://www.fiercebiotech.com/biotech/gilead-dabs-brakes-4-9b-bet-after-rival-s-failure-pushing-blood-cancer-data-out-to-22
42,,,2021/10/29 07:20,MedCity,Clinical decision support guidance tops FDA’s agenda for 2022,Clinical decision support guidance tops FDA’s agenda for 2022,At the top of the Food and Drug Administration’s agenda for the next 12 months: […],https://medcitynews.com/2021/10/clinical-decision-support-guidance-tops-fdas-agenda-for-2022/
43,,,2021/10/29 02:46,Biotech,NIH deals out $75M for health data science research in Africa,NIH deals out $75M for health data science research in Africa,The NIH will invest $74.5 million through a new program to establish data science research centers and training across Africa.,https://www.fiercebiotech.com/medtech/nih-deals-out-nearly-75m-for-new-program-focusing-data-science-research-and-critical-health
44,,,2021/10/29 14:00,Biotech,A COVID-19 vaccine in a patch rivals shots in mice,A COVID-19 vaccine in a patch rivals shots in mice,Researchers at University of Queensland collaborated with Vaxxas to develop a COVID-19 patch that warded off the virus in mice.,https://www.fiercebiotech.com/research/a-covid-19-vaccine-delivered-as-a-patch-shows-promise-against-virus-mice
45,,,2021/10/29 11:10,Biotech,Magnus Medical debuts with $25M to target severe depression,Magnus Medical debuts with $25M to target severe depression,The neurostimulation startup Magnus Medical is raising the curtain with $25 million in hand and an FDA breakthrough designation.,https://www.fiercebiotech.com/medtech/magnus-medical-debuts-25m-to-target-drug-resistant-depression-personalized-therapy
46,,,2021/10/29 10:15,Biotech,Spooky SPAC season and a $180M Entrada onto Wall Street,Spooky SPAC season and a $180M Entrada onto Wall Street,Rare diseases-focused Entrada Therapeutics becomes latest preclinical biotech to hit the Nasdaq with $181.5 million and another SPAC debuts.,https://www.fiercebiotech.com/biotech/spactacular-spooky-season-for-arbor-rapha-s-blank-check-and-entrada-entrance-onto-wall
47,,,2021/10/28 09:55,Biotech,"Pfizer, J&J sign on to streamline gene therapy development","Pfizer, J&J sign on to streamline gene therapy development","A cadre of pharmas have signed on to a new U.S. federal government initiative to go after gene therapies for rare diseases, with $76 million in funds.",https://www.fiercebiotech.com/biotech/pfizer-j-j-among-pharmas-and-biotechs-signing-to-us-agencies-new-rare-disease-gene-therapy
48,,,2021/10/28 09:30,MedCity,The IT work that Covid halted & the hurdles to jumpstarting it again,The IT work that Covid halted & the hurdles to jumpstarting it again,"Though the Covid-19 pandemic accelerated some aspects of health IT, it slowed others, including EHR replacements and back-office system upgrades. CIOs from some of the nation’s leading health systems shared not only the projects they put on hold, but also how they made those decisions and the challenges they faced when trying to reignite their efforts. ",https://medcitynews.com/2021/10/the-it-work-that-covid-halted-the-hurdles-to-jumpstarting-it-again/
49,,,2021/10/28 08:15,Biotech,Telecom tycoon's phase 3 pancreatic cancer bet flames out,Telecom tycoon's phase 3 pancreatic cancer bet flames out,The pivotal trial found devimistat had no effect on overall survival—and as a kicker another phase 3 in a blood cancer was stopped early for futility.,https://www.fiercebiotech.com/biotech/telecom-tycoon-s-phase-3-pancreatic-cancer-bet-flames-out-sending-stock-to-basement
50,,,2021/10/28 08:00,Biotech,Frazier raises $830M for first public life science fund,Frazier raises $830M for first public life science fund,Frazier is expanding its activities. The targets? Small and mid-cap biotechs that are off the beaten path or recovering from a value-crushing setback.,https://www.fiercebiotech.com/biotech/frazier-has-raised-830m-public-life-science-fund-here-s-how-it-plans-to-invest-cash
51,,,2021/10/28 07:52,MedCity,Which startups will present at INVEST Pop Health Pitch Perfect?,Which startups will present at INVEST Pop Health Pitch Perfect?,The six companies taking part in the contest November 16 will present technologies addressing chronic conditions such as kidney disease and Type 2 diabetes as well as improving patient engagement for underinsured and underserved patients. ,https://medcitynews.com/2021/10/which-startups-will-present-at-invest-pop-health-pitch-perfect/
52,,,2021/10/28 07:00,Biotech,Sanofi hit by filing delays for key drugs,Sanofi hit by filing delays for key drugs,"Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets.",https://www.fiercebiotech.com/biotech/sanofi-hit-by-filing-delays-for-key-drugs-drops-early-sangamo-thalassemia-asset
53,,,2021/10/28 14:52,MedCity,"Hinge Health raises $600M, plans all-out MSK effort","Hinge Health raises $600M, plans all-out MSK effort","The startup walks people through exercises at home, and connects them to health coaches and physical therapists. It’s now valued at $6.2 billion.",https://medcitynews.com/2021/10/hinge-raises-600m-plans-all-out-msk-effort/
54,,,2021/10/28 14:00,MedCity,The role of AI in advancing neuromodulation treatment for epilepsy,The role of AI in advancing neuromodulation treatment for epilepsy,"Vagus nerve stimulation devices still have a long way to go, but the therapeutic potential of the vagus nerve, the advent of AI and machine learning in healthcare and the opportunity to establish truly personalized digital medicine are enough to warrant further exploration into VNS.",https://medcitynews.com/2021/10/the-role-of-ai-in-advancing-neuromodulation-treatment-for-epilepsy/
55,,,2021/10/28 12:59,Biotech,Science 37 taps 2 CROs in Japan for virtual trials expansion,Science 37 taps 2 CROs in Japan for virtual trials expansion,From Los Angeles to Tokyo: Science 37 expands its work in virtual clinical trials by teaming up with two CROs in Japan to boost access to studies.,https://www.fiercebiotech.com/cro/science-37-partners-two-cros-japan-as-part-decentralized-trials-push
56,,,2021/10/28 12:23,Biotech,"FDA adds new restrictions, warning labels for breast implants","FDA adds new restrictions, warning labels for breast implants","The agency curbed the sale of breast implants from Allergan, Johnson & Johnson's Mentor division, Sientra and Ideal Implant.",https://www.fiercebiotech.com/medtech/fda-adds-new-restrictions-warning-labels-for-breast-implants-following-reports-cancer-cases
57,,,2021/10/28 10:30,Biotech,"Checkmate CEO exits one-asset biotech, board member fills post","Checkmate CEO exits one-asset biotech, board member fills post",Checkmate CEO Barry Labinger departs without explanation as board member Alan Fuhrman takes interim post while cancer biotech searches for new leader.,https://www.fiercebiotech.com/biotech/checkmate-begins-search-for-new-ceo-as-board-member-biotech-cfo-veteran-alan-fuhrman-takes
58,,,2021/10/28 10:13,Biotech,"FDA outlines best AI practices alongside Canada, UK","FDA outlines best AI practices alongside Canada, UK",The 10 principles underline what the agencies describe as “Good Machine Learning Practice” in the same vein as other industry quality standards.,https://www.fiercebiotech.com/medtech/healthcare-ai-ml-artificial-intelligence-machine-learning-fda-uk-mhra-health-canada
59,,,2021/10/27 09:52,Biotech,Potential pain remedy emerges from 'junkyard of cancer drugs',Potential pain remedy emerges from 'junkyard of cancer drugs',"An old cancer drug called kenpaullone enhances the expression of the gene KCC2, which is essential for silencing pain signals, a new study found.",https://www.fiercebiotech.com/research/duke-and-uc-scientists-find-a-potential-remedy-for-chronic-pain-from-a-junkyard-cancer
60,,,2021/10/27 09:28,Biotech,One Drop launches Bayer-boosted heart disease prevention program,One Drop launches Bayer-boosted heart disease prevention program,The digital diabetes maven One Drop is taking new steps into the broader healthcare world with the pharma giant Bayer walking alongside.,https://www.fiercebiotech.com/medtech/one-drop-launches-bayer-boosted-ai-program-for-preventing-heart-disease
61,,,2021/10/27 21:15,MedCity,"Northwell Health, Aegis team up to launch AI-focused joint venture","Northwell Health, Aegis team up to launch AI-focused joint venture","The health system and startup studio’s new joint venture will develop and launch companies that use artificial intelligence to address healthcare problems, including disparities in care. The venture will combine Northwell’s clinical expertise and patient data with Aegis’ data scientists and commercialization capabilities. ",https://medcitynews.com/2021/10/northwell-health-aegis-team-up-to-launch-ai-focused-joint-venture/
62,,,2021/10/27 09:10,Biotech,"GSK, after pushing past fail, ends work on otilimab in COVID-19","GSK, after pushing past fail, ends work on otilimab in COVID-19",GSK is stopping development of otilimab in COVID-19 in response to the failure of the drug in phase 2 and progress of its anti-SARS-CoV-2 antibody.,https://www.fiercebiotech.com/biotech/gsk-after-pushing-past-midphase-fail-ends-development-otilimab-covid-19
63,,,2021/10/27 20:43,MedCity,Hello Heart study shows potential for digital tools to help manage blood pressure ,Hello Heart study shows potential for digital tools to help manage blood pressure ,A large study published in JAMA Network Open found that people with stage II hypertension were able to reduce their systolic blood pressure and maintain it over three years using Hello Heart’s app. ,https://medcitynews.com/2021/10/hello-heart-study-shows-potential-for-digital-tools-to-help-manage-blood-pressure/
64,,,2021/10/27 08:05,Biotech,ElevateBio buys editing tech to support gene therapy pipeline,ElevateBio buys editing tech to support gene therapy pipeline,ElevateBio has enjoyed a close look at Life Edit Therapeutics over the past 11 months. The experience has persuaded ElevateBio to buy the business.,https://www.fiercebiotech.com/biotech/elevatebio-cuts-a-deal-for-life-edit-adding-genome-engineering-tech-to-support-gene-therapy
65,,,2021/10/27 07:40,Biotech,"After COVID flop, Angion's leading med fails again","After COVID flop, Angion's leading med fails again",Angion Biomedica saw its shares down more than 50% early Wednesday morning on news that its kidney transplant hopeful ANG-3777 has failed a phase 3.,https://www.fiercebiotech.com/biotech/after-covid-flop-angion-s-leading-med-fails-again-time-kidney-transplant-patients-as-shares
66,,,2021/10/27 18:01,MedCity,Report: $27B remains unspent in Covid-19 Provider Relief Fund,Report: $27B remains unspent in Covid-19 Provider Relief Fund,"Of the billions of dollars provided by the government to support providers during the pandemic, $11.7 billion has been allocated but not spent, $7.1 billion has not been allocated and $8 billion has been returned for various reasons, including that the organization recovered faster than expected.",https://medcitynews.com/2021/10/report-27b-remains-unspent-in-covid-19-provider-relief-fund/
67,,,2021/10/27 16:46,MedCity,"Bayer, One Drop release digital health program for heart disease","Bayer, One Drop release digital health program for heart disease","The app lets people track their metrics through connected devices, and access health coaching and educational materials. It’s one of multiple that Bayer and One Drop plan to develop together in the future. ",https://medcitynews.com/2021/10/bayer-one-drop-release-digital-health-program-for-heart-disease/
68,,,2021/10/27 14:00,Biotech,Boosting I-O by targeting a cellular stress pathway,Boosting I-O by targeting a cellular stress pathway,"A cellular process called the ""replication stress response"" could provide a genetic signature for selecting I-O patients, MD Anderson reported.",https://www.fiercebiotech.com/research/genetic-signature-behind-drugs-astrazeneca-bayer-eli-lilly-boost-cancer-immunotherapy
69,,,2021/10/27 12:16,Biotech,Merck HIV combo pill compares to existing meds in phase 3 trials,Merck HIV combo pill compares to existing meds in phase 3 trials,The addition of Merck's new oral pill to a cocktail of approved medicines for HIV-1 produced a viral response comparable to common treatments.,https://www.fiercebiotech.com/biotech/merck-close-to-regulatory-filings-for-hiv-treatment-combo-shows-comparable-efficacy-to
70,,,2021/10/27 12:05,Biotech,Takeda-backed cardiovascular biotech nabs $300M from Bain,Takeda-backed cardiovascular biotech nabs $300M from Bain,Takeda-backed cardiovascular disease specialist Cardurion Pharma has a new investor and $300 million in cash to play with thanks to Bain Capital.,https://www.fiercebiotech.com/biotech/takeda-backed-cardiovascular-biotech-nabs-300m-investment-from-bain
71,,,2021/10/27 12:00,Biotech,Immunai adds $215M to bank to help discovery drug targets,Immunai adds $215M to bank to help discovery drug targets,Immunai is mapping the immune system and partnering with biopharmas to find drug targets. A $215 million funding boost will expand that work.,https://www.fiercebiotech.com/cro/immunai-secures-215m-for-immune-system-map-fuel-more-acquisitions
72,,,2021/10/27 11:38,Biotech,NuVasive to launch global VR training program for spine surgery,NuVasive to launch global VR training program for spine surgery,"Working with the orthopedic VR surgery developer PrecisionOS, NuVasive aims to deliver a cadaver-less training course built around its X360 system.",https://www.fiercebiotech.com/medtech/nuvasive-to-launch-international-vr-training-program-for-spine-surgery
73,,,2021/10/27 10:33,Biotech,Takeda buys partner GammaDelta for cancer T-cell therapies,Takeda buys partner GammaDelta for cancer T-cell therapies,"Takeda's $100M R&D pact with U.K. partner GammaDelta, begun in 2017, has turned into a full-out acquisition for the biotech's cancer T-cell therapies.",https://www.fiercebiotech.com/biotech/takeda-buys-out-collaborator-gammadelta-therapeutics-for-solid-tumor-pipeline
74,,,2021/10/27 10:27,Biotech,"Novavax asks UK for COVID-19 vaccine approval, FDA by year-end","Novavax asks UK for COVID-19 vaccine approval, FDA by year-end","With an FDA filing pushed to the end of this year, Novavax has completed submission of its COVID-19 vaccine to U.K. regulators.",https://www.fiercebiotech.com/biotech/novavax-completes-uk-filing-for-covid-19-vaccine-expects-to-finish-fda-filing-by-year-s-end
75,,,2021/10/26 09:20,Biotech,"Lilly, Pfizer stop study of arthritis drug after FDA rejection","Lilly, Pfizer stop study of arthritis drug after FDA rejection","After seeing regulators on both sides of the Atlantic knock back filings, Eli Lilly and Pfizer have stopped global clinical development of tanezumab.",https://www.fiercebiotech.com/biotech/lilly-pfizer-stop-development-osteoarthritis-drug-after-fda-rejection-extending-bleak-run
76,,,2021/10/26 09:00,Biotech,"Mammoth, Vertex ink $650M biobucks deal for CRISPR gene editing","Mammoth, Vertex ink $650M biobucks deal for CRISPR gene editing","Vertex continues lining up CRISPR gene editing partners, this time linking arms with Mammoth Biosciences for $41 million upfront plus biobucks.",https://www.fiercebiotech.com/biotech/mammoth-sized-crispr-deal-mammoth-vertex-sign-650m-biobucks-collab-for-two-genetic-diseases
77,,,2021/10/26 07:18,Biotech,Novartis dumps Rett gene therapy caught up in Zolgensma scandal,Novartis dumps Rett gene therapy caught up in Zolgensma scandal,The action follows Novartis’ decision to gather extra data on the candidate in response to data manipulation during development of Zolgensma.,https://www.fiercebiotech.com/biotech/novartis-dumps-rett-gene-therapy-caught-up-zolgensma-scandal-cull-pipeline-prospects
78,,,2021/10/26 07:05,Biotech,"Cambrian snags $100M for 14 assets, 3-5 trials within 18 months","Cambrian snags $100M for 14 assets, 3-5 trials within 18 months",Is Cambrian the next Roivant or Atai biotech builder? Investors pumped $100 million into it for 14 assets—and to buy more—for age-related diseases.,https://www.fiercebiotech.com/biotech/cambrian-secures-100m-series-c-for-atai-roivant-like-approach-to-building-up-biotechs-14
79,,,2021/10/26 07:00,Biotech,Axcella jumps into long COVID with phase 2 of midstage NASH drug,Axcella jumps into long COVID with phase 2 of midstage NASH drug,"Millions of people experience fatigue, muscle weakness after recovering from COVID-19. Axcella will test its midstage NASH drug in these patients.",https://www.fiercebiotech.com/biotech/flagship-founded-axcella-to-test-midstage-nash-drug-for-long-covid-phase-2a-trial
80,,,2021/10/26 06:58,Biotech,Eli Lilly kick-starts speedy FDA review for Alzheimer's hopeful,Eli Lilly kick-starts speedy FDA review for Alzheimer's hopeful,The great Alzhimer’s R&D resurgence continues as Eli Lilly nabs an accelerated FDA review for its mixed bag drug donanemab.,https://www.fiercebiotech.com/biotech/eli-lilly-kickstarts-speedy-fda-review-for-alzheimer-s-hopeful-donanemab-plots-aduhelm-head
81,,,2021/10/26 16:54,MedCity,Bill aiming to streamline MA prior authorization gains House majority support,Bill aiming to streamline MA prior authorization gains House majority support,"The bill, if enacted into law, will establish an electronic prior authorization process and require Medicare Advantage plans to report on their use of prior authorization and the rate of approvals or denials to CMS. It has 227 co-sponsors in the U.S. House, indicating strong support from both Republicans and Democrats. ",https://medcitynews.com/2021/10/bill-aiming-to-streamline-ma-prior-authorization-gains-house-majority-support/
82,,,2021/10/26 16:44,MedCity,Decentralized clinical trials platform Medable now valued at $2.1B,Decentralized clinical trials platform Medable now valued at $2.1B,"Medable recently raised $304 million, its fourth funding round in the past two years. The company’s software can be used to virtually consent patients into clinical trials and run telehealth visits as part of a trial. ",https://medcitynews.com/2021/10/decentralized-clinical-trials-platform-medable-now-valued-at-2-1b/
83,,,2021/10/26 16:41,Biotech,Cortexyme will forge ahead with failed Alzheimer's drug,Cortexyme will forge ahead with failed Alzheimer's drug,"Cortexyme’s Alzheimer’s disease therapy failed to improve cognitive function in a phase 2/3 clinical trial, but the company will move it forward.",https://www.fiercebiotech.com/biotech/cortexyme-will-forge-ahead-failed-alzheimer-s-drug-just-like-everyone-else
84,,,2021/10/26 15:30,MedCity,Declining vaccine antibody levels require more dynamic immunity assessments ,Declining vaccine antibody levels require more dynamic immunity assessments ,"New semiquantitative tests offer a more granular understanding of our protective immunity, not only identifying Covid-19 antibodies but providing direct, individualized measures of neutralizing antibody levels. ",https://medcitynews.com/2021/10/declining-vaccine-antibody-levels-require-more-dynamic-immunity-assessments/
85,,,2021/10/26 14:49,MedCity,Point-of-Care-Ultrasound tech expands non-invasive imaging capabilities across diverse dettings,Point-of-Care-Ultrasound tech expands non-invasive imaging capabilities across diverse dettings,"Point-of-care ultrasound is increasingly being used in out-of-hospital emergency settings, or pre-hospital care settings. It can be used in doctor’s offices, remotely in rural areas, during global health and disaster situations, military, and battlefield assessments – even in outer space.",https://medcitynews.com/2021/10/point-of-care-ultrasound-tech-expands-non-invasive-imaging-capabilities-across-diverse-dettings/
86,,,2021/10/26 13:20,Biotech,FDA clears Trice Medical’s 25-degree disposable arthroscope,FDA clears Trice Medical’s 25-degree disposable arthroscope,The new generation of Trice’s Needlescope is equipped with a camera and light source to help guide surgeons through the interior of a patient's joint.,https://www.fiercebiotech.com/medtech/trice-medical-nabs-first-fda-clearance-for-disposable-needle-arthroscope-25-degree-view
87,,,2021/10/26 12:14,Biotech,Medable's virtual trials push gets $304M bet to edge out others,Medable's virtual trials push gets $304M bet to edge out others,It appears $200 million wasn't enough for virtual clinical trials. Medable tacked on $304 million as cohort of startups come out of the woodworks.,https://www.fiercebiotech.com/cro/medable-adds-304m-to-treasure-chest-fourth-raise-18-months-for-virtual-trials
88,,,2021/10/26 11:07,Biotech,Stroke trials don't match prevalence of disease in women: study,Stroke trials don't match prevalence of disease in women: study,"The prevalence of strokes in women is about 48%, but only about 37% of patients in clinical trials for the condition since 1990 have been women.",https://www.fiercebiotech.com/cro/stroke-trials-since-1990-have-a-10-gap-inclusion-women-versus-prevalence-group-study
89,,,2021/10/26 10:22,Biotech,"Lilly, Bayer, Merck catch classical buzz with $55M for Mozart Tx","Lilly, Bayer, Merck catch classical buzz with $55M for Mozart Tx","It's classical season: Bayer, Lilly and Merck join VC shops to back autoimmune, inflammatory biotech Mozart Therapeutics with $55M for the allegro.",https://www.fiercebiotech.com/biotech/eli-lilly-bayer-merck-join-symphony-no-55-as-mozart-launches-into-allegro-phase
90,,,2021/10/26 10:00,Biotech,BD primes Amazon rollout of smartphone COVID test,BD primes Amazon rollout of smartphone COVID test,"The year's biggest shopping days are right around the corner, and this Cyber Monday, BD is making it easier than ever to stock up on COVID-19 tests.",https://www.fiercebiotech.com/medtech/bd-primes-rollout-smartphone-based-rapid-covid-19-test-amazon-launch
91,,,2021/10/26 10:00,Biotech,MIT nanotube sensor detects COVID in 5 minutes,MIT nanotube sensor detects COVID in 5 minutes,The scientists were able to modify existing nanotube technology into a diagnostic in 10 days from the start of the NIH-funded project.,https://www.fiercebiotech.com/medtech/mit-researchers-develop-nanotube-based-sensor-can-detect-covid-within-five-minutes
92,,,2021/10/25 09:38,Biotech,HHS invests $560M to boost COVID-19 test supply,HHS invests $560M to boost COVID-19 test supply,"The U.S. government is making its third investment in less than two months, with the focus this time being on the supply chain.",https://www.fiercebiotech.com/medtech/biden-administration-infuses-more-than-560m-to-strengthen-covid-19-testing-supply-chain
93,,,2021/10/25 09:26,Biotech,Gilead's Immunomedics CMO exits to Aadi as it nears FDA decision,Gilead's Immunomedics CMO exits to Aadi as it nears FDA decision,"She got Trodelvy to the finish line and now Loretta Itri, M.D., hopes to get Aadi Bioscience's first drug to market.",https://www.fiercebiotech.com/biotech/gilead-s-immunomedics-cmo-jumps-to-aadi-as-biotech-looks-for-first-fda-approval-next-month
94,,,2021/10/25 09:05,Biotech,Juventas Cell Therapy closes a $63M funding round,Juventas Cell Therapy closes a $63M funding round,Juventas has grabbed a $63 million series C to advance its CASI Pharmaceuticals-partnered drug CNCT19.,https://www.fiercebiotech.com/biotech/juventas-cell-therapy-closes-a-63m-funding-round-as-it-eyes-a-big-push-for-blood-cancer
95,,,2021/10/25 20:55,MedCity,Joining forces can benefit both patients and pharma companies  ,Joining forces can benefit both patients and pharma companies  ,"By engaging in a dialogue, patients and pharma companies can have a mutually beneficial relationship, Health Union’s Jack Barrette said at HLTH’s patient engagement track, hosted by MedCity News. Not only can patients help mold clinical trials, but they can help companies improve their patient education efforts.",https://medcitynews.com/2021/10/joining-forces-can-benefit-both-patients-and-pharma-companies/
96,,,2021/10/25 08:40,Biotech,AstraZeneca veteran takes up CEO post at Medivir,AstraZeneca veteran takes up CEO post at Medivir,"Jens Lindberg will become the fourth person to hold the post, on an interim or permanent basis, in quick succession when he takes up the position.",https://www.fiercebiotech.com/biotech/astrazeneca-veteran-takes-up-ceo-post-at-medivir-become-fourth-person-to-hold-post-quick
97,,,2021/10/25 07:50,Biotech,EMA starts rolling review of Merck's COVID-19 antiviral,EMA starts rolling review of Merck's COVID-19 antiviral,"Merck has opened another front in its campaign to get molnupiravir to market, kicking off a process that could lead to EMA apprroval.",https://www.fiercebiotech.com/biotech/ema-starts-rolling-review-merck-s-molnupiravir-continuing-rapid-regulatory-response-to
98,,,2021/10/25 19:03,MedCity,"Click Therapeutics raises $52M, looks to advance digital therapeutics","Click Therapeutics raises $52M, looks to advance digital therapeutics","Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.",https://medcitynews.com/2021/10/click-therapeutics-raises-52m-looks-to-advance-digital-therapeutics/
99,,,2021/10/25 06:30,Biotech,Cedilla adds $25M to series B to test two cancer drugs in trials,Cedilla adds $25M to series B to test two cancer drugs in trials,Cedilla Therapeutics snagged an additional $25 million to bankroll studies to get two cancer drugs into human trials next year.,https://www.fiercebiotech.com/biotech/cedilla-tops-off-series-b-additional-25m-to-test-drugs-mesothelioma-certain-breast-cancers
100,,,2021/10/25 18:24,MedCity,Is Ro taking the business-to-business route next?,Is Ro taking the business-to-business route next?,"By all accounts, Ro is a successful direct-to-consumer telehealth and pharmacy services startup. At the recently-concluded HLTH conference, Ro’s chief medical officer speculated on how it might enter the business-to-business healthcare world. ",https://medcitynews.com/2021/10/is-ro-going-the-business-to-business-route-next/
101,,,2021/10/25 17:51,MedCity,Tech is connecting health systems & workers amid growing shortages,Tech is connecting health systems & workers amid growing shortages,The worsening workforce shortages have forced health systems to get creative when it comes to recruiting staff. Technology is helping health systems reach workers directly without having to go through a traditional staffing agency. ,https://medcitynews.com/2021/10/tech-is-connecting-health-systems-workers-amid-growing-shortages/
102,,,2021/10/25 14:57,MedCity,"Amazon brings Alexa devices to hospitals, assisted living","Amazon brings Alexa devices to hospitals, assisted living","The company has struck partnerships with properties owned by Cedars-Sinai, BayCare and others, and is looking to build out some healthcare-specific features, such as medication management.",https://medcitynews.com/2021/10/amazon-brings-alexa-devices-to-hospitals-assisted-living/
103,,,2021/10/25 12:02,Biotech,Guardant blood test spots 96% of early colon cancers: study,Guardant blood test spots 96% of early colon cancers: study,Guardant's Lunar-2 liquid biopsy test offers a less invasive and time-consuming alternative to the current standards for colorectal cancer screening.,https://www.fiercebiotech.com/medtech/guardant-s-liquid-biopsy-detects-96-early-stage-colorectal-cancer-cases-a-single-blood-draw
104,,,2021/10/25 11:00,Biotech,"Roche, Foundation Medicine unveil genomic profiling kit for labs","Roche, Foundation Medicine unveil genomic profiling kit for labs","In their first offering since Roche bought out the sequencing company in 2018, the kit will be made available to labs in Europe, Asia and the America.",https://www.fiercebiotech.com/medtech/roche-foundation-medicine-begin-global-launch-genomic-profiling-kit-for-cancer-research
105,,,2021/10/25 10:52,Biotech,Erytech's eryaspase flunks late-stage pancreatic cancer trial,Erytech's eryaspase flunks late-stage pancreatic cancer trial,Erytech Pharma will shift focus to acute lymphoblastic leukemia after eryaspase dropped a phase 3 pancreatic cancer trial.,https://www.fiercebiotech.com/biotech/erytech-s-eryaspase-drops-pancreatic-cancer-phase-3-trial
106,,,2021/10/25 10:37,Biotech,"Intellia, LogicBio fuel hope for in vivo gene editing: report","Intellia, LogicBio fuel hope for in vivo gene editing: report","Preclinical data from Intellia and LogicBio support the potential of in vivo gene editing to correct inherited diseases, analysts said.",https://www.fiercebiotech.com/research/intellia-logicbio-fuel-hope-for-vivo-gene-editing-new-animal-data-rare-diseases-report
107,,,2021/10/22 09:55,Biotech,Medtronic taps TikTok-famous doc as first-ever CMO of GI segment,Medtronic taps TikTok-famous doc as first-ever CMO of GI segment,"Gastroenterologist Austin Chiang, M.D., uses TikTok to educate his nearly 500,000 followers about colonoscopies and normal bowel function.",https://www.fiercebiotech.com/medtech/medtronic-taps-tiktok-famous-physician-as-first-chief-medical-officer-gi-business
108,,,2021/10/22 09:30,Biotech,Athira CEO resigns after investigation—Chutes & Ladders,Athira CEO resigns after investigation—Chutes & Ladders,Athira CEO resigns after investigation. vTv Therapeutics hired investor Deepa Prasad as CEO and president. Opus Genetics snagged two C-suite leaders.,https://www.fiercebiotech.com/biotech/chutes-ladders-vtv-therapeutics-names-deepa-prasad-ceo-and-president
109,,,2021/10/22 09:05,Biotech,Egle Therapeutics nabs $46M for pipeline push,Egle Therapeutics nabs $46M for pipeline push,"After launching last year and swiftly grabbing a Takeda deal, European biotech Egle Therapeutics has bulked up its coffers with 40 million euros.",https://www.fiercebiotech.com/biotech/egle-therapeutics-nabs-46m-as-it-looks-to-push-into-clinic-its-next-gen-tregs-platform
110,,,2021/10/22 08:35,Biotech,2 cancer drugs show promise in a hard-to-treat lung disease,2 cancer drugs show promise in a hard-to-treat lung disease,A computational analysis concluded that two investigational cancer drugs might have promise in treating the lung disease pulmonary hypertension.,https://www.fiercebiotech.com/research/investigational-cancer-drugs-might-be-tools-for-fighting-rare-lung-disease-too-researchers
111,,,2021/10/22 08:00,Biotech,Agenus withdraws cervical cancer application for balstilimab,Agenus withdraws cervical cancer application for balstilimab,Agenus is withdrawing an application for a cervical cancer drug after the FDA granted full approval to Merck’s Keytruda in the same indication.,https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes
112,,,2021/10/22 07:15,MedCity,StartUPDATES: New developments for healthcare startups,StartUPDATES: New developments for healthcare startups,"Read about news from Seven Bridges, HealthMine, Redi.Health, Xealth, and more.",https://medcitynews.com/2021/10/startupdates-new-developments-for-healthcare-startups-23/
113,,,2021/10/22 06:30,Biotech,Metacrine shares halved as NASH work thrown out,Metacrine shares halved as NASH work thrown out,Metacrine is dumping work on an experimental fatty liver disease drug program after a phase 2 mixed bag result and resetting its clinical focus.,https://www.fiercebiotech.com/biotech/metacrine-shares-halved-as-it-throws-out-its-mixed-bag-nash-program-investigates-potential
114,,,2021/10/22 14:40,Biotech,Sanofi joins $52M series B for digital therapeutics maker Click,Sanofi joins $52M series B for digital therapeutics maker Click,"With its third multimillion-dollar influx of funding in barely a year, another medtech’s plans to create digital therapeutics are clicking into place.",https://www.fiercebiotech.com/medtech/sanofi-joins-click-therapeutics-52m-series-b-to-advance-digital-therapeutics-for-depression
115,,,2021/10/22 14:07,MedCity,23andMe to buy online pharmacy Lemonaid for $400M ,23andMe to buy online pharmacy Lemonaid for $400M ,The company plans to pair its direct-to-consumer genetic testing with Lemonaid’s online coaching and prescription delivery. It plans to buy the company for $400 million in stock and cash. ,https://medcitynews.com/2021/10/23andme-to-buy-online-pharmacy-lemonaid-for-400m/
116,,,2021/10/22 14:00,MedCity,Internal culture: The hidden barrier to innovation in healthcare,Internal culture: The hidden barrier to innovation in healthcare,"With major efforts under way to make healthcare more accessible to all, organizations need to be aware of powerful force that could be creating an invisible barrier — their internal culture.",https://medcitynews.com/2021/10/internal-culture-the-hidden-barrier-to-innovation-in-healthcare/
117,,,2021/10/22 11:09,Biotech,Ocular's drug-eluting insert for dry eye disease misses endpoint,Ocular's drug-eluting insert for dry eye disease misses endpoint,"The phase 2 trial of Ocular Therapeutix’s drug-eluting insert didn’t end in tears, but in this case, that translated to the opposite of success.",https://www.fiercebiotech.com/medtech/ocular-s-insert-for-dry-eye-disease-misses-primary-endpoint-phase-2-trial
118,,,2021/10/22 10:35,Biotech,"MIT prof, biotech founder Sabatini sues accuser, institute","MIT prof, biotech founder Sabatini sues accuser, institute","MIT professor David Sabatini alleges the sexual harassment claims against him are false, says he was referred to as ""a Harvey Weinstein"" by ex-lover.",https://www.fiercebiotech.com/biotech/biotech-founder-mit-researcher-david-sabatini-alleges-false-sexual-harrassment-claims
119,,,2021/10/21 09:20,Biotech,Ventyx nabs an upsized IPO to challenge BMS' Zeposia,Ventyx nabs an upsized IPO to challenge BMS' Zeposia,"Ventyx Biosciences is in the fast lane, racing to grab an upsized $152 million IPO.",https://www.fiercebiotech.com/biotech/ventyx-nabs-upsized-ipo-to-challenge-bristol-s-zeposia-and-a-backer-intimate-knowledge-its
120,,,2021/10/21 20:51,MedCity,ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs,ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs,"ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.",https://medcitynews.com/2021/10/recode-therapeutics-gets-80m-to-deliver-on-new-rna-therapies-for-the-lungs/
121,,,2021/10/21 08:25,Biotech,VCs back Leucid to trial CAR-T twist in ovarian cancer patients,VCs back Leucid to trial CAR-T twist in ovarian cancer patients,Maher has pushed the idea that the configuration of co-stimulatory modules is key to success in CAR-T—and now he has the cash to test the approach.,https://www.fiercebiotech.com/biotech/vcs-back-leucid-to-trial-car-t-twist-ovarian-cancer-patients
122,,,2021/10/21 20:21,MedCity,Oak Street plans to add virtual specialty care with $130M acquisition of RubiconMD,Oak Street plans to add virtual specialty care with $130M acquisition of RubiconMD,"Oak Street Health plans to integrate virtual specialty care into its primary care centers for Medicare patients. It struck a deal to acquire RubiconMD for $130 million in cash, with another $60 million in milestone payments.",https://medcitynews.com/2021/10/oak-street-plans-to-add-virtual-specialty-care-with-130m-acquisition-of-rubiconmd/
123,,,2021/10/21 08:00,Biotech,"Atreca, Gates Research Institute ink pact on malaria antibody","Atreca, Gates Research Institute ink pact on malaria antibody",Oncology biotech Atreca will license its monoclonal antibody to the Bill & Melinda Gates Medical Research Institute to potentially treat malaria.,https://www.fiercebiotech.com/biotech/atreca-inks-license-gates-medical-research-institute-for-malaria-asset
124,,,2021/10/21 08:00,Biotech,"ReCode snags $80M from Pfizer, Sanofi for mRNA work in CF, lungs","ReCode snags $80M from Pfizer, Sanofi for mRNA work in CF, lungs","ReCode thinks the mRNA revolution can be applied to cystic fibrosis and other lung diseases, and it's snagged a second $80 million round to fund it.",https://www.fiercebiotech.com/biotech/another-80m-mrna-biotech-recode-matches-2020-series-a-for-trials-cystic-fibrosis-other-lung
125,,,2021/10/21 07:05,Biotech,"Menarini, chased by 3 Big Pharmas, records breast cancer win","Menarini, chased by 3 Big Pharmas, records breast cancer win","Menarini and Radius have gained a lead over AstraZeneca, Roche and Sanofi in the race to bring a new class of oral breast cancer drugs to market.",https://www.fiercebiotech.com/biotech/menarini-chased-by-three-big-pharmas-records-win-breast-cancer-phase-3-plots-path-to-fda
126,,,2021/10/21 16:29,Biotech,Athira CEO Kawas out after findings confirm she altered research,Athira CEO Kawas out after findings confirm she altered research,Athira CEO Leen Kawas gets the boot after independent investigation confirms she did alter graduate school research and will be replaced by COO.,https://www.fiercebiotech.com/biotech/athira-ceo-leen-kawas-officially-out-after-investigation-found-she-did-alter-grad-research
127,,,2021/10/21 16:02,MedCity,FDA’s proposal for over-the-counter hearing aids draws mixed response from manufacturers ,FDA’s proposal for over-the-counter hearing aids draws mixed response from manufacturers ,"The proposed rule would allow adults to buy hearing aids without an exam or fitting, with the goal of driving more competitive pricing. Some companies expressed enthusiasm about over-the-counter hearing aids, while industry incumbents were more wary.",https://medcitynews.com/2021/10/fdas-proposal-for-over-the-counter-hearing-aids-draws-mixed-response-from-manufacturers/
128,,,2021/10/21 15:51,MedCity,Improve patients’ outcomes with AI-powered remote monitoring devices and increase revenue for your practice,Improve patients’ outcomes with AI-powered remote monitoring devices and increase revenue for your practice,"A webinar from MedCity News sponsored by 100Plus scheduled for November 9 at 12pm ET will explore remote patient monitoring to achieve greater patient adherence and clinically meaningful outcomes for conditions such as hypertension, obesity, and diabetes. ",https://medcitynews.com/2021/10/improve-patients-outcomes-with-ai-powered-remote-monitoring-devices-and-increase-revenue-for-your-practice/
129,,,2021/10/21 14:00,MedCity,Engagement at home: How home healthcare organizations can improve patient and staff satisfaction,Engagement at home: How home healthcare organizations can improve patient and staff satisfaction,"By freeing up resources and automating manual processes, home care organizations can better identify areas of risk, improve clinical and operational processes, improve staff well-being, and enhance outcomes for patients across the board.",https://medcitynews.com/2021/10/engagement-at-home-how-home-healthcare-organizations-can-improve-patient-and-staff-satisfaction/
130,,,2021/10/21 12:28,Biotech,Zerigo Health beams up $43M for at-home psoriasis treatment,Zerigo Health beams up $43M for at-home psoriasis treatment,Zerigo’s system pairs a smartphone app with a hand-held device that emits narrowband UVB light.,https://www.fiercebiotech.com/medtech/zerigo-health-beams-up-43m-from-bayer-cigna-and-more-for-at-home-psoriasis-uv-light-therapy
131,,,2021/10/21 11:08,MedCity,FDA refusal of Stealth Bio drug shows challenges of ultra-rare disease studies,FDA refusal of Stealth Bio drug shows challenges of ultra-rare disease studies,"The FDA refused to review Stealth BioTherapeutics’ Barth syndrome drug, telling the company results in a study of just eight patients are insufficient to support its submission. The impasse highlights the challenges of testing drugs for ultra-rare diseases. Barth is so rare that Stealth is unsure it can recruit patients to run a new study.",https://medcitynews.com/2021/10/fda-refusal-of-stealth-bio-drug-shows-challenges-of-ultra-rare-disease-studies/
132,,,2021/10/21 10:31,Biotech,FDA approves Luminopia’s VR system to treat kids with lazy eye,FDA approves Luminopia’s VR system to treat kids with lazy eye,"In a dream come true for kids, rather than dissuading pediatric patients from watching too much TV, physicians may now prescribe them screen time.",https://www.fiercebiotech.com/medtech/fda-approves-luminopia-s-vr-based-digital-therapeutic-to-treat-children-lazy-eye
133,,,2021/10/20 09:30,Biotech,Stealth rare disease drug denied by FDA in I told you so moment,Stealth rare disease drug denied by FDA in I told you so moment,The FDA has rejected Stealth's Barth syndrome drug elamipretide just under two months after the Hail Mary application was filed.,https://www.fiercebiotech.com/biotech/stealth-s-not-so-sneaky-strategy-to-file-unprepared-drug-application-foiled-by-fda
134,,,2021/10/20 09:00,MedCity,Digital identity vital to delivering on the promise of virtual care,Digital identity vital to delivering on the promise of virtual care,"Using the innovations of digital identity, payers, providers and retail health clinics can meet the demands of today’s tech-savvy consumers by allowing them to be the single source of truth of their identity while acquiring full control of their personal data.",https://medcitynews.com/2021/10/digital-identity-vital-to-delivering-on-the-promise-of-virtual-care/
135,,,2021/10/20 08:55,Biotech,"Chase gets cash for pivotal trials in depression, Parkinson's ","Chase gets cash for pivotal trials in depression, Parkinson's ","Armed with $20 million, the biotech plans to start phase 3 clinical trials of candidates based on an old Boehringer Ingelheim drug.",https://www.fiercebiotech.com/biotech/chase-after-selling-last-biotech-to-allergan-gets-cash-to-start-pivotal-trials-depression
136,,,2021/10/20 08:40,MedCity,FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody,FDA approves Humira biosimilar as first-ever interchangeable monoclonal antibody,Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won’t come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?,https://medcitynews.com/2021/10/fda-approves-humira-biosimilar-as-first-ever-interchangeable-monoclonal-antibody/
137,,,2021/10/20 08:15,Biotech,Merck KGaA taps CytoReason AI to profile immuno-oncology drug,Merck KGaA taps CytoReason AI to profile immuno-oncology drug,"To ensure its cancer immunotherapy drugs end up in the right hands, Merck KGaA is looking to CytoReason.",https://www.fiercebiotech.com/medtech/merck-kgaa-taps-cytoreason-s-machine-learning-platform-to-profile-immuno-oncology-drug
138,,,2021/10/20 08:10,Biotech,Takeda crashes out of Wave discovery pact at cost of $23M,Takeda crashes out of Wave discovery pact at cost of $23M,"Takeda’s interest in Wave’s discovery programs has ebbed, leading it to exit that part of the alliance while keeping options on more advanced assets.",https://www.fiercebiotech.com/biotech/takeda-crashes-out-wave-discovery-pact-at-cost-23m
139,,,2021/10/20 08:00,Biotech,ShouTi snags $100M for oral drugs to treat chronic diseases,ShouTi snags $100M for oral drugs to treat chronic diseases,"ShouTi will use a $100 million series B to bankroll trials of its small-molecule oral drug in cardiovascular, pulmonary and metabolic conditions.",https://www.fiercebiotech.com/biotech/receptos-founder-returns-shoutti-and-100m-for-chronic-diseases
140,,,2021/10/20 08:00,MedCity,ShouTi secures $100M to hit biologic and peptide targets with small molecules,ShouTi secures $100M to hit biologic and peptide targets with small molecules,"ShouTi Pharmaceuticals, a startup that brings computational techniques to drug discovery, has raised $100 million in Series B financing. The clinical-stage biotech designs small molecules intended to do the work of biologic and peptide drugs.",https://medcitynews.com/2021/10/shouti-secures-100m-to-hit-biologic-and-peptide-targets-with-small-molecules/
141,,,2021/10/20 06:25,Biotech,AstraZeneca slams the brakes on MCL-1 blood cancer drug,AstraZeneca slams the brakes on MCL-1 blood cancer drug,"AstraZeneca has paused an active phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing the need to suss out a potential safety issue.",https://www.fiercebiotech.com/biotech/amid-amgen-s-similar-struggles-astrazeneca-slams-brakes-mcl-1-blood-cancer-drug
142,,,2021/10/20 15:25,Biotech,Charles River expands development lab space in Cambridge,Charles River expands development lab space in Cambridge,Charles River triples size of accelerator and development lab in Cambridge and plans to open first phase of another lab in the biotech hub this year.,https://www.fiercebiotech.com/cro/charles-river-expands-development-lab-space-cambridge
143,,,2021/10/20 15:10,Biotech,Medtronic issues EU safety warning for Percept PC brain implant,Medtronic issues EU safety warning for Percept PC brain implant,Medtronic identified an issue in which its Percept PC brain stimulation implant may stop working after an implanted patient undergoes a cardioversion.,https://www.fiercebiotech.com/medtech/medtronic-issues-eu-safety-warning-for-percept-pc-deep-brain-stimulation-implant
144,,,2021/10/20 13:57,Biotech,FDA slaps clinical hold on AstraZeneca cancer drug,FDA slaps clinical hold on AstraZeneca cancer drug,The FDA has hit the drug with a clinical hold after one patient appeared to show hearty safety signals,https://www.fiercebiotech.com/biotech/fda-slaps-clinical-hold-astrazeneca-cancer-drug-amid-heart-safety-scare-combo-test
145,,,2021/10/20 12:46,MedCity,CMS chief at HLTH: We need to stop taking it for granted that people know they are eligible for coverage,CMS chief at HLTH: We need to stop taking it for granted that people know they are eligible for coverage,"There are about 17 million people eligible for coverage through Medicaid or the Affordable Care Act marketplaces, and one of CMS’ priorities is to make them aware of their insurance options, Administrator Chiquita Brooks-LaSure said at this year’s HLTH conference. ",https://medcitynews.com/2021/10/cms-chief-at-hlth-we-need-to-stop-taking-it-for-granted-that-people-know-they-are-eligible-for-coverage/
146,,,2021/10/20 11:36,Biotech,Medtronic's newest insulin pump effective in kids: study,Medtronic's newest insulin pump effective in kids: study,The 780G pump is designed to work with Medtronic’s Guardian sensors to continuously monitor glucose levels and adjust insulin dosage around the clock.,https://www.fiercebiotech.com/medtech/medtronic-s-newest-minimed-insulin-pump-improves-glycemic-control-children-study
147,,,2021/10/20 11:00,Biotech,Princeton and MIT team uncovers clues for improving gene editing,Princeton and MIT team uncovers clues for improving gene editing,"A Princeton and MIT team identified pathways affecting gene-editing outcomes in platforms including CRISPR/Cas9, prime editing and base editing.",https://www.fiercebiotech.com/research/improving-gene-editing-tools-david-liu-mit-and-princeton-scientists-uncover-clues
148,,,2021/10/20 10:39,Biotech,Abbott's COVID test sales make comeback with delta-driven demand,Abbott's COVID test sales make comeback with delta-driven demand,"After weathering a nearly billion-dollar dip in rapid COVID testing sales earlier this year, Abbott's BinaxNow antigen tests have rebounded.",https://www.fiercebiotech.com/medtech/covid-test-demand-returns-to-buoy-abbott-s-quarterly-sales
149,,,2021/10/20 10:18,Biotech,F-Star's J&J deal is largest yet with $1.35B in biobucks,F-Star's J&J deal is largest yet with $1.35B in biobucks,"F-star Therapeutics added to its pharma arsenal with another pact, this time $1.35 billion in biobucks from J&J's Janssen for up to five bispecifics.",https://www.fiercebiotech.com/biotech/again-again-again-f-star-s-latest-big-pharma-partner-janssen-17-5m-upfront-1-35b-biobucks
150,,,2021/10/20 10:15,Biotech,NYU surgeons transplant gene-edited pig kidney into a human,NYU surgeons transplant gene-edited pig kidney into a human,"The kidney came from a pig that was genetically modified by United Therapeutics subsidiary Revivicor, which received FDA approval last year.",https://www.fiercebiotech.com/medtech/nyu-surgeons-successfully-transplant-kidney-from-genetically-modified-pig-into-human
151,,,2021/10/19 09:40,Biotech,Dicerna flops efficacy endpoint on nedosiran in PH2,Dicerna flops efficacy endpoint on nedosiran in PH2,Dicerna is still paving a way forward for its troubled late-stage RNAi asset nedosiran after a flop in PH2.,https://www.fiercebiotech.com/biotech/dicerna-flops-efficacy-endpoint-nedosiran-ph2-but-will-file-for-fda-approval-just-ph1-after
152,,,2021/10/19 08:25,Biotech,Atea and Roche's COVID-19 antiviral flunks phase 2,Atea and Roche's COVID-19 antiviral flunks phase 2,"A phase 2 trial of the candidate missed its primary endpoint, prompting Atea and Roche to consider changes that will delay data from a pivotal study.",https://www.fiercebiotech.com/biotech/atea-and-roche-s-covid-19-antiviral-flunks-phase-2-prompting-switch-will-delay-pivotal-data
153,,,2021/10/19 07:50,Biotech,"Biogen, Sage plot 2022 filing for zuranolone approval","Biogen, Sage plot 2022 filing for zuranolone approval","After talking to the FDA, the partners outlined plans to start a rolling submission early in 2022 and finish the filing in the back half of the year.",https://www.fiercebiotech.com/biotech/biogen-sage-plot-2022-filing-for-zuranolone-approval-furthering-turnaround-depression-drug
154,,,2021/10/19 19:27,MedCity,"HLTH: How Mass General Brigham plans to navigate evolving care delivery options, rising prices","HLTH: How Mass General Brigham plans to navigate evolving care delivery options, rising prices","As health systems pivot to virtual and at-home care, Mass General Brigham is continuing to invest in brick-and-mortar facilities as CEO Dr. Anne Klibanski believes there will always be a need for inpatient care. At HLTH, she discussed the health system’s investment in its facilities and how it is leveraging enterprise services to help keep costs down. ",https://medcitynews.com/2021/10/hlth-how-mass-general-brigham-plans-to-navigate-evolving-care-delivery-options-rising-prices/
155,,,2021/10/19 19:24,MedCity,"At HLTH, Amazon confirms plans to bring hybrid care model to new markets","At HLTH, Amazon confirms plans to bring hybrid care model to new markets","The online retailer confirmed plans to bring Amazon Care to Dallas, Chicago, Philadelphia, Boston and Los Angeles, to name a few. But it’s still not clear how many other employers are buying into its telehealth and in-home care service.",https://medcitynews.com/2021/10/at-hlth-amazon-confirms-plans-to-bring-hybrid-care-model-to-new-markets/
156,,,2021/10/19 07:00,Biotech,D&D Pharma nabs $51M before Korean IPO for Alzheimer's,D&D Pharma nabs $51M before Korean IPO for Alzheimer's,"Ahead of a likely IPO in Korea, D&D Pharmatech secured $51 million to bankroll mid-stage trials in Alzheimer's, Parkinson's and other diseases.",https://www.fiercebiotech.com/biotech/d-d-pharma-snags-51m-ahead-1q22-korean-ipo-for-alzheimer-s-parkinson-s
157,,,2021/10/19 06:25,Biotech,Sofinnova bulks out VC shop with a hefty $548M,Sofinnova bulks out VC shop with a hefty $548M,Sofinnova Partners has raised 472 million euros ($548 million) to create the largest early-stage healthcare VC fund in Europe.,https://www.fiercebiotech.com/biotech/sofinnova-bulks-out-vc-shop-a-hefty-548m-as-it-zeroes-early-stage-european-biotechs
158,,,2021/10/19 15:51,MedCity,"Blue Shield of California, Google Cloud to develop real-time claims processing platform","Blue Shield of California, Google Cloud to develop real-time claims processing platform","The companies will build their claims processing platform on Google Cloud’s infrastructure, leveraging artificial intelligence and machine learning capabilities. The goal of the collaboration is to improve patient and provider experience and reduce spending on administrative processes. ",https://medcitynews.com/2021/10/blue-shield-of-california-google-cloud-to-develop-real-time-claims-processing-platform/
159,,,2021/10/19 15:40,MedCity,Don’t delay: Register now for INVEST Pop Health,Don’t delay: Register now for INVEST Pop Health,"Industry executives will share their insights at the INVEST Pop Health conference, held in collaboration with New Orleans Business Alliance, scheduled for November 15-16.",https://medcitynews.com/2021/10/dont-delay-register-now-for-invest-pop-health/
160,,,2021/10/19 14:00,MedCity,Personalizing digital care management: How dynamic care paths drive patient engagement and support better outcomes,Personalizing digital care management: How dynamic care paths drive patient engagement and support better outcomes,"A patient-centered digital care management platform functions as a kind of continuous feedback loop, serving as a virtual partner in the patient’s journey to better health. Here are the primary factors at work in effective digital care management design.",https://medcitynews.com/2021/10/personalizing-digital-care-management-how-dynamic-care-paths-drive-patient-engagement-and-support-better-outcomes/
161,,,2021/10/19 14:00,Biotech,Injured tumor cells activate I-O drugs in cancer models,Injured tumor cells activate I-O drugs in cancer models,"Combining injured tumor cells with checkpoint-inhibiting drugs to stimulate an immune response eliminated 40% of tumors in mice, an MIT team said.",https://www.fiercebiotech.com/research/injured-tumor-cells-activate-immuno-oncology-drugs-to-combat-breast-cancer-and-melanoma
162,,,2021/10/19 13:26,Biotech,Castle Bio taps into Cernostics' GI franchise with $80M deal,Castle Bio taps into Cernostics' GI franchise with $80M deal,Cernostics' AI-driven biopsy test evaluates patients with Barrett’s esophagus and predicts their chances of developing potentially fatal cancer.,https://www.fiercebiotech.com/medtech/castle-biosciences-taps-into-cernostics-gi-cancer-test-franchise-80m-deal
163,,,2021/10/19 13:22,Biotech,Intrivo launches at-home COVID test powered by an AI app,Intrivo launches at-home COVID test powered by an AI app,"There’s an app for just about everything these days—including, now, to generate the results of an at-home COVID-19 test.",https://www.fiercebiotech.com/medtech/intrivo-launches-at-home-covid-test-returns-results-10-minutes-via-ai-powered-app
164,,,2021/10/19 11:53,Biotech,Galera shares slide as radiotherapy complication drug fails,Galera shares slide as radiotherapy complication drug fails,"Galera Therapeutics’ drug for a radiotherapy complication called severe oral mucositis failed in a phase 3 trial, sending shares sliding.",https://www.fiercebiotech.com/biotech/galera-shares-slide-nearly-70-as-radiotherapy-complication-drug-flunks-out-phase-3
165,,,2021/10/19 11:15,Biotech,Not for sale: Intellia CEO Leonard talks dealmaking,Not for sale: Intellia CEO Leonard talks dealmaking,Intellia CEO John Leonard didn't rule out some dealmaking to come during Fierce Biotech's Cell & Gene Therapy Summit.,https://www.fiercebiotech.com/biotech/intellia-ceo-john-loenard-potential-m-a-dealmaking-gene-editing-fierce-biotech-cell-gene
166,,,2021/10/19 11:09,Biotech,FDA opens doors to over-the-counter hearing aids,FDA opens doors to over-the-counter hearing aids,A newly proposed rule would establish a new category of hearing aids that can be sold over-the-counter online or in stores.,https://www.fiercebiotech.com/medtech/fda-opens-doors-to-a-new-class-over-counter-hearing-aids
167,,,2021/10/19 10:47,Biotech,Struggling Calithera nabs 2 cheap cancer assets from Takeda,Struggling Calithera nabs 2 cheap cancer assets from Takeda,Calithera Biosciences is tapping Japanese Big Pharma Takeda for two oncology assets worth $10 million upfront.,https://www.fiercebiotech.com/biotech/struggling-calithera-nabs-two-cheap-cancer-assets-from-takeda-for-just-10m-upfront
168,,,2021/10/19 10:35,Biotech,Entasis antibiotic beats last resort treatment in phase 3 trial,Entasis antibiotic beats last resort treatment in phase 3 trial,A new antibiotic by Entasis Therapeutics has matched an existing therapy against a pathogen deemed by the CDC to be an urgent threat.,https://www.fiercebiotech.com/biotech/entasis-zai-labs-antibiotic-sul-dur-beats-comparator-phase-3-trial
169,,,2021/10/19 10:25,Biotech,SPR Therapeutics nabs $37M funding for Sprint pain relief device,SPR Therapeutics nabs $37M funding for Sprint pain relief device,"The single-lead Sprint system received initial FDA clearance in 2016, followed two years later by another OK for the dual-lead version of the device.",https://www.fiercebiotech.com/medtech/spr-therapeutics-runs-up-37m-vc-funding-for-sprint-pain-relief-device
170,,,2021/10/18 09:05,Biotech,"Valneva tops AstraZeneca's COVID-19 vax, preps for filing in EU","Valneva tops AstraZeneca's COVID-19 vax, preps for filing in EU",Valneva prepping for conditional EU approval of its COVID-19 vaccine after topping AstraZeneca's jab in a head-to-head late-stage pivotal trial.,https://www.fiercebiotech.com/biotech/valneva-tops-astrazeneca-s-covid-19-vaccine-prepping-for-conditional-ema-approval
171,,,2021/10/18 08:30,MedCity,Data mobility empowers better patient care,Data mobility empowers better patient care,BetterHealthcare is laser-focused on improving the first stage of the patient journey while collecting critical data to help providers retain patients and improve referrals within their physician networks.,https://medcitynews.com/2021/10/data-mobility-empowers-better-patient-care/
172,,,2021/10/18 08:15,Biotech,FDA rejects Omeros drug over difficulties estimating its effect,FDA rejects Omeros drug over difficulties estimating its effect,"Weeks after flagging deficiencies with the stem cell transplant filing, the FDA has issued the CRL foreshadowed by its earlier communication. ",https://www.fiercebiotech.com/biotech/fda-rejects-omeros-transplant-drug-over-difficulties-estimating-its-effect
173,,,2021/10/18 07:30,Biotech,"Quris launches with $9M for AI to predict drug success, safety","Quris launches with $9M for AI to predict drug success, safety",Quris wants to erase the risks and costs of failed clinical trials. The AI drug discovery startup launches with $9M for start in rare diseases.,https://www.fiercebiotech.com/cro/ai-drug-discovery-startup-quris-launches-9m-to-predict-drug-success-starting-rare-diseases
174,,,2021/10/18 07:10,MedCity,After Grand Rounds and Doctor on Demand merged — what’s next?,After Grand Rounds and Doctor on Demand merged — what’s next?,"The combined company, now called Included Health, is selling employers on its integrated virtual care and patient navigation services. Doctor on Demand President Robin Glass shared more about what the company has planned next and how it’s setting itself apart from other digital health platforms.",https://medcitynews.com/2021/10/after-grand-rounds-and-doctor-on-demand-merged-whats-next/
175,,,2021/10/18 07:10,Biotech,"Sensyne, OMNY team up on 22M patient records for research","Sensyne, OMNY team up on 22M patient records for research","With 22 million patient records in hand, OMNY Health partners with Sensyne for data analytics and clinical medical research for life sciences clients.",https://www.fiercebiotech.com/cro/sensyne-teams-up-omny-for-22-million-patient-records-for-clinical-research
176,,,2021/10/18 07:05,Biotech,Biogen's ALS drug has failed phase 3. Will FDA approve anyway?,Biogen's ALS drug has failed phase 3. Will FDA approve anyway?,"The neurodegenerative disease prospect has failed a pivotal study, but Biogen has latched onto biomarker data and “trends favoring” the treatment.",https://www.fiercebiotech.com/biotech/biogen-s-als-drug-has-failed-phase-3-will-fda-approve-anyway
177,,,2021/10/18 16:14,Biotech,Crinetics creates Radionetics with $30M for 10 cancer candidates,Crinetics creates Radionetics with $30M for 10 cancer candidates,Crinetics launched radiopharmaceuticals biotech Radionetics with $30 million from 5AM and Frazier and a pipeline of 10 candidates for various cancers.,https://www.fiercebiotech.com/biotech/crinetics-forms-radionetics-initial-30m-1b-plus-biobucks-for-radiopharmaceuticals
178,,,2021/10/18 16:13,MedCity,"Engage at HLTH: As patient engagement solutions abound, here’s what investors are looking for","Engage at HLTH: As patient engagement solutions abound, here’s what investors are looking for","Investors noted the challenges of changing patient behaviors using digital solutions at the engagement track at HLTH, hosted by MedCity News. They also shared what health systems and insurers are looking for in a potential partner. ",https://medcitynews.com/2021/10/engage-at-hlth-as-patient-engagement-solutions-abound-heres-what-investors-are-looking-for/
179,,,2021/10/18 15:10,Biotech,Phathom's erosive esophagitis drug bests Prevacid in phase 3,Phathom's erosive esophagitis drug bests Prevacid in phase 3,Phathom Pharmaceuticals' erosive esophagitis drug vonoprazan performed as well as over-the-counter Prevacid in a head-to-head phase 3 clinical trial.,https://www.fiercebiotech.com/biotech/phathom-pharmaceuticals-study-shows-its-erosive-esophogitis-drug-bests-prevacid-head-to
180,,,2021/10/18 12:43,MedCity,"Biogen ALS drug fails main goal of key test, but company points to other results","Biogen ALS drug fails main goal of key test, but company points to other results","Biogen amyotrophic lateral sclerosis drug, tofersen, failed a Phase 3 clinical trial, but the drug showed improvement according to secondary and exploratory goals of the study. Based on those results, the company said it is talking with regulators to find a path forward for the drug.",https://medcitynews.com/2021/10/biogen-als-drug-fails-main-goal-of-key-test-but-company-points-to-other-results/
181,,,2021/10/18 00:30,Biotech,Medtronic sizing up $300M insulin pump patch buy: report,Medtronic sizing up $300M insulin pump patch buy: report,"Amid back-to-back expansions of two Class I recalls of its MiniMed insulin pumps, Medtronic is reportedly eyeing a purchase of another pump maker.",https://www.fiercebiotech.com/medtech/medtronic-to-leap-ahead-diabetes-tech-race-300m-triple-jump-purchase-report
182,,,2021/10/18 11:38,Biotech,Natera launches lung DNA test for catching transplant rejections,Natera launches lung DNA test for catching transplant rejections,"The lung test launch marks Natera's third in as many months for its Prospera DNA test, which recently debuted heart- and kidney-focused diagnostics.",https://www.fiercebiotech.com/medtech/natera-launches-lung-dna-test-for-catching-transplant-rejections
183,,,2021/10/18 11:21,Biotech,Vertex reports success in 1 patient after islet cell therapy,Vertex reports success in 1 patient after islet cell therapy,Vertex is providing an initial peek at the 1st patient to receive a new diabetes cell therapy that could prevent the need for organ transplant.,https://www.fiercebiotech.com/biotech/vertex-diabetes-cell-therapy-vx-880-restores-islet-cell-function-single-patient
184,,,2021/10/18 10:35,Biotech,ReCor's renal denervation device misses blood pressure endpoint,ReCor's renal denervation device misses blood pressure endpoint,ReCor Medical’s method for tackling stubbornly high blood pressure failed to meet its target in a clinical trial conducted in Japan and Korea.,https://www.fiercebiotech.com/medtech/recor-medical-s-renal-denervation-device-misses-blood-pressure-endpoint-after-european
185,,,2021/10/18 10:21,MedCity,Insiteflow raises $2.3M to solve workflow interoperability ,Insiteflow raises $2.3M to solve workflow interoperability ,"Seeing challenges in making third-party solutions actionable, Anthony Gerardi co-founded a startup to make it easier to view and pull more clinical solutions into the EHR. After bootstrapping his startup, Insiteflow raised $2 million in funding. ",https://medcitynews.com/2021/10/insiteflow-raises-2-3m-to-solve-workflow-interoperability/
186,,,2021/10/18 10:15,Biotech,Philips CPAP recall still chips away at quarterly earnings,Philips CPAP recall still chips away at quarterly earnings,"Even as Philips began the process of repairing and replacing the ventilators affected by its ongoing recall, the devicemaker still saw its sales slip.",https://www.fiercebiotech.com/medtech/philips-cpap-recall-still-chipping-away-at-earnings-nearly-40-drop-q3-connected-care-sales
187,,,2021/10/18 10:00,Biotech,TAK1 blocker teams up with chemo to kill myeloma cells: study,TAK1 blocker teams up with chemo to kill myeloma cells: study,A Norwegian team has preliminary evidence that targeting a protein kinase called TAK1 could restore the power of chemotherapy in multiple myeloma.,https://www.fiercebiotech.com/research/a-new-target-multiple-myeloma-tak1-blocker-boosts-chemo-s-cancer-killing-power-preclinical
188,,,2021/10/17 09:00,MedCity,"Report: Provider, payer websites are go-to online resources for patients making care decisions","Report: Provider, payer websites are go-to online resources for patients making care decisions","Healthcare consumers are increasingly turning to the internet to research their care options, and provider and payer websites are among their top choices for information, according to a new survey of 1,000 U.S. adults. Over half of the respondents said they would use a provider or payer website to search for a new doctor. ",https://medcitynews.com/2021/10/report-provider-payer-websites-are-go-to-online-resources-for-patients-making-care-decisions/
189,,,2021/10/17 14:00,MedCity,Who is Generation C and how will healthcare adapt to meet their expectations?,Who is Generation C and how will healthcare adapt to meet their expectations?,"The term “Gen C” was first introduced circa 2012 by futurist Brian Solis as a way of describing a generation of connected consumers defined not by their age, geography, or income but by their hyper-connected, mobile-first mentality. ",https://medcitynews.com/2021/10/who-is-generation-c-and-how-will-healthcare-adapt-to-meet-their-expectations/
190,,,2021/10/17 22:44,MedCity,Heard at HLTH: Can we get Ironman’s J.A.R.V.I.S. in the world of drug development?,Heard at HLTH: Can we get Ironman’s J.A.R.V.I.S. in the world of drug development?,A panel of data and biopharma experts at the annual HLTH conference in Boston tried to answer questions about where AI can be best used in the world of drug development. ,https://medcitynews.com/2021/10/can-we-get-ironmans-j-a-r-v-i-s-in-the-world-of-drug-development/
191,,,2021/10/17 10:05,MedCity,Four big pharma companies team up in AI initiative focused on drug R&D,Four big pharma companies team up in AI initiative focused on drug R&D,"A new startup initiative in Israel aims to create and invest in startups that use artificial intelligence to address challenges in drug discovery and development. Called AION Labs, this innovation lab stems from an economic development effort from the Israeli government and will have contributions from AstraZeneca, Merck, Pfizer and Teva Pharmaceutical.",https://medcitynews.com/2021/10/four-big-pharma-companies-team-up-in-ai-initiative-focused-on-drug-rd/
192,,,2021/10/15 09:55,Biotech,Hologic dreams bigger for Bolder Surgical with $160M acquisition,Hologic dreams bigger for Bolder Surgical with $160M acquisition,Hologic is taking intrepid steps to build out its surgical franchise with a $160 million deal for Bolder Surgical.,https://www.fiercebiotech.com/medtech/hologic-bolder-surgical-160-million-acquisition-laparoscopic-surgery
193,,,2021/10/15 09:30,Biotech,J&J science chief Stoffels latest exec to exit—Chutes & Ladders,J&J science chief Stoffels latest exec to exit—Chutes & Ladders,J&J science leader leaving at year-end. Bayer's Parkinson's leader heads to gene therapy biotech Ensoma. Shiva Malek jumps from Genentech to Novartis.,https://www.fiercebiotech.com/biotech/chutes-ladders-j-j-science-chief-paul-stoffels-latest-c-suite-leader-to-retire
194,,,2021/10/15 09:09,Biotech,Resilience commits $30M to form new biotechs out of Harvard labs,Resilience commits $30M to form new biotechs out of Harvard labs,Manufacturing and tech shop National Resilience is committing $30 million to form new biotechs out of Harvard's labs.,https://www.fiercebiotech.com/biotech/first-moderna-then-intergalactic-and-now-harvard-resilience-commits-30m-forms-circle
195,,,2021/10/15 08:50,Biotech,Inhalable antibody tamps down COVID-19 in hamsters,Inhalable antibody tamps down COVID-19 in hamsters,An inhalable COVID drug made using a “thin freezing film” technology reduced viral load in hamsters and could be ready for clinical trials next year.,https://www.fiercebiotech.com/research/inhalable-anti-covid-19-antibody-from-tff-and-augmenta-tamps-down-viral-load-hamsters
196,,,2021/10/15 08:15,Biotech,"AstraZeneca posts rare cancer win for treme, beating Nexavar","AstraZeneca posts rare cancer win for treme, beating Nexavar","After multiple flops, AstraZeneca has reported improved survival in a phase 3 checkpoint inhibitor combination study in liver cancer patients.  ",https://www.fiercebiotech.com/biotech/astrazeneca-delivers-rare-win-for-treme-liver-cancer-bouncing-back-from-flops-to-beat-bayer
197,,,2021/10/15 07:58,MedCity,StartUPDATES: New developments from healthcare startups,StartUPDATES: New developments from healthcare startups,"Check out news from Healthmine, Marley Medical, Alloy, Culture Biosciences and more.",https://medcitynews.com/2021/10/startupdates-new-developments-from-healthcare-startups-45/
198,,,2021/10/15 07:15,Biotech,Chinese powerhouse continues charge into siRNA with Silence pact,Chinese powerhouse continues charge into siRNA with Silence pact,"Days after disclosing a siRNA pact with OliX, Hansoh has unveiled a separate gene silencing alliance with Silence Therapeutics.",https://www.fiercebiotech.com/biotech/chinese-biopharma-powerhouse-continues-charge-into-sirna-silence-r-d-pact
199,,,2021/10/15 12:12,Biotech,"Agenus cell therapy spinout MiNK inks $40M IPO for cancer, COVID","Agenus cell therapy spinout MiNK inks $40M IPO for cancer, COVID",MiNK Therapeutics inked its spot on the Nasdaq with a $40 million initial public offering on Friday to take its lead candidate through phase 1 trials.,https://www.fiercebiotech.com/biotech/agenus-cell-therapy-spin-off-mink-inks-mark-wall-street-low-end-40m-ipo-for-cancer-covid-19
200,,,2021/10/15 11:23,Biotech,NIH deals out $77M to develop 12 new rapid COVID tests,NIH deals out $77M to develop 12 new rapid COVID tests,"The new RADx awardees span home and point-of-care diagnostics, with a focus on low-cost tests to spot multiple respiratory infections within an hour.",https://www.fiercebiotech.com/medtech/nih-deals-out-77-7m-to-develop-12-new-rapid-covid-diagnostics-from-bd-quidel-and-more
201,,,2021/10/15 11:19,Biotech,Roche welcomes PathAI into its open digital pathology initiative,Roche welcomes PathAI into its open digital pathology initiative,Roche has tapped PathAI for a collaboration that looks to merge AI programs with its digital pathology work.,https://www.fiercebiotech.com/medtech/roche-pathai-digital-pathology-cancer-artificial-intelligence
202,,,2021/10/15 10:20,Biotech,Greenwood takes the top job at Kojin Therapeutics,Greenwood takes the top job at Kojin Therapeutics,Kojin Therapeutics nabs Luba Greenwood to lead its startup and run an all-woman leadership team.,https://www.fiercebiotech.com/biotech/luba-greenwood-takes-top-job-at-kojin-therapeutics-leading-all-woman-biotech-c-suite
203,,,2021/10/15 10:05,Biotech,FDA recalls Abbott COVID tests at risk of false positives,FDA recalls Abbott COVID tests at risk of false positives,Abbott identified an issue with the software used by lab equipment to process swab samples for testing with two of its Alinity m assays.,https://www.fiercebiotech.com/medtech/fda-adds-class-i-recall-label-to-abbott-alinity-covid-tests-high-risk-false-positives
204,,,2021/10/14 09:25,Biotech,"COVID testing, turnarounds still uneven this far into pandemic","COVID testing, turnarounds still uneven this far into pandemic","Labs of all stripes are facing worker shortages just like restaurants, though many are no longer hamstrung by supply bottlenecks.",https://www.fiercebiotech.com/medtech/covid-testing-turnaround-times-are-still-uneven-far-into-pandemic
205,,,2021/10/14 09:05,Biotech,Omega taps Stanford to find targets for genome-tuning tech,Omega taps Stanford to find targets for genome-tuning tech,"Having pulled off a $126 million IPO, the epigenomic specialist has teamed up with Stanford University School of Medicine to find eye disease targets.",https://www.fiercebiotech.com/biotech/omega-eyeing-new-uses-for-genome-tuning-tech-taps-stanford-to-find-ocular-disease-targets
206,,,2021/10/14 08:15,Biotech,OnKure sets Diamond in C-suite ahead of Pfizer drug combo trial,OnKure sets Diamond in C-suite ahead of Pfizer drug combo trial,"OnKure has put another piece of its C-suite in place, hiring Jennifer Diamond as chief medical officer to support oncology clinical development.",https://www.fiercebiotech.com/biotech/onkure-sets-diamond-c-suite-ahead-pfizer-drug-combo-trial
207,,,2021/10/14 08:00,Biotech,"Digital trials peaked amid COVID, but benefits mixed bag: survey","Digital trials peaked amid COVID, but benefits mixed bag: survey","Decentralized clinical trial uptake leaped nearly 60% during the pandemic, but less than 60% of clinical R&D leaders said patient retention improved.",https://www.fiercebiotech.com/cro/decentralized-clinical-trials-skyrocketed-during-pandemic-but-patient-experience-mixed-bag
208,,,2021/10/14 19:39,MedCity,"Jefferson Health, CommonSpirit Health CEOs to retire","Jefferson Health, CommonSpirit Health CEOs to retire","CommonSpirit Health CEO Lloyd Dean is retiring next summer, while Jefferson Health CEO Dr. Stephen Klasko will step down at the end of the year. The longtime leaders have led their respective systems through several highs and lows, including the turbulent first 18 months of the Covid-19 pandemic. ",https://medcitynews.com/2021/10/jefferson-health-commonspirit-health-ceos-to-retire/
209,,,2021/10/14 19:31,MedCity,Proscia touts study showing digital pathology software detected melanoma ,Proscia touts study showing digital pathology software detected melanoma ,The startup shared results of a prospective study showing its deep learning software detected melanoma with 93% sensitivity and 91% specificity. ,https://medcitynews.com/2021/10/proscia-touts-study-showing-digital-pathology-software-detected-melanoma/
210,,,2021/10/14 07:10,Biotech,Malek jumps ship to run Novartis' NIBR oncology unit,Malek jumps ship to run Novartis' NIBR oncology unit,"The Novartis Institutes for BioMedical Research's oncology department has poached Genentech’s Shiva Malek, Ph.D., to help lead its cancer research.",https://www.fiercebiotech.com/biotech/after-15-years-helping-lead-early-cancer-research-at-genentech-shiva-malek-jumps-ship-to
211,,,2021/10/14 07:00,Biotech,"Restore your ABCs: Rectify nabs $100M, Vertex founding scientist","Restore your ABCs: Rectify nabs $100M, Vertex founding scientist","Formed by Vertex founding scientist Jonathan Moore, Rectify gets $100 million series A to rectify ABC transporters for genetic diseases.",https://www.fiercebiotech.com/biotech/rectify-s-work-abcs-lands-100m-series-a-vertex-founding-scientist
212,,,2021/10/14 18:44,MedCity,INVEST DH Pitch Perfect winner spotlight: EHR-integrated Navimize wants to cut down a key patient pain point,INVEST DH Pitch Perfect winner spotlight: EHR-integrated Navimize wants to cut down a key patient pain point,"The startup, which won a Pitch Perfect contest at MedCity INVEST Digital Health, offers a solution that integrates with EHRs to predict wait times in doctors’ offices and texts patients in real time to let them know what to expect. This virtual waiting room can help increase efficiency and improve patient experience. ",https://medcitynews.com/2021/10/invest-dh-pitch-perfect-winner-spotlight-ehr-integrated-navimize-wants-to-cut-down-on-a-key-patient-pain-point/
213,,,2021/10/14 16:35,MedCity,"Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets","Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets",Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.,https://medcitynews.com/2021/10/tentarix-bio-unveils-50m-for-biologics-with-multiple-functions-multiple-targets/
214,,,2021/10/14 16:00,MedCity,What a platform for employee healthcare management including for mental health should look like,What a platform for employee healthcare management including for mental health should look like,"Employers today realize they must give workers choices to support their whole being, including resources to meet their psychological needs. Fortunately, digital health management platforms bring together robust offerings that evolve as health needs change.",https://medcitynews.com/2021/10/heres-what-a-platform-for-employee-healthcare-management-for-mental-health-employers-are-expanding-access-to-mental-health-management-options/
215,,,2021/10/14 15:58,MedCity,"Walgreens doubles down on VillageMD investment, plans broader health strategy","Walgreens doubles down on VillageMD investment, plans broader health strategy","Walgreens plans to invest a total of $5.2 billion in VillageMD, up from its original plans to buy a $1 billion stake in the primary care company. It’s part of a broader consumer health strategy Walgreens plans to use to grow its business in the future. ",https://medcitynews.com/2021/10/walgreens-doubles-down-on-villagemd-investment-plans-broader-health-strategy/
216,,,2021/10/14 14:31,Biotech,Seasoned executive team launches Tentarix with $50M,Seasoned executive team launches Tentarix with $50M,Industry vets from Eli Lilly and more are ready for the next venture: launching Tentarix Biotherapeutics with a $50 million series A fundraising.,https://www.fiercebiotech.com/biotech/stacked-cohort-industry-vets-set-to-launch-biotech-tentarix-biotherapeutics-50m-series-a
217,,,2021/10/14 14:00,MedCity,Necessary tools for nursing,Necessary tools for nursing,It is clear that money and morning huddles have proven insufficient in improving compassion satisfaction or nurse retention. We must combine modern medical and esoteric thinking with the best practices of the largest corporations in the country.,https://medcitynews.com/2021/10/necessary-tools-for-nursing/
218,,,2021/10/14 12:57,MedCity,Mapping the digital future of pharma,Mapping the digital future of pharma,"Real-world data has long been touted as the solution to many challenges faced in the healthcare space – but more data doesn’t necessarily mean more answers. RWD has become the lynchpin to a more patient-centric approach to care, from drug development to therapy access and provider engagement. But until the tools and technology are in place to turn that data into actionable insights, in context, they’re nothing but numbers. Join us for a discussion on the crucial role of real world data and advanced analytics in the digital transformation of the life sciences industry.",https://medcitynews.com/2021/10/mapping-the-digital-future-of-pharma/
219,,,2021/10/14 12:24,Biotech,Cue Health reups NBA COVID testing contract,Cue Health reups NBA COVID testing contract,"For the third NBA season in a row, Cue Health is hoping to lead the league in assists as its go-to COVID-19 testing company.",https://www.fiercebiotech.com/medtech/cue-health-snags-rebound-re-upping-nba-covid-testing-contract-for-another-season
220,,,2021/10/14 11:27,Biotech,Exscientia AI spots which therapies work in blood cancer study,Exscientia AI spots which therapies work in blood cancer study,"At its core, the method follows a basic idea: take a test to see if the drug will work before it’s given. But AI has scaled up clinicians' efforts.",https://www.fiercebiotech.com/medtech/exscientia-ai-artificial-intelligence-study-results-blood-cancer-hematology-oncology
221,,,2021/10/14 10:40,Biotech,Laborie acquires Pelvalon and its fecal incontinence device,Laborie acquires Pelvalon and its fecal incontinence device,"For its fourth acquisition in as many years, Laborie Medical Technologies has opted to build out its gastroenterology offerings.",https://www.fiercebiotech.com/medtech/laborie-expands-gi-profile-acquisition-pelvalon-and-its-female-fecal-incontinence-device
222,,,2021/10/14 10:22,Biotech,Protein that manipulates gene expression could steer RSV drugs,Protein that manipulates gene expression could steer RSV drugs,New findings shed light on how the NS1 protein lurks into the cell nucleus to undermine the body's ability to off the common virus RSV.,https://www.fiercebiotech.com/research/protein-manipulates-gene-expression-inside-nucleus-could-steer-new-rsv-drugs-vaccines
223,,,2021/10/14 10:05,Biotech,Sanofi tries to quiet naysayers with data on Principia MS drug,Sanofi tries to quiet naysayers with data on Principia MS drug,"Tolebrutinib reduced multiple sclerosis disease activity seen on MRI scans from the patients in the trial at the 48-week point, Sanofi reported.",https://www.fiercebiotech.com/biotech/sanofi-tolebrutinib-extension-data-analyst-reaction-multiple-sclerosis-candidate
224,,,2021/10/13 09:00,MedCity,CMS delays enforcement of Payer-to-Payer data exchange,CMS delays enforcement of Payer-to-Payer data exchange,The current delay is specific to one part of the law that needed rework; it should not be seen as an indicator that interoperability will not happen.,https://medcitynews.com/2021/10/cms-delays-enforcement-of-payer-to-payer-data-exchange/
225,,,2021/10/13 08:40,Biotech,"Aum bags $27M to hit cancer targets pursued by Bayer, Roche","Aum bags $27M to hit cancer targets pursued by Bayer, Roche","Aum is moving on to oncology turf targeted by companies including Bayer and Roche, securing $27 million to advance inhibitors of MNK and TRK.",https://www.fiercebiotech.com/biotech/aum-bags-27m-to-hit-cancer-targets-pursued-by-bayer-roche
226,,,2021/10/13 08:00,Biotech,Takeda inks another biobucks pact: $900M for Immusoft's B cells,Takeda inks another biobucks pact: $900M for Immusoft's B cells,"Takeda links arms with yet another regenerative medicine biotech, this time in an up to $900 million pact with Immusoft for cell therapies.",https://www.fiercebiotech.com/biotech/takeda-bets-up-to-900m-immusoft-s-cell-therapies-for-neurometabolic-disorders
227,,,2021/10/13 07:55,Biotech,More diversity needed in breast cancer clinical trials: report,More diversity needed in breast cancer clinical trials: report,Breastcancer.org urges more diversity in breast cancer clinical trials after 4 treatments approved by the FDA in 2020 enrolled few patients of color.,https://www.fiercebiotech.com/cro/barriers-exist-but-participation-urgent-breast-cancer-clinical-trials-report
228,,,2021/10/13 07:45,Biotech,"UPDATE: CRISPR hails safety, efficacy of off-the-shelf CAR-Ts","UPDATE: CRISPR hails safety, efficacy of off-the-shelf CAR-Ts","The prospect triggered responses in 58% of patients without causing grade 3 or higher CRS, but six-month durability compared unfavorably to rivals.",https://www.fiercebiotech.com/biotech/crispr-hails-safety-efficacy-off-shelf-car-t-but-stock-slides-amid-durability-doubts
229,,,2021/10/13 07:30,Biotech,Apnimed sees positives in new sleep apnea drug data,Apnimed sees positives in new sleep apnea drug data,"Just a few months after a modest $25 million raise, little Apnimed has released some broadly positive data for its experimental sleep apnea drug.",https://www.fiercebiotech.com/biotech/apnimed-sees-positives-midstage-data-for-its-attempt-at-drugging-sleep-apnea-problem
230,,,2021/10/13 07:00,Biotech,Intellia expands ocular pipeline with 10% stake in SparingVision,Intellia expands ocular pipeline with 10% stake in SparingVision,Intellia Therapeutics is beefing up its ocular disease pipeline with a 10% equity stake in SparingVision. ,https://www.fiercebiotech.com/biotech/after-a-gene-editing-first-intellia-grabs-10-stake-sparingvision-for-collab-eye-gene
231,,,2021/10/13 07:00,Biotech,Axial tops up funding for phase 2 autism trial with $37M round,Axial tops up funding for phase 2 autism trial with $37M round,Axial Therapeutics has raised $37.3 million to bankroll a phase 2b study testing a small molecule for improving irritability in children with autism.,https://www.fiercebiotech.com/biotech/axial-therapeutics-secures-37m-for-mid-stage-trial-autism-work-neurological-diseases
232,,,2021/10/13 15:20,Biotech,"Charles River dumps research model site, Swedish CDMO for $115M","Charles River dumps research model site, Swedish CDMO for $115M","Charles River Laboratories is parting ways with two divisions for about $115 million, including a Swedish contract developer and manufacturer site.",https://www.fiercebiotech.com/cro/charles-river-offloads-japan-research-model-site-swedish-gene-therapy-cdmo-for-115m
233,,,2021/10/13 15:00,Biotech,Protein degrader against 'undruggable' target blocks cancer,Protein degrader against 'undruggable' target blocks cancer,"A protein degrader targeting SUMO1 inhibited breast, colon and lung tumors in mice and is now being developed by startup HB Therapeutics.",https://www.fiercebiotech.com/research/novel-protein-degrader-against-undruggable-cancer-target-inhibits-tumors-mice
234,,,2021/10/13 14:34,MedCity,Dexcom taps Garmin for first real-time API integration ,Dexcom taps Garmin for first real-time API integration ,"In July, Dexcom got FDA clearance to allow third parties to access its CGM data. To start, it is integrating with Garmin’s wearable devices. ",https://medcitynews.com/2021/10/dexcom-taps-garmin-for-first-real-time-api-integration/
235,,,2021/10/13 14:00,MedCity,"Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft","Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft","Takeda Pharmaceutical is partnering with startup Immusoft in a research alliance aiming to develop B cell therapies that cross the blood-brain barrier to treat rare neurometabolic disorders. Depending on the progress of the research, Takeda could pay its new partner more than $900 million.",https://medcitynews.com/2021/10/taking-aim-at-the-brain-takeda-strikes-up-cell-therapy-rd-alliance-with-immusoft/
236,,,2021/10/13 14:00,MedCity,Automating patient engagement can improve national roll-out of Covid-19 booster vaccine,Automating patient engagement can improve national roll-out of Covid-19 booster vaccine,"By automating patient engagement, these organizations can reduce the burden on both resources and personnel in fighting this pandemic while improving efficiency in the administration of booster vaccines.",https://medcitynews.com/2021/10/automating-patient-engagement-can-improve-national-roll-out-of-covid-19-booster-vaccine/
237,,,2021/10/13 11:53,Biotech,Olympus investigating 2nd cybersecurity incident in a month,Olympus investigating 2nd cybersecurity incident in a month,"The suspected incident occurred weeks after Olympus reported an attempted malware attack on its IT systems in Europe, the Middle East and Africa.",https://www.fiercebiotech.com/medtech/olympus-investigating-potential-cybersecurity-incident-american-it-systems-its-second
238,,,2021/10/13 11:18,Biotech,Regulus again reprioritizes in attempt to turn ship around,Regulus again reprioritizes in attempt to turn ship around,Regulus Therapeutics is once again shuffling its pipeline and sliding a new kidney disease candidate into the high-priority queue.,https://www.fiercebiotech.com/biotech/microrna-biotech-regulus-therapeutics-drops-first-generation-adpkd-candidate-focuses-next
239,,,2021/10/13 11:02,Biotech,Dexcom brings real-time diabetes data to Garmin fitness devices,Dexcom brings real-time diabetes data to Garmin fitness devices,"After receiving an FDA green light for the project earlier this year, Dexcom is now making its diabetes data available through consumer devices.",https://www.fiercebiotech.com/medtech/dexcom-garmin-diabetes-fitness-smartwatch-blood-sugar-glucose-tracking
240,,,2021/10/13 10:15,Biotech,FDA OKs Cochlear's remote programming tool for hearing implants,FDA OKs Cochlear's remote programming tool for hearing implants,"Hear ye, hear ye: Patients using Cochlear’s hearing implants can now undergo routine adjustments and receive clinical counseling completely virtually.",https://www.fiercebiotech.com/medtech/cochlear-secures-two-fda-nods-for-telehealth-solution-to-program-hearing-implants-from-afar
241,,,2021/10/12 09:35,Biotech,"Poseida, Takeda ink $3.6B pact for 8 non-viral gene therapies","Poseida, Takeda ink $3.6B pact for 8 non-viral gene therapies",Takeda is on a gene therapy collaboration roll in October with the latest push an up to $3.6 billion pact with Poseida for 6 to 8 gene therapies.,https://www.fiercebiotech.com/biotech/billions-club-takeda-taps-poseida-for-second-1b-plus-gene-therapy-pact-2-weeks
242,,,2021/10/12 08:50,Biotech,"J&J science chief Stoffels to retire, adding to C-suite changes ","J&J science chief Stoffels to retire, adding to C-suite changes ","J&J CSO Paul Stoffels is to retire at the end of the year, ending a nine-year stint at the top of the rejuvenated R&D unit and creating more turnover.",https://www.fiercebiotech.com/biotech/j-j-science-chief-stoffels-to-retire-after-decade-at-top-adding-to-c-suite-changes
243,,,2021/10/12 08:05,Biotech,Biotech backers quit Dana-Farber board after policy U-turn ,Biotech backers quit Dana-Farber board after policy U-turn ,"Dana-Farber has barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members.",https://www.fiercebiotech.com/biotech/boston-biotech-backers-quit-dana-farber-board-after-u-turn-investment-policy
244,,,2021/10/12 07:40,Biotech,CureVac giving up on first COVID mRNA vaccine,CureVac giving up on first COVID mRNA vaccine,"With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year",https://www.fiercebiotech.com/biotech/curevac-giving-up-first-covid-mrna-vax-focusing-gsk-partnered-second-attempt
245,,,2021/10/12 18:04,MedCity,Bionano frames $90M BioDiscovery buy as way to expand genomics analysis,Bionano frames $90M BioDiscovery buy as way to expand genomics analysis,"Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its technology with BioDiscovery’s software will provide the integrated offering that many labs want.",https://medcitynews.com/2021/10/bionano-frames-90m-biodiscovery-buy-as-way-to-expand-genomics-analysis/
246,,,2021/10/12 17:50,MedCity,Best Buy makes another bet on healthcare with Current Health acquisition,Best Buy makes another bet on healthcare with Current Health acquisition,"Through a string of recent acquisitions, Best Buy has been building out its health business, with a focus on consumer technology and support for seniors. With its acquisition of Current Health, the company is making a bet that demand for remote patient monitoring will continue to increase. ",https://medcitynews.com/2021/10/best-buy-makes-another-bet-on-healthcare-with-current-health-acquisition/
247,,,2021/10/12 15:00,MedCity,"Oshi Health targets costly GI conditions with virtual care, raises $23M ","Oshi Health targets costly GI conditions with virtual care, raises $23M ","Oshi Health raised $23 million in funding, with CVS Health and Takeda joining as strategic investors. The company has built a digital health platform to help people manage GI conditions, such as Crohn’s disease and IBS. ",https://medcitynews.com/2021/10/oshi-health-targets-costly-gi-conditions-with-virtual-care-raises-23m/
248,,,2021/10/12 14:07,MedCity,"Takeda broadens gene therapy scope, turns to Poseida for non-viral approach","Takeda broadens gene therapy scope, turns to Poseida for non-viral approach",The progress of gene therapies continues to be stymied by safety risks associated with the viruses used to deliver them. Takeda Pharmaceutical is partnering with Poseida Therapeutics in a bet that the biotech’s non-viral technologies could offer a safer alternative.,https://medcitynews.com/2021/10/takeda-broadens-gene-therapy-scope-turns-to-poseida-for-non-viral-approach/
249,,,2021/10/12 14:00,MedCity,AI can aid clinicians in the delivery of standardization of care,AI can aid clinicians in the delivery of standardization of care,"We have an incredible opportunity to further streamline processes and workflows like never before. By incorporating practices driven by analytics and emerging technology, healthcare systems can meet the goal of delivering consistent, quality care.",https://medcitynews.com/2021/10/ai-can-aid-clinicians-in-the-delivery-of-standardization-of-care/
250,,,2021/10/12 12:56,Biotech,"FDA clears Withings’ smartwatch to detect afib, sleep apnea","FDA clears Withings’ smartwatch to detect afib, sleep apnea","There’s a new medical-grade smartwatch in town, and it just might give the long-dominant Apple Watch a run for its money.",https://www.fiercebiotech.com/medtech/withings-goes-head-to-head-apple-nabbing-fda-ok-for-smartwatch-to-detect-afib-sleep-apnea
251,,,2021/10/12 12:46,Biotech,Mayo Clinic taps Personalis for cancer genomic testing efforts,Mayo Clinic taps Personalis for cancer genomic testing efforts,Mayo hopes to put Personalis to work expanding genomic testing to diverse patient populations who have not had access to personalized medicine.,https://www.fiercebiotech.com/medtech/mayo-clinic-taps-personalis-for-comprehensive-genomic-testing-for-cancer
252,,,2021/10/12 10:49,Biotech,BioNova adds to blood cancer portfolio with $200M Sutro deal,BioNova adds to blood cancer portfolio with $200M Sutro deal,BioNova wants in on Sutro Biopharma's phase 1 antibody-drug conjugate for hematologic cancers and will pay up to $200 million in a licensing deal.,https://www.fiercebiotech.com/biotech/bionova-signs-204m-collab-for-sutro-s-early-stage-hematologic-cancer-asset-china
253,,,2021/10/12 10:35,Biotech,"To ease children through an MRI, Philips makes scans into games","To ease children through an MRI, Philips makes scans into games",Philips launched a digital coach to help parents and children cope with the stress of the procedure and get out the jitters.,https://www.fiercebiotech.com/medtech/to-ease-children-through-a-scary-mri-philips-makes-scanner-a-playground
254,,,2021/10/12 10:25,Biotech,Roche's Spark adds epilepsy asset to pipeline with $328M deal,Roche's Spark adds epilepsy asset to pipeline with $328M deal,Roche’s Spark Therapeutics unit is offering up to $328.5 million in biobucks for CombiGene’s gene therapy for epilepsy.,https://www.fiercebiotech.com/biotech/roche-s-spark-adds-epilepsy-asset-to-pipeline-328m-combigene-licensing-deal
255,,,2021/10/12 10:05,Biotech,MindMaze finds its way to $125M for neuro-rehab game platform,MindMaze finds its way to $125M for neuro-rehab game platform,"With the new funding, MindMaze has now achieved the elusive unicorn status, with an estimated valuation of $1.5 billion.",https://www.fiercebiotech.com/medtech/mindmaze-finds-its-way-to-125m-for-neuro-rehabilitation-video-game-platform
256,,,2021/10/12 10:00,Biotech,"Broad Institute, Intel upgrade genomic data collab with Google","Broad Institute, Intel upgrade genomic data collab with Google","After half a decade of working together, Intel and the Broad Institute of MIT and Harvard are taking their relationship to the next level.",https://www.fiercebiotech.com/medtech/broad-institute-looks-to-intel-google-cloud-to-upgrade-genomic-data-processing
257,,,2021/10/11 09:38,Biotech,Medtronic's Hugo surgical robot heads to Europe with new CE mark,Medtronic's Hugo surgical robot heads to Europe with new CE mark,"Medtronic has secured European approval for its Hugo surgical robot, clearing the way for its continental debut.",https://www.fiercebiotech.com/medtech/medtronic-s-hugo-surgical-robot-heads-to-europe-regulatory-green-light
258,,,2021/10/11 08:44,Biotech,Brain atlas unveils dozens of cell types that control movement,Brain atlas unveils dozens of cell types that control movement,Researchers discovered that the primary motor cortex in the brain houses up to 116 distinct cells—five times more than had been identified before.,https://www.fiercebiotech.com/research/brain-atlas-study-from-uc-berkeley-unveils-dozens-cell-types-control-movement-and-could
259,,,2021/10/11 08:39,Biotech,Idorsi's Fabry drug fails to relieve pain in phase 3 test,Idorsi's Fabry drug fails to relieve pain in phase 3 test,"Idorsia’s Fabry disease therapy “did exactly what we were expecting,” according to one executive—except relieve neuropathic pain.",https://www.fiercebiotech.com/biotech/idorsia-s-fabry-med-fails-phase-3-clinical-trial-does-not-relieve-neuropathic-pain
260,,,2021/10/11 08:30,MedCity,"Pyxis IPO leads way as four life science firms kick off 4Q, raising nearly $500M","Pyxis IPO leads way as four life science firms kick off 4Q, raising nearly $500M","Pyxis Oncology’s IPO raised $168 million as the biotech steers toward the clinic with drug candidates and technology licensed from Pfizer. Theseus Pharma, IsoPlexis, and Cognition Therapeutics also went public; combined the four companies raised nearly half a billion dollars.",https://medcitynews.com/2021/10/pyxis-ipo-leads-way-as-four-life-science-firms-kick-off-4q-raising-nearly-500m/
261,,,2021/10/11 08:15,Biotech,Protagonist's story gets a happy ending as FDA's hold lifted,Protagonist's story gets a happy ending as FDA's hold lifted,"A month ago, Protagonist Therapeutics saw its shares more than halved on an FDA clinical hold of its blood cancer drug after safety issues arose",https://www.fiercebiotech.com/biotech/protagonist-s-story-gets-a-happy-ending-as-fda-s-hold-swiftly-lifted-rusfertide-program
262,,,2021/10/11 07:45,Biotech,Merck seeks FDA nod for COVID antiviral 10 days after data drop,Merck seeks FDA nod for COVID antiviral 10 days after data drop,"Ten days after reporting data on its oral COVID-19 antiviral molnupiravir, Merck has filed for emergency use authorization from the FDA.",https://www.fiercebiotech.com/biotech/merck-makes-beeline-to-fda-seeking-approval-for-covid-19-antiviral-10-days-after-reporting
263,,,2021/10/11 07:20,Biotech,"AstraZeneca's COVID trial hits goal, but efficacy falls short","AstraZeneca's COVID trial hits goal, but efficacy falls short","With AstraZeneca arriving late to the market with efficacy results that fall short of its rivals, its commercial prospects are uncertain.",https://www.fiercebiotech.com/biotech/astrazeneca-s-covid-19-therapy-hits-goal-phase-3-but-efficacy-falls-short-rivals
264,,,2021/10/11 18:55,Biotech,Gossamer unveils 2 new therapies after midstage failures,Gossamer unveils 2 new therapies after midstage failures,"Almost a year after Gossamer Bio’s lead program failed twice in phase 2, the biotech is unveiling two new preclinical assets set to enter the clinic.",https://www.fiercebiotech.com/biotech/gossamer-unveils-2-new-pipeline-candidates-a-year-after-lead-program-fizzled-out-phase-2
265,,,2021/10/11 06:55,Biotech,Senate to cull Biden's biomedical research agency,Senate to cull Biden's biomedical research agency,President Joe Biden’s $3 billion Advanced Research Projects Agency for Health is in jeopardy as the Senate is set to cut the plan;,https://www.fiercebiotech.com/biotech/senate-to-cull-biden-s-biomedical-research-agency-from-social-care-bill-report
266,,,2021/10/11 06:30,Biotech,Ensoma nabs Bayer's $1B Parkinson's head Nuwaysir for gene meds,Ensoma nabs Bayer's $1B Parkinson's head Nuwaysir for gene meds,"He landed Bayer's $1B bet on Parkinson's into the clinic in June. Now, Emile Nuwaysir steps into his next venture: Steering Takeda-partnered Ensoma.",https://www.fiercebiotech.com/biotech/he-led-bayer-s-1b-parkinson-s-bet-via-bluerock-now-emile-nuwaysir-will-helm-ensoma
267,,,2021/10/11 11:56,Biotech,FDA warns against using needle-free devices for facial fillers,FDA warns against using needle-free devices for facial fillers,The FDA’s crackdown on online sales of unauthorized medical devices and substances rages on.,https://www.fiercebiotech.com/medtech/fda-warns-against-using-over-counter-lip-and-facial-fillers-unauthorized-needle-free
268,,,2021/10/11 11:14,Biotech,Veracyte begins limited release of nasal swab lung cancer test,Veracyte begins limited release of nasal swab lung cancer test,The company also delivered recent findings that showed the test’s ability to more accurately separate groups of patients based on cancer risk.,https://www.fiercebiotech.com/medtech/veracyte-kicks-off-limited-release-its-nasal-swab-lung-cancer-test-as-it-gears-up-for-full
269,,,2021/10/11 10:35,Biotech,Protalix sees a path for Fabry resubmission down the line,Protalix sees a path for Fabry resubmission down the line,"Protalix sees a path forward for resubmitting an application for a Fabry disease medicine with the FDA, it’s just going to take a while.",https://www.fiercebiotech.com/biotech/protalix-biotherapeutics-fabry-disease-drug-complete-response-letter-fda-update
270,,,2021/10/11 10:09,Biotech,Mount Sinai unveils department to enhance AI in healthcare,Mount Sinai unveils department to enhance AI in healthcare,"Hospitals talk a big game about integrating AI into clinical care, but Mount Sinai, for one, is actually putting its money where its mouth is.",https://www.fiercebiotech.com/medtech/mount-sinai-unveils-first-its-kind-department-to-develop-ai-tools-for-healthcare
271,,,2021/10/10 09:00,MedCity,Equity in service delivery: When patients don’t speak your language,Equity in service delivery: When patients don’t speak your language,"Getting medical care, whether of a routine or urgent nature, can be stressful for patients at the best of times. When the patient doesn’t speak the language, communication can present an insurmountable obstacle for both the patient and the provider.",https://medcitynews.com/2021/10/equity-in-service-delivery-when-patients-dont-speak-your-language/
272,,,2021/10/10 14:00,MedCity,The need for ethical data models for comprehensive data sharing,The need for ethical data models for comprehensive data sharing,"It is imperative for health systems to form data sharing partnerships that allow for the analysis of de-identified clinical data, while effectively and comprehensively protecting patient information.",https://medcitynews.com/2021/10/the-need-for-ethical-data-models-for-comprehensive-data-sharing/
273,,,2021/10/8 09:30,Biotech,Pfizer development head Rod MacKenzie retiring—Chutes & Ladders,Pfizer development head Rod MacKenzie retiring—Chutes & Ladders,Pfizer's development head to retire early next year. NIH Director Francis Collins to hit exit before year's end. Sanofi snags Gilead cancer executive.,https://www.fiercebiotech.com/biotech/chutes-ladders-pfizer-s-development-leader-retiring-early-next-year
274,,,2021/10/8 09:15,Biotech,"Pfizer, Bayer-backed Pyxis ups IPO price","Pfizer, Bayer-backed Pyxis ups IPO price","As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Pyxis Oncology is upping its IPO",https://www.fiercebiotech.com/biotech/pfizer-bayer-backed-pyxis-ups-ipo-price-as-biotech-s-public-run-continues-unabated
275,,,2021/10/8 09:05,Biotech,Takeda's transplant drug gets unanimous support of FDA AdComm,Takeda's transplant drug gets unanimous support of FDA AdComm,"Having seen its other prospects stumble in recent months, Takeda got back on track with unanimous FDA advisory committee votes.",https://www.fiercebiotech.com/biotech/takeda-s-transplant-drug-gets-unanimous-support-fda-adcomm-despite-concerns-over-diversity
276,,,2021/10/8 09:00,MedCity,Sepsis: Treating a global health crisis at the point of care,Sepsis: Treating a global health crisis at the point of care,"Utilizing POC testing for sepsis is a pragmatic solution for risk-stratification of new patients, helping physicians to prioritize those for treatment based on the severity of their condition.",https://medcitynews.com/2021/10/sepsis-treating-a-global-health-crisis-at-the-point-of-care/
277,,,2021/10/8 08:45,Biotech,"Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo","Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo",Mirati is teaming up with Sanofi to try to boost its KRAS drug's efficacy in lung cancer.,https://www.fiercebiotech.com/biotech/mirati-sanofi-join-forces-lung-cancer-a-kras-shp2-combo-approach
278,,,2021/10/8 17:03,MedCity,INVEST DH Pitch Perfect winner spotlight: Sonavi Labs founder builds on father’s legacy with tech to detect respiratory diseases,INVEST DH Pitch Perfect winner spotlight: Sonavi Labs founder builds on father’s legacy with tech to detect respiratory diseases,"Judges picked Sonavi Labs as the winner of the home health track at MedCity INVEST Digital Health. The Baltimore-based startup makes a smart stethoscope that can be used at home, and plans to seek FDA clearance for a feature to detect pneumonia. ",https://medcitynews.com/2021/10/invest-pitch-perfect-winner-spotlight-sonavi-labs-founder-builds-on-fathers-legacy-with-tech-to-detect-respiratory-diseases/
279,,,2021/10/8 04:59,MedCity,FDA halts all Allogene cell therapy trials after chromosome problem detected,FDA halts all Allogene cell therapy trials after chromosome problem detected,All of Allogene Therapeutics’ clinical trials are now under an FDA clinical hold. The halt was handed down after one patient in the company’s most advanced study developed what the company described as a “chromosomal abnormality.”,https://medcitynews.com/2021/10/fda-halts-all-allogene-cell-therapy-trials-after-chromosome-problem-detected/
280,,,2021/10/8 16:52,MedCity,"With FDA nod, ChemoCentryx pill stands out in a sea of injectable & infused meds","With FDA nod, ChemoCentryx pill stands out in a sea of injectable & infused meds","ChemoCentryx has spent decades developing oral alternatives to injectable and infused biologic drugs that treat chronic autoimmune conditions. The research finally paid off with FDA approval of Tavneos, a ChemoCentryx pill for a rare autoimmune disease.",https://medcitynews.com/2021/10/with-fda-nod-chemocentryx-pill-stands-out-in-a-sea-of-injectable-infused-meds/
281,,,2021/10/8 03:45,Biotech,FDA stops all Allogene's CAR-T trials over safety scare,FDA stops all Allogene's CAR-T trials over safety scare,The FDA has sent shockwaves through the off-the-shelf CAR-T space by slapping a clinical hold on all of Allogene Therapeutics’ AlloCAR T trials.,https://www.fiercebiotech.com/biotech/fda-stops-all-allogene-s-car-t-trials-over-safety-scare-raising-questions-about-future-gene
282,,,2021/10/8 15:11,MedCity,"Devoted Health raises $1.1B, sending valuation soaring past $12B","Devoted Health raises $1.1B, sending valuation soaring past $12B","Though the Medicare Advantage-focused insurance technology startup is smaller than rivals like Clover Health in terms of membership and revenues, this latest financing round places it ahead of, or at least on par with, several larger competitors with regard to total funds raised.",https://medcitynews.com/2021/10/devoted-health-raises-1-1b-sending-valuation-soaring-past-12b/
283,,,2021/10/8 14:00,MedCity,How using plain language in health research drives participant engagement,How using plain language in health research drives participant engagement,Good communication and engagement practices are critical to participant engagement and retention.,https://medcitynews.com/2021/10/how-using-plain-language-in-health-research-drives-participant-engagement/
284,,,2021/10/8 13:35,Biotech,Caris Life Sciences finds new finance head in ex-Medtronic SVP,Caris Life Sciences finds new finance head in ex-Medtronic SVP,Caris Life Sciences’ new CFO takes on the role as the sequencing startup enters an entirely new financial realm.,https://www.fiercebiotech.com/medtech/caris-life-sciences-taps-former-medtronic-svp-mike-weinstein-as-cfo
285,,,2021/10/8 10:27,Biotech,Schrödinger ropes MD Anderson into its cancer inhibitor program,Schrödinger ropes MD Anderson into its cancer inhibitor program,"The status of Schrödinger’s cat may be up in the air, but Schrödinger’s computational drug discovery platform is certainly still alive and kicking.",https://www.fiercebiotech.com/medtech/schrodinger-ropes-md-anderson-into-its-development-program-for-wee1-inhibitors
286,,,2021/10/8 10:10,Biotech,DreaMed Diabetes' clinical support AI expands to Type 2 diabetes,DreaMed Diabetes' clinical support AI expands to Type 2 diabetes,The software analyzes patient data to generate treatment recommendations and suggest insulin pump settings.,https://www.fiercebiotech.com/medtech/dreamed-diabetes-digital-endocrinologist-ai-expands-to-type-2-diabetes-fda-green-light
287,,,2021/10/8 10:00,Biotech,Novel vaccine shields mice from COVID-19 and 4 related viruses,Novel vaccine shields mice from COVID-19 and 4 related viruses,A Japanese team engineered antibodies that target a part of the SARS-CoV-2 spike protein that's conserved among all coronaviruses.,https://www.fiercebiotech.com/research/novel-vaccine-strategy-protects-mice-from-covid-19-and-4-related-coronaviruses
288,,,2021/10/7 09:45,Biotech,Ellume COVID tests recalled over false positive risk,Ellume COVID tests recalled over false positive risk,The recall comes less than a year after the Ellume test became the first over-the-counter self-test to receive emergency authorization from the FDA.,https://www.fiercebiotech.com/medtech/ellume-at-home-covid-tests-recalled-over-false-positive-risk-caused-by-manufacturing-issue
289,,,2021/10/7 09:10,Biotech,Twin Health doubles down with $140M for 'digital twin' tech,Twin Health doubles down with $140M for 'digital twin' tech,"Seeing double may often be a sign of a larger health issue, but, in this case, it could be the key to reversing chronic diseases like diabetes.",https://www.fiercebiotech.com/medtech/twin-health-doubles-down-digital-twin-technology-for-diabetes-reversal-140m-series-c
290,,,2021/10/7 09:00,MedCity,Aetna’s prior authorization policy harms California patients,Aetna’s prior authorization policy harms California patients,"Beginning July 1, Aetna now requires prior authorization for all cataract surgeries, across all its members and plans. Here in California and across the country, ophthalmologists are going to great lengths to secure approval from Aetna for cataract surgery, while the backlog caused by prior authorization and delayed elective care during the Covid-19 pandemic only grows.",https://medcitynews.com/2021/10/aetnas-prior-authorization-policy-harms-california-patients/
291,,,2021/10/7 09:00,Biotech,Yale spinout targets cancer's acidic environment to boost I-O,Yale spinout targets cancer's acidic environment to boost I-O,Cybrexa Therapeutics has developed a peptide-drug conjugate that improved the efficacy of checkpoint inhibitors in mouse models of cancer.,https://www.fiercebiotech.com/research/yale-spinout-shows-targeting-cancer-cells-acidic-environment-might-enhance-immunotherapy
292,,,2021/10/7 08:51,MedCity,"Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs","Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs",Neumora Therapeutics unveiled $500 million in capital and a research partnership with Amgen. The startup analyzes neurological data to inform its drug research and development; President and Chief Operating Officer Lori Lyons-Williams said researching psychiatric drugs and neurodegenerative drugs within the same company allows brain insights from one area to inform the other.,https://medcitynews.com/2021/10/allied-with-amgen-and-backed-by-500m-neumora-brings-data-science-to-brain-drugs/
293,,,2021/10/7 08:20,Biotech,BMS' deucravacitinib flunks midphase IBD trial,BMS' deucravacitinib flunks midphase IBD trial,"After blowing Otezla away in psoriasis, deucravacitinib went into a phase 2 readout in ulcerative colitis flying high—only to fail comprehensively.",https://www.fiercebiotech.com/biotech/bristol-myers-deucravacitinib-flunks-midphase-ibd-trial-raising-questions-about-potential
294,,,2021/10/7 08:00,Biotech,AffyImmune snags $30M for 'tune and track' platform for CAR-T,AffyImmune snags $30M for 'tune and track' platform for CAR-T,AffyImmune gets $30 million from ORI Capital in second series A financing round to improve CAR-T therapies' success in solid tumors.,https://www.fiercebiotech.com/biotech/affyimmune-raises-30m-to-reduce-toxicity-increase-longevity-car-t-cells-solid-tumors
295,,,2021/10/7 07:35,Biotech,"Denali makes ALS play, hustling Sanofi-allied drug into phase 2 ","Denali makes ALS play, hustling Sanofi-allied drug into phase 2 ",Denali revealed early-phase data on one ALS asset and plans to move a Sanofi-partnered program into phase 2 early in 2022.,https://www.fiercebiotech.com/biotech/denali-makes-als-play-hustling-sanofi-partnered-drug-into-phase-2-and-sharing-early-data
296,,,2021/10/7 07:00,Biotech,Intergalactic nabs $75M to rocket eye gene therapy to the clinic,Intergalactic nabs $75M to rocket eye gene therapy to the clinic,"With a telescope pointed at the eyes, cancer and CNS diseases, Intergalactic Therapeutics is counting down from 10 with $75M to jettison into clinic.",https://www.fiercebiotech.com/biotech/intergalactic-shoots-for-non-viral-gene-therapy-stars-75m-rocket-fuel
297,,,2021/10/7 06:30,Biotech,"Arch unveils $500M, Amgen-allied bet on neuroscience's future","Arch unveils $500M, Amgen-allied bet on neuroscience's future","Neumora starts life with $500 million, a pact with Amgen, a pipeline of eight prospects and plans to create precision medicines for brain diseases.  ",https://www.fiercebiotech.com/biotech/meet-neumora-arch-s-500m-amgen-partnered-play-for-targeted-future-neuroscience-r-d
298,,,2021/10/7 16:55,Biotech,FDA tightens regulations for surgical staplers and staples,FDA tightens regulations for surgical staplers and staples,"Between 2011 and 2018, the FDA received more than 41,000 reports concerning surgical staples and staplers, including 366 deaths linked to the devices.",https://www.fiercebiotech.com/medtech/fda-tightens-regulations-broadens-oversight-surgical-staplers-implantable-staples
299,,,2021/10/7 14:57,MedCity,"Specialty physicians in Connecticut gain path to value-based care, payment boost via private health plan","Specialty physicians in Connecticut gain path to value-based care, payment boost via private health plan","The State of Connecticut Health Plan is the first commercial plan in the country to have its episodes-of-care payment model designated as an Advanced APM by CMS. With limited Advanced APM options via CMS, this designation will provide specialty physicians in the state a path to value-based care payments through the private sector.",https://medcitynews.com/2021/10/specialty-physicians-in-connecticut-gain-path-to-value-based-care-payment-boost-via-private-health-plan/
300,,,2021/10/7 14:00,MedCity,Don’t settle for less. What we should be striving for in healthcare price transparency,Don’t settle for less. What we should be striving for in healthcare price transparency,"A robust price estimator should incorporate AI into its pricing calculations by recognizing that any estimate should automatically “link” and merge the hospital facility fee, physician professional fee and other billable fees into a final patient estimate.",https://medcitynews.com/2021/10/dont-settle-for-less-what-we-should-be-striving-for-in-healthcare-price-transparency/
301,,,2021/10/7 12:37,Biotech,No sweat for Brickell to submit to FDA with 2 phase 3 trials,No sweat for Brickell to submit to FDA with 2 phase 3 trials,Brickell to ask FDA for approval of its sweat gel in mid-2022 after reaching statistical significance on all goals in two pivotal late-stage studies.,https://www.fiercebiotech.com/biotech/no-more-sweat-for-brickell-biotech-will-submit-for-fda-approval-its-sweat-gel-2-phase-3
302,,,2021/10/7 11:06,Biotech,White House funnels another $1B into at-home COVID test makers,White House funnels another $1B into at-home COVID test makers,"The billion-dollar investment is estimated to quadruple the total number of at-home, rapid tests available to Americans by December.",https://www.fiercebiotech.com/medtech/white-house-funnels-1b-into-at-home-covid-test-makers-quadrupling-monthly-supply-by
303,,,2021/10/7 10:59,Biotech,Oculis improves its vision with CMO Chang from Novartis,Oculis improves its vision with CMO Chang from Novartis,"Oculis snags fresh set of eyes to lead medical affairs team, as it picks up Novartis medical lead for ophthalmology and opens a Hong Kong office.",https://www.fiercebiotech.com/biotech/oculis-snags-novartis-head-ophthalmology-joanne-chang-for-cmo-role
304,,,2021/10/7 10:33,Biotech,Cue Health taps Google Cloud to connect its portable COVID tests,Cue Health taps Google Cloud to connect its portable COVID tests,"Cue plans to add real-time tracking of viral variants and sequencing data, bolstered by artificial intelligence programs.",https://www.fiercebiotech.com/medtech/to-track-down-covid-variants-cue-health-taps-google-cloud-to-connect-its-portable-tests
305,,,2021/10/6 09:30,Biotech,"Acquisition autumn: Syneos pens another deal, for RxDataScience","Acquisition autumn: Syneos pens another deal, for RxDataScience",It was StudyKIK in September. Now it's RxDataScience in October. Contract research organization Syneos Health is on the acquisition hunt this fall.,https://www.fiercebiotech.com/cro/fresh-off-september-buy-syneos-inks-another-deal-for-ai-firm-rxdatascience
306,,,2021/10/6 20:47,MedCity,"Twin Health raises $140M to manage diabetes, other chronic conditions","Twin Health raises $140M to manage diabetes, other chronic conditions","The startup, which says it uses “digital twins” to help people manage their diabetes, recently raised a series C round led by ICONIQ Growth. It uses data from connected devices, blood tests and consultations to come up with personalized recommendations. ",https://medcitynews.com/2021/10/twin-health-raises-140m-to-manage-diabetes-other-conditions/
307,,,2021/10/6 08:20,Biotech,EQRx's affordable drug drive leads to Absci discovery pact,EQRx's affordable drug drive leads to Absci discovery pact,"EQRx has identified a partner to support its effort to cut the price of medicines, teaming up with newly public drug and target discovery shop Absci.",https://www.fiercebiotech.com/biotech/eqrx-s-affordable-drug-drive-leads-to-absci-discovery-pact
308,,,2021/10/6 07:40,Biotech,Sanofi poaches Gilead cancer exec to run its cancer R&D,Sanofi poaches Gilead cancer exec to run its cancer R&D,"After a short tenure at Gilead running its cancer R&D, Valeria Fantin, Ph.D., has been poached by French Big Pharma Sanofi.",https://www.fiercebiotech.com/biotech/sanofi-poaches-gilead-cancer-exec-valeria-fantin-to-run-its-oncology-research
309,,,2021/10/6 07:00,Biotech,Retrotope misses mark but boosts survival in rare child disorder,Retrotope misses mark but boosts survival in rare child disorder,Retrotope looks to speak with FDA about regulatory options after its treatment missed the main endpoint but improved survival in an ultrarare disease.,https://www.fiercebiotech.com/biotech/retrotope-misses-main-endpoint-but-improves-survival-late-stage-trial-ultrarare-disorder
310,,,2021/10/6 07:00,Biotech,Voyager pens Pfizer gene therapy pact worth $630M,Voyager pens Pfizer gene therapy pact worth $630M,"Hoping to make gene therapies safer, Pfizer is putting down as much as $630 million for an R&D pact with Voyager.",https://www.fiercebiotech.com/biotech/voyager-therapeutics-looks-to-shake-off-a-tough-year-as-it-pens-pfizer-gene-therapy-pact
311,,,2021/10/6 18:43,MedCity,Carbon Health grows home care capabilities with Alertive Healthcare acquisition ,Carbon Health grows home care capabilities with Alertive Healthcare acquisition ,The acquisition enables primary and urgent care provider Carbon Health to remotely monitor patients’ vitals and intervene when needed. The move follows Carbon Health’s purchase of diabetes platform Steady Health — its first major foray into home-based care. ,https://medcitynews.com/2021/10/carbon-health-grows-home-care-capabilities-with-alertive-healthcare-acquisition/
312,,,2021/10/6 17:40,MedCity,Study: Apps integrating with EHRs grew 20% during 2020,Study: Apps integrating with EHRs grew 20% during 2020,"Though the total number of unique apps that integrate with major EHRs, like Epic and Cerner, increased from 600 at the end of 2019 to 734 in December 2020, growth in the number of apps that support the FHIR data exchange standard was stagnant. ",https://medcitynews.com/2021/10/study-apps-integrating-with-ehrs-grew-20-during-2020/
313,,,2021/10/6 17:05,MedCity,Medtronic expands recall of MiniMed insulin pumps ,Medtronic expands recall of MiniMed insulin pumps ,"Medtronic is expanding a recall of two of its MiniMed 600 series insulin pumps after reports found several had broken retainer rings cracked, resulting in insulin doses that were too high or too low. ",https://medcitynews.com/2021/10/medtronic-expands-recall-of-minimed-insulin-pumps/
314,,,2021/10/6 04:45,Biotech,Takeda stops narcolepsy clinical trials because of safety signal,Takeda stops narcolepsy clinical trials because of safety signal,"Takeda has hit the brakes hard on its narcolepsy program in response to a safety signal, stopping its two midphase clinical trials early.",https://www.fiercebiotech.com/biotech/takeda-slams-brakes-narcolepsy-program-stopping-2-studies-early-response-to-safety-signal
315,,,2021/10/6 15:15,Biotech,"Venture banks on virtual trials: Lightship, Slope nab funding","Venture banks on virtual trials: Lightship, Slope nab funding","Lightship and Slope haul in $60 million total to rival remote trial startups like Medable, Castor, ObvioHealth and Reify.",https://www.fiercebiotech.com/cro/lightship-lures-40m-slope-snags-20m-for-virtual-decentralized-clinical-trials
316,,,2021/10/6 15:10,Biotech,Pfizer development head MacKenzie to retire in early 2022,Pfizer development head MacKenzie to retire in early 2022,"With a COVID-19 vaccine milestone to bookend 35 years of moving up the ranks, Pfizer's development head, Rod MacKenzie, will retire in early 2022.",https://www.fiercebiotech.com/biotech/pfizer-s-development-leader-becomes-second-executive-to-retire-early-2022
317,,,2021/10/6 15:03,Biotech,Ginkgo bowled over as short seller dubs it 'a hoax for the ages',Ginkgo bowled over as short seller dubs it 'a hoax for the ages',"Calling its business model “hocus-pocus” and “a colossal scam,” activist short seller firm Scorpion Capital has stung Ginkgo Bioworks.",https://www.fiercebiotech.com/medtech/ginkgo-bioworks-suffers-short-attack-firm-calling-it-a-hoax-for-ages
318,,,2021/10/6 14:35,MedCity,Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance,Voyager Therapeutics’ strategy shift to gene therapy tech leads to a Pfizer alliance,"The gene therapy pipeline of Voyager Therapeutics has hit several setbacks in the past year, but a strategy shift to its capsid technology is now showing promise. Pfizer has signed on as partner in a wager that Voyager’s tech holds the key to delivery of gene therapies for cardiovascular and neurological disorders.",https://medcitynews.com/2021/10/voyager-therapeutics-strategy-shift-to-gene-therapy-tech-leads-to-a-pfizer-alliance/
319,,,2021/10/6 12:19,Biotech,SyncThink clocks FDA nod for AI-powered concussion test,SyncThink clocks FDA nod for AI-powered concussion test,SyncThink's technology previously received FDA clearance in 2016 for use in detecting impairments in patients’ gaze and visual tracking abilities.,https://www.fiercebiotech.com/medtech/syncthink-clocks-fda-nod-for-concussion-test-based-ai-powered-eye-tracking
320,,,2021/10/6 11:00,Biotech,Dengue compound backed by J&J shows potency in mice,Dengue compound backed by J&J shows potency in mice,"A dengue treatment developed by J&J's Janssen and Belgian researchers was effective in mouse models and will move into clinical trials, they said.",https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
321,,,2021/10/6 10:59,Biotech,Boston Scientific puts down $1.7B to scoop up Baylis Medical,Boston Scientific puts down $1.7B to scoop up Baylis Medical,The Canadian company specializes in minimally invasive platforms that let surgeons cross the thin barrier separating the heart's upper chambers.,https://www.fiercebiotech.com/medtech/boston-scientific-puts-down-1-75b-to-team-up-its-cardiac-devices-baylis-medical-s-heart
322,,,2021/10/6 10:20,Biotech,Medtronic expands 2 Class I recalls of MiniMed insulin pumps,Medtronic expands 2 Class I recalls of MiniMed insulin pumps,"Years after initiating a pair of recalls for various models of its MiniMed insulin pumps, Medtronic expanded the alerts to include even more devices.",https://www.fiercebiotech.com/medtech/medtronic-expands-two-class-i-recalls-minimed-insulin-pumps-spanning-nearly-500k-devices
323,,,2021/10/5 09:20,Biotech,"Collins, after 12 years at the NIH helm, will exit","Collins, after 12 years at the NIH helm, will exit","The search is on for a new director of the National Institutes of Health as long-serving Francis Collins, M.D., Ph.D., will depart.",https://www.fiercebiotech.com/biotech/francis-collins-after-12-years-at-nih-helm-to-exit-by-year-s-end
324,,,2021/10/5 09:00,MedCity,Why the right-to-repair conversation needs to extend further,Why the right-to-repair conversation needs to extend further,President Joe Biden’s July executive order supported the repair and reuse of many different products but excluded that for healthcare products. It is disappointing that the President’s order ignores established healthcare re-use practices that pose no elevated patient risk and follow manufacturer standards. ,https://medcitynews.com/2021/10/why-the-right-to-repair-conversation-needs-to-extend-further/
325,,,2021/10/5 08:30,Biotech,Gemini axes CSO and 20% of staff to focus on late-phase plans,Gemini axes CSO and 20% of staff to focus on late-phase plans,"Having built up early-stage activities in gene therapy and other areas, Gemini is now sweeping those programs aside to focus on the lead program.",https://www.fiercebiotech.com/biotech/gemini-axes-cso-and-20-staff-to-focus-late-phase-asset
326,,,2021/10/5 08:05,Biotech,AstraZeneca files for EUA for COVID-preventing antibody,AstraZeneca files for EUA for COVID-preventing antibody,"AstraZeneca has taken another step toward bringing its COVID-19 antibody cocktail to market, filing for EUA of the long-acting candidate.",https://www.fiercebiotech.com/biotech/astrazeneca-files-for-fda-approval-covid-preventing-antibody
327,,,2021/10/5 07:00,Biotech,Eli Lilly-backed IpiNovyx Bio snags $10M for 2023 clinical entry,Eli Lilly-backed IpiNovyx Bio snags $10M for 2023 clinical entry,"Backed by Eli Lilly and based on science out of Weill Cornell Medicine, IpiNovyx Bio is emerging with $10 million to get into clinical trials in 2023.",https://www.fiercebiotech.com/biotech/eli-lilly-backed-ipinovyx-bio-emerges-10m-for-2023-clinical-entry
328,,,2021/10/5 06:00,Biotech,Novartis-backed Exo says 'XO' to investors for $78M series B,Novartis-backed Exo says 'XO' to investors for $78M series B,VC firms with public markets experience add to Exo Therapeutics lineup of investors including Novartis in $78 million series B for exosites.,https://www.fiercebiotech.com/biotech/novartis-backed-exo-therapeutics-secures-78m-to-reprogram-enzymes-sans-side-effects
329,,,2021/10/5 16:43,MedCity,"Virtual care is here to stay, but providers need to make the experience more seamless","Virtual care is here to stay, but providers need to make the experience more seamless","At a recent panel discussion, healthcare executives agreed that telehealth will remain an important part of care delivery post-pandemic, so now is the time for providers to figure out how best to incorporate these services alongside in-person care. Actionable data will prove to be a key resource for providers as they tweak their strategies. ",https://medcitynews.com/2021/10/virtual-care-is-here-to-stay-but-providers-need-to-make-the-experience-more-seamless/
330,,,2021/10/5 16:19,MedCity,"Home care company Honor raises $370M in equity, debt","Home care company Honor raises $370M in equity, debt","Honor, which builds software for home care agencies, raised $370 million in equity and debt. The funding round will give it a valuation of more than $1.25 billion. ",https://medcitynews.com/2021/10/home-care-company-honor-raises-370m-in-equity-debt/
331,,,2021/10/5 15:05,Biotech,Inotiv inks $15M acquisition of drug discovery company Plato,Inotiv inks $15M acquisition of drug discovery company Plato,Contract research organization Inotiv will dish out $15 million for drug discovery company Plato BioPharma for its second deal in three months.,https://www.fiercebiotech.com/cro/inotiv-acquires-drug-discovery-company-plato-biopharma-15m-deal
332,,,2021/10/5 14:00,MedCity,Why there is great need for additional treatments to manage hyperphosphatemia in patients with CKD on dialysis,Why there is great need for additional treatments to manage hyperphosphatemia in patients with CKD on dialysis,"Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially address.",https://medcitynews.com/2021/10/why-there-is-great-need-for-additional-treatments-to-manage-hyperphosphatemia-in-patients-with-ckd-on-dialysis/
333,,,2021/10/5 12:50,Biotech,Henrietta Lacks' estate sues Thermo Fisher for selling her cells,Henrietta Lacks' estate sues Thermo Fisher for selling her cells,"A tissue sample was taken from Lacks without her consent in 1951 and was subsequently used to develop the first polio vaccine, HPV vaccines and more.",https://www.fiercebiotech.com/medtech/henrietta-lacks-estate-sues-thermo-fisher-for-continued-sale-hela-cells-without-family
334,,,2021/10/5 12:00,MedCity,What’s on the agenda for INVEST Pop Health Virtual on November 15-16?,What’s on the agenda for INVEST Pop Health Virtual on November 15-16?,MedCity News is once again partnering with the New Orleans Business Alliance to host the executive summit INVEST Pop Health Virtual.,https://medcitynews.com/2021/10/whats-on-the-agenda-for-invest-pop-health-virtual-on-november-15-16/
335,,,2021/10/5 11:39,Biotech,FDA clears thumb-sized robot for placing cochlear implants,FDA clears thumb-sized robot for placing cochlear implants,"iotaMotion’s minimalist system focuses on the single task of planting electrode arrays within the inner ear, with more precision than the human hand.",https://www.fiercebiotech.com/medtech/fda-clears-thumb-sized-robot-for-placing-cochlear-implants
336,,,2021/10/5 10:31,Biotech,GraphWear nabs $20M for needle-free wearable glucose monitor,GraphWear nabs $20M for needle-free wearable glucose monitor,"The race is on to develop continuous glucose monitors that don’t require regular fingersticks or any other invasive technologies, no matter how mild.",https://www.fiercebiotech.com/medtech/graphwear-tallies-up-20m-vc-funding-for-needle-free-wearable-glucose-monitor
337,,,2021/10/5 10:25,Biotech,Hologic begins European launch of its tabletop Novodiag tester,Hologic begins European launch of its tabletop Novodiag tester,Hologic is hitting the road with its newfound prize and launching the Novodiag system for labs in Europe.,https://www.fiercebiotech.com/medtech/hologic-begins-broad-european-launch-its-tabletop-novodiag-tester-after-its-795m
338,,,2021/10/5 10:05,Biotech,Parexel poaches former GSK executive to ramp up digital strategy,Parexel poaches former GSK executive to ramp up digital strategy,"He led digital data and analytics at GlaxoSmithKline. Now, Stephen Pyke is tasked with leading digital services and clinical data at CRO Parexel.",https://www.fiercebiotech.com/cro/parexel-snags-former-gsk-executive-stephen-pyke-to-boost-digital-strategy-clinical-data
339,,,2021/10/4 09:55,Biotech,OraSure nabs $109M in DOD funding to churn out COVID tests,OraSure nabs $109M in DOD funding to churn out COVID tests,"With the contract, OraSure will be able to increase its manufacturing output by an additional 100 million tests per year by March 2024.",https://www.fiercebiotech.com/medtech/orasure-tacks-another-109m-dod-funding-to-churn-out-rapid-covid-tests
340,,,2021/10/4 09:50,Biotech,FDA approves Abbott's latest Amplatzer Talisman heart implant,FDA approves Abbott's latest Amplatzer Talisman heart implant,"The Talisman device builds off the company’s previous Amplatzer occluder for treating a patent foramen ovale, a gap between the left and right atria.",https://www.fiercebiotech.com/medtech/fda-approves-abbott-s-latest-implant-for-closing-holes-heart-leftover-from-childbirth
341,,,2021/10/4 08:40,Biotech,"Enanta pulls plug on NASH, seeks to offload assets for combos","Enanta pulls plug on NASH, seeks to offload assets for combos","After getting a look at interim phase 2b data, the biotech has decided to stop the monotherapy trial and seek to outlicense its candidates.",https://www.fiercebiotech.com/biotech/enanta-pulls-plug-nash-seeks-to-offload-assets-for-combos
342,,,2021/10/4 08:00,Biotech,"J&J spends $100M to join Roche, Regeneron in blood cancer race","J&J spends $100M to join Roche, Regeneron in blood cancer race","In return for the upfront fee and a $25 million equity investment, J&J has secured global rights to Xencor’s CD20xCD3 bispecific antibody.",https://www.fiercebiotech.com/biotech/j-j-spends-100m-to-join-roche-and-regeneron-bispecific-blood-cancer-race
343,,,2021/10/4 19:35,MedCity,J&J commits $125M in bet that Xencor’s bispecific antibody has an edge in blood cancers,J&J commits $125M in bet that Xencor’s bispecific antibody has an edge in blood cancers,"Clinical-stage Xencor is receiving $100 million up front and a $25 million equity investment, while Johnson & Johnson’s Janssen Biotech subsidiary gets global rights to plamotamab, a bispecific antibody. Regeneron Pharmaceuticals and Roche are also developing bispecific antibodies against the same targets, but Xencor’s drug has a feature that could be a competitive advantage.",https://medcitynews.com/2021/10/jj-commits-125m-in-bet-that-xencors-bispecific-antibody-has-an-edge-in-blood-cancers/
344,,,2021/10/4 19:17,MedCity,"Mount Sinai, Empire BlueCross BlueShield to extend access to home-based care models","Mount Sinai, Empire BlueCross BlueShield to extend access to home-based care models","Empire members will gain access to three Mount Sinai Health System care models, which enable patients to opt for in-home care when medically appropriate. The agreement also includes a plan to improve bi-directional data exchange between the provider and payer.",https://medcitynews.com/2021/10/mount-sinai-empire-bluecross-blueshield-to-extend-access-to-home-based-care-models/
345,,,2021/10/4 07:10,Biotech,Amgen reveals midphase eczema data behind its $400M bet,Amgen reveals midphase eczema data behind its $400M bet,"After 16 weeks, scores on an eczema scale in the four treatment arms had fallen by between 48% and 61%, compared to a 15% drop in the placebo cohort.",https://www.fiercebiotech.com/biotech/amgen-reveals-midphase-eczema-data-behind-its-400m-bet
346,,,2021/10/4 18:16,MedCity,"FDA authorizes Labcorp’s at-home test kit for Covid-19, flu","FDA authorizes Labcorp’s at-home test kit for Covid-19, flu",The Food and Drug Administration granted an emergency use authorization for an at-home Covid-19 and flu test kit by Labcorp. It uses a test that was developed by Roche and authorized last year. ,https://medcitynews.com/2021/10/fda-authorizes-labcorps-at-home-test-kit-for-covid-19-flu/
347,,,2021/10/4 15:51,MedCity,Report: Walgreens considers acquiring health IT company Evolent,Report: Walgreens considers acquiring health IT company Evolent,"Walgreens is considering buying Evolent Health, which makes software to help providers manage their value-based care programs, according to a recent report by Bloomberg. Evolent’s stock rose more than 18% on the news of the potential deal. ",https://medcitynews.com/2021/10/report-walgreens-considers-acquiring-health-it-company-evolent/
348,,,2021/10/4 15:30,Biotech,UCSF develops custom brain implant for severe depression,UCSF develops custom brain implant for severe depression,The brain stimulation system includes a small device implanted on the patient’s brain that continuously monitors neurological activity.,https://www.fiercebiotech.com/medtech/ucsf-health-s-customized-pacemaker-for-brain-successfully-treats-severe-depression
349,,,2021/10/4 15:10,Biotech,MoonLake inks $230M SPAC deal for llama-derived Cosentyx rival,MoonLake inks $230M SPAC deal for llama-derived Cosentyx rival,"MoonLake Immunotherapeutics is headed to the moon, err Wall Street, in a $230 million SPAC deal to bankroll antibodies naturally found in llamas.",https://www.fiercebiotech.com/biotech/moonlake-over-moon-230m-spac-deal-for-llama-antibodies-to-challenge-novartis-cosentyx
350,,,2021/10/4 12:52,Biotech,"Anatara, ObvioHealth partner for virtual trials in Australia","Anatara, ObvioHealth partner for virtual trials in Australia",Anatara will test the virtual trial world with a study of its medicine in patients with IBS via a partnership with ObvioHealth in Australia.,https://www.fiercebiotech.com/biotech/anatara-partners-virtual-trials-company-obviohealth-for-siteless-study-ibs-australia
351,,,2021/10/4 11:29,Biotech,Beyeonics eyes $36M for head-mounted surgical camera tech,Beyeonics eyes $36M for head-mounted surgical camera tech,"Surgeons may not yet have the ability to go on a Magic School Bus-like journey through the human body, but Beyeonics’ tech can get them pretty close.",https://www.fiercebiotech.com/medtech/beyeonics-eyes-36m-funding-for-head-mounted-surgical-visualization-system
352,,,2021/10/4 11:20,Biotech,BioMarin picks up Vertex VP for CMO post month after trial hold,BioMarin picks up Vertex VP for CMO post month after trial hold,"Hoping to secure a second pivotal approval, BioMarin beefs up leadership with CMO from Vertex and senior vice president from Amgen.",https://www.fiercebiotech.com/biotech/biomarin-snags-vertex-vp-as-cmo-a-month-after-clinical-snag-gene-therapy-trial
353,,,2021/10/4 11:05,Biotech,"FDA greenlights combination at-home test for COVID, influenza","FDA greenlights combination at-home test for COVID, influenza","Labcorp aims to tackle both infections with a single test, with an at-home sample collection kit for children as young as two years old.",https://www.fiercebiotech.com/medtech/fda-greenlights-combination-at-home-test-for-covid-and-influenza-children-as-flu-season
354,,,2021/10/4 10:35,Biotech,MSU team reveals new insights into the 'second brain' in the gut,MSU team reveals new insights into the 'second brain' in the gut,MSU researchers discovered that glial cells actively modify electrical signals in the gut to maintain normal functions like motility.,https://www.fiercebiotech.com/research/new-insights-into-second-brain-gut-could-inspire-treatments-for-intestinal-diseases-msu
355,,,2021/10/4 10:20,Biotech,"Magenta nabs Constellation CMO after 5-month search, trial snag","Magenta nabs Constellation CMO after 5-month search, trial snag","After clearing a regulatory hurdle for its blood cancer trial last month, Magenta now has a new CMO, from Constellation, to lead clinical development.",https://www.fiercebiotech.com/biotech/magenta-poaches-constellation-cmo-jeffrey-humphrey-after-five-month-search-setback-to-blood
356,,,2021/10/4 10:10,Biotech,Takeda taps Selecta for $1.1B gene therapy research pact,Takeda taps Selecta for $1.1B gene therapy research pact,Selecta Biosciences is bouncing back with a major new biobucks pact with Japan’s Takeda.,https://www.fiercebiotech.com/biotech/takeda-reeling-from-audentes-safety-issues-taps-selecta-for-1-1b-gene-therapy-research-pact
357,,,2021/10/3 09:00,MedCity,AMA report: U.S. has “highly concentrated” payer markets that stifle competition  ,AMA report: U.S. has “highly concentrated” payer markets that stifle competition  ,"About 73% of health insurance markets are highly concentrated, and in 46% of markets, one insurer had a share of 50% or more, a new report from the American Medical Association shows. The report comes a few months after President Joe Biden directed federal agencies to ramp up oversight of healthcare consolidation. ",https://medcitynews.com/2021/10/ama-report-u-s-has-highly-concentrated-payer-markets-that-stifle-competition/
358,,,2021/10/3 09:00,MedCity,Patient engagement: Investing in the future of your product,Patient engagement: Investing in the future of your product,"Investing in patient engagement strategies that facilitate enrollment and keep people on board, on track, and on drug could be the answer developers have been looking for.",https://medcitynews.com/2021/10/patient-engagement-investing-in-the-future-of-your-product/
359,,,2021/10/3 08:15,MedCity,GRIP Molecular goes with graphene to put powerful diagnostics into patient hands,GRIP Molecular goes with graphene to put powerful diagnostics into patient hands,"Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.",https://medcitynews.com/2021/10/grip-molecular-goes-with-graphene-to-put-powerful-diagnostics-into-patient-hands/
360,,,2021/10/3 07:17,MedCity,"Smartphones could be used to detect depression, Verily finds","Smartphones could be used to detect depression, Verily finds","A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way. ",https://medcitynews.com/2021/10/smartphones-could-be-used-to-detect-depression-verily-finds/
361,,,2021/10/2 13:15,Biotech,J&J offers 80% efficacy for RSV vaccine in Big Pharma race,J&J offers 80% efficacy for RSV vaccine in Big Pharma race,"Janssen is adding to the pile of RSV data, announcing efficacy as high as 80% for preventing severe infections in a mid-stage clinical trial.",https://www.fiercebiotech.com/biotech/janssen-johnson-johnson-rsv-vaccine-shows-80-efficacy-phase-2-trial-at-idweek
362,,,2021/10/1 09:30,Biotech,FDA's vaccine office now headed by Marks—Chutes & Ladders,FDA's vaccine office now headed by Marks—Chutes & Ladders,FDA's vaccine office gets new leader as top 2 officials pack their bags. Ovid CMO now CEO at biotech incubator Sporos. Amicus CEO to head up spinoff.,https://www.fiercebiotech.com/biotech/chutes-ladders-fda-s-vaccine-office-gets-new-leader-as-two-officials-head-toward-exit
363,,,2021/10/1 09:00,Biotech,New cancer targets unveiled in map of protein interactions,New cancer targets unveiled in map of protein interactions,A new map of protein interactions in cancer uncovers previously unrecognized mutations that researchers believe could drive metastasis.,https://www.fiercebiotech.com/research/new-map-protein-interactions-offers-opportunity-to-do-such-damage-to-cancer-scientists-say
364,,,2021/10/1 08:30,MedCity,The future is digital – reimagining patient engagement,The future is digital – reimagining patient engagement,"Interactive patient systems provide a path forward, bringing much-needed efficiency to day-to-day operations for our caregivers, and providing patients and families with the comfort and information they need during one of the most difficult times in history. ",https://medcitynews.com/2021/10/the-future-is-digital-reimagining-patient-engagement/
365,,,2021/10/1 08:05,Biotech,Micreos lands $37M to show whether antibiotic alternative works,Micreos lands $37M to show whether antibiotic alternative works,"With backers putting up $37 million, Micreos is now poised to show if it can generate more targeted, harder-to-resist ways of taking out bacteria.",https://www.fiercebiotech.com/biotech/micreos-lands-37m-to-show-if-antibiotic-alternative-delivers-clinic
366,,,2021/10/1 06:47,Biotech,Merck's oral COVID-19 antiviral slashes hospitalizations,Merck's oral COVID-19 antiviral slashes hospitalizations,"The prospect halved the risk of hospitalization and death in phase 3, spurring Merck to stop the study and race to get emergency use authorization.",https://www.fiercebiotech.com/biotech/merck-s-oral-covid-19-antiviral-slashes-hospitalizations-prevents-deaths-phase-3-sparking
367,,,2021/10/1 15:21,MedCity,Dexcom finds CGM use helps people with Type 2 diabetes stay in range,Dexcom finds CGM use helps people with Type 2 diabetes stay in range,"The company recently published new results on its MOBILE study, which found that CGM use increased time in range for people with Type 2 diabetes. New data shows people who stopped using a CGM saw time in range decrease. ",https://medcitynews.com/2021/10/dexcom-points-to-more-data-on-cgm-use-for-type-2-diabetes/
368,,,2021/10/1 14:00,MedCity,Healthcare organizations remain at risk despite proper HIPAA compliance,Healthcare organizations remain at risk despite proper HIPAA compliance,"Patients expect their healthcare providers to meet compliance regulations and keep their valuable information safe. Though, if you are HIPAA compliant, it doesn’t necessarily mean your data is secure. This article discusses the details of proper email security when it comes to HIPAA compliance.",https://medcitynews.com/2021/10/healthcare-organizations-remain-at-risk-despite-proper-hipaa-compliance/
369,,,2021/10/1 02:00,Biotech,BioNTech's life after Pfizer COVID jab gets boost via cancer vax,BioNTech's life after Pfizer COVID jab gets boost via cancer vax,"Now that its Pfizer-partnered COVID-19 vaccine has been delivered to millions of people, BioNTech is preparing its next candidate for testing.",https://www.fiercebiotech.com/biotech/biontech-looks-beyond-pfizer-covid-19-shot-mrna-vaccine-for-colorectal-cancer
370,,,2021/10/1 12:50,MedCity,"Health2047’s new company plans to use AI, research access to improve clinical decision making","Health2047’s new company plans to use AI, research access to improve clinical decision making","Called RecoverX, the company will leverage AI to mine evidence-based research, medical charts, patient conversations and test results and provide clinical insights for clinicians in real time.",https://medcitynews.com/2021/10/health2047s-new-company-plans-to-use-ai-research-access-to-improve-clinical-decision-making/
371,,,2021/10/1 12:32,Biotech,Medtronic expands minimally invasive spine surgery portfolio,Medtronic expands minimally invasive spine surgery portfolio,"The latest offerings focus on TLIF procedures and join up with the medtech giant’s suite of navigation, AI and robotics tools.",https://www.fiercebiotech.com/medtech/medtronic-expands-minimally-invasive-spine-surgery-portfolio-three-additions
372,,,2021/10/1 12:15,Biotech,"Sophia Genetics, OncoDNA team up to automate tumor profiling","Sophia Genetics, OncoDNA team up to automate tumor profiling","By combining their respective software tools, Sophia and OncoDNA will create a platform that automates the entire tumor profiling process.",https://www.fiercebiotech.com/medtech/sophia-genetics-automates-tumor-profiling-adding-oncodna-s-interpretation-tools-to-its
373,,,2021/10/1 11:25,MedCity,Clinical trials vendor TrialSpark raises $156M to transform into a drug company,Clinical trials vendor TrialSpark raises $156M to transform into a drug company,"TrialSpark, a startup whose software manages various aspects of clinical trials, is becoming a drug developer. Led by CEO and cofounder Benjamine Liu, the company now plans to to acquire or partner on drug candidates, and to invest in biotech companies.",https://medcitynews.com/2021/10/clinical-trials-vendor-trialspark-raises-156m-to-transform-into-a-drug-company/
374,,,2021/10/1 10:32,Biotech,Siemens nets groundbreaking FDA clearance for photon-counting CT,Siemens nets groundbreaking FDA clearance for photon-counting CT,"The Naeotom Alpha’s detectors measure X-rays individually, compared to current systems, which gauge the total sum of energy passing through the body.",https://www.fiercebiotech.com/medtech/siemens-nets-groundbreaking-fda-clearance-for-photon-counting-ct-scanner
375,,,2021/10/1 10:25,Biotech,"SpinaFX taps Medtronic, Zimmer Biomet alum as CEO","SpinaFX taps Medtronic, Zimmer Biomet alum as CEO","Jeff Cambra has held top spots at Zimmer Biomet, Medtronic and more, and is now offering up that expertise to take on the role of CEO at SpinaFX.",https://www.fiercebiotech.com/medtech/spinafx-taps-medtronic-zimmer-biomet-alum-as-ceo-image-guided-pain-treatment-startup
376,,,2021/9/30 09:55,Biotech,Apple Watch ECG could detect multiple arrhythmias: study,Apple Watch ECG could detect multiple arrhythmias: study,Apple first earned an FDA clearance in 2018 for the electrocardiogram function embedded in the Apple Watch.,https://www.fiercebiotech.com/medtech/apple-watch-s-built-ecg-could-detect-non-afib-arrhythmias-follow-up-analysis-finds
377,,,2021/9/30 09:00,Biotech,AstraZeneca closes in on EUA filing for COVID-19 antibody,AstraZeneca closes in on EUA filing for COVID-19 antibody,AstraZeneca has a shot at putting its vaccine woes behind it with a product that may address one of the remaining unmet COVID-19 needs in the West.,https://www.fiercebiotech.com/biotech/astrazeneca-nearly-ready-to-seek-approval-for-its-covid-19-antibody-can-it-stick-landing
378,,,2021/9/30 08:45,Biotech,Researchers unravel a potentially preventable genetic disease,Researchers unravel a potentially preventable genetic disease,"A UCSD-led team reported a potential way to prevent a newly discovered genetic condition called Zaki syndrome, which hampers prenatal development.",https://www.fiercebiotech.com/research/researchers-discover-genetic-condition-might-be-prevented-via-wnt-focused-drug
379,,,2021/9/30 08:30,MedCity,"Five barriers to unleashing clinical decision support, and how to overcome them","Five barriers to unleashing clinical decision support, and how to overcome them",Clinical decision support systems have been with us since the 1980s. It’s time they delivered on their full promise.,https://medcitynews.com/2021/09/five-barriers-to-unleashing-clinical-decision-support-and-how-to-overcome-them/
380,,,2021/9/30 08:00,Biotech,Lilly adds liver fat data to mountain of tirzepatide evidence,Lilly adds liver fat data to mountain of tirzepatide evidence,"At all three doses, tirzepatide drove greater reductions in the various fat types in type 2 diabetics than insulin degludec.",https://www.fiercebiotech.com/biotech/lilly-adds-liver-fat-cgm-blood-sugar-data-to-mountain-evidence-hot-diabetes-prospect
381,,,2021/9/30 07:50,Biotech,Sunovion pens $890M Otsuka neuropsychiatric drug pact,Sunovion pens $890M Otsuka neuropsychiatric drug pact,"Sunovion, owned by Japan’s Sumitomo Dainippon Pharma, has signed a near $1 billion upfront/biobucks mix deal with fellow Japanese native Otsuka.",https://www.fiercebiotech.com/biotech/sunovion-pens-890m-otsuka-pact-for-a-clutch-neuropsychiatric-drugs
382,,,2021/9/30 05:00,MedCity,Former Shire asset becomes Mirum’s first FDA-approved rare disease drug,Former Shire asset becomes Mirum’s first FDA-approved rare disease drug,"Mirum Pharmaceuticals drug Livmarli is now approved to treat pruritus caused by Alagille syndrome, a rare liver disease that can worsen to the point of requiring a transplant. Mirum licensed the drug from Shire in 2018.",https://medcitynews.com/2021/09/former-shire-asset-becomes-mirums-first-fda-approved-rare-disease-drug/
383,,,2021/9/30 15:35,Biotech,Blood storage tech developer Hemanext adds $15M to VC stores,Blood storage tech developer Hemanext adds $15M to VC stores,"Hemanext is hoping to give standard blood storage practices a transfusion of their own—but of innovation, rather than blood cells.",https://www.fiercebiotech.com/medtech/blood-storage-tech-developer-hemanext-adds-15m-to-vc-stores-as-it-preps-for-fda-submission
384,,,2021/9/30 15:30,Biotech,Ventyx files for $100M IPO to fund 6 or more trials by 2023,Ventyx files for $100M IPO to fund 6 or more trials by 2023,Ventyx Biosciences is headed from California to Wall Street with plans for a customary $100 million IPO.,https://www.fiercebiotech.com/biotech/at-least-six-trials-planned-before-2023-ventyx-biosciences-lines-up-for-100m-ipo
385,,,2021/9/30 14:32,MedCity,"With 5 patents under its belt, RCM tech company Ensemble Health Partners files for IPO","With 5 patents under its belt, RCM tech company Ensemble Health Partners files for IPO","The company, which provides revenue cycle management solutions for providers, is filing for the IPO less than two years after Bon Secours Mercy Health sold its majority stake in Ensemble to private equity firm Golden Gate Capital. Per the filing, the company aims to raise $100 million, but that is likely a placeholder figure. ",https://medcitynews.com/2021/09/with-5-patents-under-its-belt-rcm-tech-company-ensemble-health-partners-files-for-ipo/
386,,,2021/9/30 14:00,MedCity,Building pharma resilience by establishing a culture of quality,Building pharma resilience by establishing a culture of quality,"The dirty secret that many life sciences and medical device companies don’t want people to know is that, to date, quality management has primarily been paper-based AND an afterthought in comparison to key strategic initiatives such as product development.",https://medcitynews.com/2021/09/building-pharma-resilience-by-establishing-a-culture-of-quality/
387,,,2021/9/30 12:51,Biotech,Laurent's COVID oral therapy fails in hospitalized patient trial,Laurent's COVID oral therapy fails in hospitalized patient trial,Laurent Pharmaceuticals' COVID-19 oral therapy did not meet its goal of improving the proportion of patients alive and free of respiratory failure.,https://www.fiercebiotech.com/biotech/laurent-s-covid-19-pill-fails-phase-2-but-data-helps-narrow-down-patients-who-may-benefit
388,,,2021/9/30 12:12,Biotech,AR software maker Activ Surgical augments VC funding with $45M,AR software maker Activ Surgical augments VC funding with $45M,"The series B came courtesy of a baker’s dozen of new and existing investors, led by Cota Capital.",https://www.fiercebiotech.com/medtech/activ-surgical-augments-vc-funding-45m-for-ar-based-software
389,,,2021/9/30 11:44,Biotech,Artificial heart maker SynCardia beamed up by Picard Medical,Artificial heart maker SynCardia beamed up by Picard Medical,"The company takes its inspiration from the eponymous captain of the starship Enterprise, who is known to carry an artificial heart of his own.",https://www.fiercebiotech.com/medtech/total-artificial-heart-maker-syncardia-beamed-up-by-newcomer-picard-medical
390,,,2021/9/30 11:07,Biotech,"Merck KGaA, GSK cut ties on $4.2B bintrafusp alfa deal","Merck KGaA, GSK cut ties on $4.2B bintrafusp alfa deal",Merck KGaA and GSK are ending a partnership for the cancer drug bintrafusp alfa which could have netted billions for the German pharma if successful.,https://www.fiercebiotech.com/biotech/merck-kgaa-gsk-cut-ties-bintrafusp-alfa-deal-had-4-2b-biobucks-line
391,,,2021/9/30 11:00,Biotech,Bausch-Novaliq's eye drop beats placebo again in phase 3 trial,Bausch-Novaliq's eye drop beats placebo again in phase 3 trial,Patients with dry eye disease taking Bausch + Lomb's eye drop reported an improvement in the severity of eye dryness during a phase 3 clinical trial.,https://www.fiercebiotech.com/biotech/bausch-novaliq-s-eye-drop-beats-placebo-2nd-phase-3-trial-dry-eye-disease-filing-2022
392,,,2021/9/30 10:54,Biotech,"AstraZeneca, others support newly private Cellular with $120M","AstraZeneca, others support newly private Cellular with $120M",Cellular Biomedicine Group is hitting the ground running as a newly private company with $120 million from AstraZeneca and others.,https://www.fiercebiotech.com/biotech/now-private-cellular-biomedicine-snags-120m-from-astrazeneca-others-for-oncology
393,,,2021/9/30 10:13,Biotech,Novartis claims win with BTK inhibitor where others have failed,Novartis claims win with BTK inhibitor where others have failed,"After a string of Big Pharmas reported failures for their BTK inhibitors in autoimmune disorders, Novartis finally appears to have a winner.",https://www.fiercebiotech.com/biotech/novartis-btk-inhibitor-successful-phase-2b-clinical-trial-remibrutinib
394,,,2021/9/29 09:55,Biotech,"FDA clears wireless, blood pressure-monitoring finger sensor","FDA clears wireless, blood pressure-monitoring finger sensor","Attached around the patient’s finger, the VitalStream device aims to catch the changes in blood pressure that may occur during surgery.",https://www.fiercebiotech.com/medtech/fda-clears-wireless-blood-pressure-monitoring-finger-sensor-from-caretaker-medical
395,,,2021/9/29 09:00,Biotech,Editas claims proof of concept in vision loss gene-editing,Editas claims proof of concept in vision loss gene-editing,Editas has confirmed safety—and its concept—in a small group of patients who have received the gene-editing therapy EDIT-101.,https://www.fiercebiotech.com/biotech/editas-presents-gene-editing-first-human-results-for-edit-101-lca10
396,,,2021/9/29 09:00,Biotech,What's next for the NIH's RADx program for COVID tests?,What's next for the NIH's RADx program for COVID tests?,"Bruce Tromberg, director of the NIH’s National Institute of Biomedical Imaging and Bioengineering, outlined what’s next for RADx.",https://www.fiercebiotech.com/medtech/what-s-next-for-radx-nih-drafts-a-to-do-list-for-its-1-5b-diagnostics-competition-through
397,,,2021/9/29 08:35,Biotech,Amicus spins off gene therapy unit in $600M SPAC deal,Amicus spins off gene therapy unit in $600M SPAC deal,"Amicus has endured a tough few years of pipeline flops and a roller coaster stock ride, but now it’s riding the SPAC wave.",https://www.fiercebiotech.com/biotech/amicus-spins-off-gene-therapy-unit-600m-spac-deal-as-ceo-moves-over-to-caritas-therapeutics
398,,,2021/9/29 08:20,Biotech,I-Mab hits the deal table with biopharma majors: report,I-Mab hits the deal table with biopharma majors: report,I-Mab is reportedly conducting a strategic review that could lead to cooperation on clinical development in China or the sale of an equity stake.,https://www.fiercebiotech.com/biotech/i-mab-hits-deal-table-biopharma-majors-to-talk-partnerships-and-investments-report
399,,,2021/9/29 08:00,Biotech,Leo Pharma inks digital clinical trials partnership with Veeva,Leo Pharma inks digital clinical trials partnership with Veeva,The COVID-19 pandemic accelerated LEO Pharma's clinical trial transformation and it's doubling down in a digital trial partnership with Veeva Systems.,https://www.fiercebiotech.com/cro/leo-pharma-inks-partnerships-veeva-systems-industry-movement-toward-digital-trials
400,,,2021/9/29 19:40,MedCity,"Amicus deal puts it on path to profitability, infuses its gene therapies with $400M","Amicus deal puts it on path to profitability, infuses its gene therapies with $400M",Amicus Therapeutics is spinning its gene therapy pipeline into a separate entity that will go public via a SPAC merger. Executives say the transaction puts Amicus on a path to profitability while simultaneously securing the cash needed to develop the gene therapy assets.,https://medcitynews.com/2021/09/amicus-deal-puts-it-on-path-to-profitability-infuses-its-gene-therapies-with-400m/
401,,,2021/9/29 07:15,Biotech,AstraZeneca bags late-phase hematology prospect in $150M buyout,AstraZeneca bags late-phase hematology prospect in $150M buyout,"AstraZeneca is continuing to build out its rare disease pipeline, pulling the trigger on an option to buy Caelum it picked up in its Alexion deal.",https://www.fiercebiotech.com/biotech/astrazeneca-moves-deeper-into-rare-diseases-spending-150m-late-phase-hematology-prospect
402,,,2021/9/29 07:00,Biotech,Sanofi-backed Expansion nabs $80M for RNA neurodegenerative work,Sanofi-backed Expansion nabs $80M for RNA neurodegenerative work,"Expansion Therapeutics wants to go up against Dyne, Locanabio in myotonic dystrophy. The Sanofi, Novartis-backed biotech now has $80M for the rivalry.",https://www.fiercebiotech.com/biotech/novartis-sanofi-backed-expansion-snags-80m-for-neurodegenerative-assets-to-rival-dyne
403,,,2021/9/29 18:48,MedCity,"Addiction treatment startup Wayspring gets new name, $75M in funding","Addiction treatment startup Wayspring gets new name, $75M in funding","The Nashville-based startup offers services to help people navigate treatment for substance use disorder. It recently raised $75 million, with backers including value-based care investor Valtruis and multiple payers. ",https://medcitynews.com/2021/09/addiction-treatment-startup-wayspring-gets-new-name-75m-in-funding/
404,,,2021/9/29 18:11,MedCity,Provider-led Truveta strikes partnership with Microsoft,Provider-led Truveta strikes partnership with Microsoft,"Truveta, a company owned by 17 U.S. health systems, will build its data analytics solution on the Microsoft Azure cloud computing platform. Microsoft will also help the company scale the solution globally and engage new customers. ",https://medcitynews.com/2021/09/provider-led-truveta-strikes-partnership-with-microsoft/
405,,,2021/9/29 16:42,MedCity,"Apple Watch could be used to detect arrhythmias other than AFib, study shows","Apple Watch could be used to detect arrhythmias other than AFib, study shows","A study published in Circulation showed that the Apple Watch’s ECG detected some arrhythmias other than atrial fibrillation. The device is currently cleared to take ECGs and general irregular pulse alerts, which could indicate potential cases of atrial fibrillation.",https://medcitynews.com/2021/09/apple-watch-could-be-used-to-detect-arrhythmias-other-than-afib-study-shows/
406,,,2021/9/29 03:00,Biotech,In vivo gene editing grabs the spotlight after Intellia triumph,In vivo gene editing grabs the spotlight after Intellia triumph,"Several companies are advancing in vivo gene editing to treat a range of diseases, but they're doing so amid safety concerns surrounding gene therapy.",https://www.fiercebiotech.com/research/vivo-gene-editing-grabs-spotlight-after-intellia-triumph-but-challenges-loom
407,,,2021/9/29 14:00,Biotech,Exploiting a protective gene mutation to fend off Alzheimer's,Exploiting a protective gene mutation to fend off Alzheimer's,"A mutation in the APOE3 gene increases the formation of fatty molecules that may shield against Alzheimer's, a Mayo Clinic team reported.",https://www.fiercebiotech.com/research/how-a-genetic-factor-might-protect-brain-from-alzheimer-s-disease
408,,,2021/9/29 12:23,MedCity,AbbVie drug approval sets up competition with Biohaven in migraine prevention,AbbVie drug approval sets up competition with Biohaven in migraine prevention,"AbbVie drug Quilpta, developed specifically for migraine prevention, is now FDA approved, the latest product in a new class of migraine medicines. The AbbVie drug is the second oral migraine prevention drug that the FDA has approved this year.",https://medcitynews.com/2021/09/abbvie-drug-approval-sets-up-competition-with-biohaven-in-migraine-prevention/
409,,,2021/9/29 12:23,Biotech,Biotech incubator Sporos' new CEO arrives from Ovid,Biotech incubator Sporos' new CEO arrives from Ovid,"Amit Rakhit has jumped from Ovid Therapeutics to be CEO of Sporos Bioventures, a Houston incubator with four biotechs under its wings.",https://www.fiercebiotech.com/biotech/ovid-cmo-amit-rakhit-heads-to-houston-biotech-incubator-sporos-as-ceo
410,,,2021/9/29 11:56,Biotech,FDA takes note of stroke-preventing heart implant risk in women,FDA takes note of stroke-preventing heart implant risk in women,"The agency alerted providers about findings published in JAMA Cardiology, which tracked procedures with Boston Scientific’s Watchman device.",https://www.fiercebiotech.com/medtech/study-finds-stroke-preventing-heart-implant-more-risky-for-women-as-fda-takes-notice
411,,,2021/9/29 11:38,Biotech,FDA approves TransMedics’ donor liver preservation system,FDA approves TransMedics’ donor liver preservation system,"Weeks after receiving an FDA nod for its heart-preserving cart, TransMedics' “miniature ICU” for extending donor liver function won a nod of its own.",https://www.fiercebiotech.com/medtech/transmedics-locks-2nd-fda-approval-a-month-nod-for-donor-liver-preservation-system
412,,,2021/9/29 10:35,Biotech,"Bayer, Huma begin building AI to classify lung cancer types","Bayer, Huma begin building AI to classify lung cancer types",The latest of Bayer and Huma's joint projects has the duo building an AI-powered tool that will analyze CT scans to improve lung cancer diagnoses.,https://www.fiercebiotech.com/medtech/bayer-strengthens-ties-huma-collaborating-ai-to-classify-lung-cancer-types
413,,,2021/9/29 10:05,Biotech,"FDA said no in July, so Iterum will test UTI antibiotic again","FDA said no in July, so Iterum will test UTI antibiotic again",Iterum Therapeutics will give its uncomplicated UTI antibiotic a second shot at FDA approval by conducting another phase 3 trial.,https://www.fiercebiotech.com/biotech/iterum-will-give-uti-antibiotic-another-go-new-trial-after-meeting-fda
414,,,2021/9/28 09:10,Biotech,Shionogi licenses out 3rd-gen HIV asset to ViiV,Shionogi licenses out 3rd-gen HIV asset to ViiV,Japanese pharma Shionogi has penned a new licensing deal for a long-acting HIV asset from ViiV.,https://www.fiercebiotech.com/biotech/shionogi-licences-third-gen-hiv-asset-ultra-long-dosing-prospect-from-its-partly-owned
415,,,2021/9/28 09:00,MedCity,The patient is the point: The changing landscape innovation in drug development,The patient is the point: The changing landscape innovation in drug development,"Bringing in market access and collaboration earlier in the process, viewing reimbursement as the last leg of the drug developmental journey, and collaborating across key functions are practices we can evolve so that as many patients as possible can reap the rewards that are waiting for them.",https://medcitynews.com/2021/09/the-patient-is-the-point-the-changing-landscape-innovation-in-drug-development/
416,,,2021/9/28 08:00,Biotech,"Eisai, Biogen start rolling submission for Alzheimer's drug","Eisai, Biogen start rolling submission for Alzheimer's drug","Having reset the bar to U.S. market access with Aduhelm, the partners have begun a rolling submission for another anti-amyloid beta antibody.",https://www.fiercebiotech.com/biotech/here-we-go-again-eisai-starts-rolling-fda-approval-submission-for-biogen-partnered
417,,,2021/9/28 07:45,Biotech,Sanofi dumps mRNA COVID-19 vaccine after seeing early data,Sanofi dumps mRNA COVID-19 vaccine after seeing early data,Sanofi is dumping the mRNA COVID-19 vaccine prospect after seeing interim phase 1/2 data and accelerating its switch to modified mRNA. ,https://www.fiercebiotech.com/biotech/after-3-2b-deal-sanofi-pivots-mrna-dumping-covid-19-vaccine-and-accelerating-switch-to
418,,,2021/9/28 07:30,Biotech,Valneva sees Lyme disease vaccine drop-off in phase 2,Valneva sees Lyme disease vaccine drop-off in phase 2,Valneva and partner Pfizer say their experimental Lyme disease vaccine has seen a drop-off in protection after 18 months and will need a booster.,https://www.fiercebiotech.com/biotech/valneva-hit-by-covid-contract-chaos-sees-lyme-disease-vaccine-drop-off-phase-2-but-boosters
419,,,2021/9/28 06:30,Biotech,Anji Pharma snags $70M for phase 3 diabetes and mid-stage asset,Anji Pharma snags $70M for phase 3 diabetes and mid-stage asset,"Anji Pharma picks up $70 million for phase 3 diabetes treatment, mid-stage constipation drug and preclinical oncology asset from the Broad Institute.",https://www.fiercebiotech.com/biotech/anji-pharma-secures-70m-series-b-for-phase-3-diabetes-asset-mid-stage-constipation
420,,,2021/9/28 06:05,Biotech,Roche's Genentech to use Lifelink Systems' chatbot for patients,Roche's Genentech to use Lifelink Systems' chatbot for patients,Patients looking for info about Genentech's clinical trials and drugs have a new tool at their fingertips: a digital chatbot from Lifelink Systems.,https://www.fiercebiotech.com/cro/roche-s-genentech-will-communicate-patients-trial-participants-using-lifelink-system-s-chatbot
421,,,2021/9/28 15:51,MedCity,Epic deploys Covid-19 vaccine credentialing feature,Epic deploys Covid-19 vaccine credentialing feature,"Epic’s Covid-19 vaccine credential, which shows up as a QR code within the MyChart patient portal, can be used to verify a person’s immunization status. About 25 million people currently have access to the vaccine credential, and Epic plans to expand it to 100 million by 2022. ",https://medcitynews.com/2021/09/epic-deploys-covid-19-vaccine-credential-feature/
422,,,2021/9/28 15:10,Biotech,Medtronic's newly acquired radial artery catheters go global,Medtronic's newly acquired radial artery catheters go global,"Barely a year after the Rist radial access catheter technology made its operating room debut in Chicago, Medtronic is bringing the devices overseas.",https://www.fiercebiotech.com/medtech/medtronic-s-newly-acquired-radial-artery-catheters-go-global-european-approval
423,,,2021/9/28 15:00,Biotech,Eli Lilly taps Reify's Care Access to diversify oncology trials,Eli Lilly taps Reify's Care Access to diversify oncology trials,"They partnered on testing the COVID-19 antibody bamlanivimab. Now, Eli Lilly and Care Access are working to diversify a phase 3 breast cancer trial.",https://www.fiercebiotech.com/cro/eli-lilly-taps-reify-health-s-care-access-to-diversify-oncology-clinical-trials
424,,,2021/9/28 14:36,MedCity,CVS sues pharmacy benefit startup Capital Rx over ‘unenforceable’ non-compete clause,CVS sues pharmacy benefit startup Capital Rx over ‘unenforceable’ non-compete clause,"After Capital Rx’s former medical director of pharmacy services got a job offer at CVS, the PBM startup claimed he couldn’t work there because of a noncompete agreement. CVS recently sued the company, saying its non-compete clause was unenforceable.",https://medcitynews.com/2021/09/cvs-sues-pharmacy-benefit-startup-capital-rx-over-unenforceable-non-compete-clause/
425,,,2021/9/28 14:00,MedCity,We can prevent the next pandemic with data,We can prevent the next pandemic with data,"To be effective at preventing the next pandemic, everyone will have to play their part, from global agencies and governments right down to individuals. At all levels, digital and data must drive our planning and preparation.",https://medcitynews.com/2021/09/we-can-prevent-the-next-pandemic-with-data/
426,,,2021/9/28 02:00,Biotech,"Union, Innovent ink $247M biobucks deal for psoriasis therapy","Union, Innovent ink $247M biobucks deal for psoriasis therapy","Innovent Biologics to dish out up to $267 million for rights to Union's atopic dermatitis and psoriasis drug hopeful, acquired from Leo Pharma.",https://www.fiercebiotech.com/biotech/innovent-to-pay-union-up-to-267m-for-china-rights-to-mid-stage-psoriasis-eczema-asset
427,,,2021/9/28 13:55,MedCity,"Another Eisai, Biogen Alzheimer’s drug is filed for speedy FDA review","Another Eisai, Biogen Alzheimer’s drug is filed for speedy FDA review","Eisai is seeking accelerated FDA approval of lecanemab, an Alzheimer’s disease drug that is part of a research alliance with Biogen. The drug is following the same path blazed earlier this year with FDA approval of Biogen Alzheimer’s drug Aduhelm.",https://medcitynews.com/2021/09/another-eisai-biogen-alzheimers-drug-is-filed-for-speedy-fda-review/
428,,,2021/9/28 13:09,Biotech,Pfizer tightens DMD trial criteria over safety concerns,Pfizer tightens DMD trial criteria over safety concerns,Pfizer is tightening up the criteria for a Duchenne muscular dystrophy gene therapy after three serious adverse events were seen in ongoing studies.,https://www.fiercebiotech.com/biotech/pfizer-tightening-duchenne-muscular-dystrophy-phase-3-criteria-adverse-events
429,,,2021/9/28 13:04,Biotech,FDA asks for study do-overs at 2 CROs due to data concerns,FDA asks for study do-overs at 2 CROs due to data concerns,The FDA has asked biopharmas to repeat studies they had already conducted at two CROs in India.,https://www.fiercebiotech.com/cro/fda-asks-pharmas-to-repeat-studies-done-at-two-indian-cros-due-to-data-integrity-issues-report
430,,,2021/9/28 11:55,Biotech,MIT cell-engineering spinout nets $30M for production platform,MIT cell-engineering spinout nets $30M for production platform,"One of the tricks of getting cell therapies to work is getting the payload you want into the cell itself—be it RNA, DNA or CRISPR proteins.",https://www.fiercebiotech.com/medtech/mit-cell-engineering-spinout-nets-30m-for-mass-manufacturing-platform
431,,,2021/9/28 10:29,Biotech,Vensana Capital ups medtech investments with $325M 2nd fund,Vensana Capital ups medtech investments with $325M 2nd fund,Vensana Capital II will enable the VC firm to significantly scale up its investments in medtechs in both the development and commercial stage.,https://www.fiercebiotech.com/medtech/vensana-capital-redoubles-medtech-investment-efforts-325m-second-fund
432,,,2021/9/28 10:05,Biotech,Ziopharm's new CEO fires half of his workforce in first month,Ziopharm's new CEO fires half of his workforce in first month,"Less than 30 days into his post as CEO, Kevin Boyle laid off more than 50% of his staff as the company looks to move into a phase 1/2 trial next year.",https://www.fiercebiotech.com/biotech/ziopharm-s-new-ceo-cuts-50-workforce-amid-trial-delays-for-t-cell-receptor-therapy
433,,,2021/9/27 09:20,Biotech,Pfizer's oral COVID-19 antiviral gets rolling in phase 2/3 trial,Pfizer's oral COVID-19 antiviral gets rolling in phase 2/3 trial,Pfizer is kick-starting a phase 2/3 clinical trial for an oral therapeutic antiviral for adults who have been exposed to the coronavirus.,https://www.fiercebiotech.com/biotech/pfizer-s-preventative-covid-19-oral-antiviral-gets-rolling-phase-2-3-trial
434,,,2021/9/27 08:00,Biotech,Connecting Big Pharma's shelved drugs with new investors: report,Connecting Big Pharma's shelved drugs with new investors: report,"If a potentially promising treatment sits idle in a Big Pharma's stockroom, shouldn’t patients have access to it? A new report says yes.",https://www.fiercebiotech.com/biotech/milken-institute-report-big-pharma-donating-shelved-medicines-to-nonoprofits
435,,,2021/9/27 07:40,Biotech,Delix snags $70M series A for psychedelic analog trials in 2022,Delix snags $70M series A for psychedelic analog trials in 2022,"Delix Therapeutics, a 2021 Fierce 15 winner, aims to test two psychedelic analogs in clinical trials next year with the help of $70 million series A.",https://www.fiercebiotech.com/biotech/delix-raises-70m-to-test-psychedelic-analogs-for-treating-brain-disorders-clinical-trials
436,,,2021/9/27 07:25,Biotech,"Syndax, Incyte pen chronic graft-versus-host disease collab","Syndax, Incyte pen chronic graft-versus-host disease collab",Syndax Pharmaceuticals and Incyte are coming together with an R&D collaboration focused on chronic graft-versus-host disease.,https://www.fiercebiotech.com/biotech/syndax-and-incyte-both-reeling-from-cancer-drug-setbacks-pen-chronic-graft-versus-host
437,,,2021/9/27 07:10,Biotech,Mystery suitor lines up $11B Acceleron acquisition: report,Mystery suitor lines up $11B Acceleron acquisition: report,Which large pharma company is preparing to splash $11 billion to acquire Acceleron? That is the question raised by an article in Bloomberg.,https://www.fiercebiotech.com/biotech/mystery-suitor-lines-up-11b-acceleron-acquisition-report
438,,,2021/9/27 07:05,Biotech,Pfizer stumbles close to finish line in growth hormone race,Pfizer stumbles close to finish line in growth hormone race,"The FDA has pushed back approval of Pfizer’s once-weekly prospect, giving rival Ascendis a longer window in which to convert physicians and patients.",https://www.fiercebiotech.com/biotech/pfizer-stumbles-close-to-finish-line-growth-hormone-race-extending-lead-rival-ascendis
439,,,2021/9/27 18:55,MedCity,Cedars-Sinai Accelerator selects 8 new health tech startups,Cedars-Sinai Accelerator selects 8 new health tech startups,"The seventh accelerator class includes startups with a range of offerings, from accessible fitness for aging patients to skeletal reconstruction. Each of the eight companies will receive $100,000 and access to clinicians, researchers and administrators to develop their products and grow their businesses. ",https://medcitynews.com/2021/09/cedars-sinai-accelerator-selects-8-new-health-tech-startups/
440,,,2021/9/27 18:01,MedCity,Portable diagnostics company Cue raises $200M in IPO,Portable diagnostics company Cue raises $200M in IPO,"The diagnostics company currently has an authorized at-home Covid-19 test, and plans to expand into flu tests and other diagnostics. After pricing its stock at $16 per share, it climbed to $20 on Friday. ",https://medcitynews.com/2021/09/portable-diagnostics-company-cue-raises-200m-in-ipo/
441,,,2021/9/27 16:17,MedCity,Report: 22% of providers saw death rates spike following a ransomware attack,Report: 22% of providers saw death rates spike following a ransomware attack,"Ransomware attacks had an impact beyond mortality rates as well, with 71% of respondents saying that these cyberattacks drove up lengths of stay and 36% saying they led to an increase in clinical complications. ",https://medcitynews.com/2021/09/report-22-of-providers-saw-death-rates-spike-following-a-ransomware-attack/
442,,,2021/9/27 15:45,MedCity,"Psychedelic drugs, but safer: Delix raises $70M to bring new neuro meds to clinic","Psychedelic drugs, but safer: Delix raises $70M to bring new neuro meds to clinic","Delix Therapeutics is developing drugs that offer the therapeutic benefits of psychedelic drugs, but without the hallucinations and other side effects that accompany these compounds. The startup has closed $70 million in Series A financing as it works to bring its lead candidates into the clinic next year.",https://medcitynews.com/2021/09/psychedelic-drugs-but-safer-delix-raises-70m-to-bring-new-neuro-drugs-to-clinic/
443,,,2021/9/27 03:00,Biotech,Fierce Biotech's 2021 Fierce 15,Fierce Biotech's 2021 Fierce 15,Check out this year's Fierce 15 winners.,https://www.fiercebiotech.com/special-report/fierce-biotech-s-2021-fierce-15-0
444,,,2021/9/27 11:50,Biotech,Eyevensys upgrades ocular device to advance gene therapy trials,Eyevensys upgrades ocular device to advance gene therapy trials,"Eyevensys' device delivers DNA to the eye's ciliary muscle, essentially turning the eye into a protein-producing “biofactory.”",https://www.fiercebiotech.com/medtech/eyevensys-taps-phillips-medisize-minnetronix-to-up-production-gene-therapy-device-for-eye
445,,,2021/9/27 11:49,Biotech,Elligo’s $135M fuels acquisition to expand digital R&D platforms,Elligo’s $135M fuels acquisition to expand digital R&D platforms,The electronic medical records miner Elligo Health Research has raised $135 million to help power its acquisition of the clinical R&D firm ClinEdge.,https://www.fiercebiotech.com/medtech/135m-bank-elligo-taps-new-buyout-to-build-out-its-digital-r-d-platforms
446,,,2021/9/27 10:55,Biotech,Biohaven's CNS drug from AstraZeneca fails phase 3 trial,Biohaven's CNS drug from AstraZeneca fails phase 3 trial,"Biohaven thought the AstraZeneca drug could pass muster when buying the rights in 2018, but the CNS treatment has now failed a phase 3 test.",https://www.fiercebiotech.com/biotech/a-phase-3-fail-biohaven-learned-hard-way-why-astrazeneca-dropped-cns-drug-2018
447,,,2021/9/27 10:17,Biotech,Zebra Medical earns its stripes with heart disease-spotting AI,Zebra Medical earns its stripes with heart disease-spotting AI,"Zebra Medical is hoofing its way through the FDA gauntlet, racking up eight clearances for its artificial intelligence software in barely three years.",https://www.fiercebiotech.com/medtech/zebra-medical-earns-its-stripes-fda-nod-for-ai-to-measure-calcium-build-up-arteries-0
448,,,2021/9/27 10:15,Biotech,"Novo Nordisk, Biocorp sign digital insulin pen deal","Novo Nordisk, Biocorp sign digital insulin pen deal",Biocorp’s Mallya digital device clips directly onto prefilled insulin injectors and logs delivery amounts and times by linking to a smartphone.,https://www.fiercebiotech.com/medtech/novo-nordisk-to-smarten-up-its-disposable-insulin-pens-digital-diabetes-devicemaker-biocorp
449,,,2021/9/27 10:05,Biotech,Novel 'nanosized' drug carriers tamp down HIV in the brain,Novel 'nanosized' drug carriers tamp down HIV in the brain,"A novel drug-delivery method that penetrates remote tissues could provide a way to ""block and lock"" HIV in a dormant state, a study showed.",https://www.fiercebiotech.com/research/novel-nanosized-drug-carriers-tamp-down-hiv-brain-and-other-remote-tissues-mice
450,,,2021/9/26 09:21,MedCity,"With $33M in funding, startup looks to broaden access to OCD treatment","With $33M in funding, startup looks to broaden access to OCD treatment","NOCD recently closed a $33 million funding round, led by F-Prime Capital. The startup plans to reach more people with OCD to offer exposure and response prevention therapy, a type of therapy that is considered an effective treatment for OCD, but can be difficult to find.",https://medcitynews.com/2021/09/with-33m-in-funding-startup-looks-to-broaden-access-to-ocd-treatment/
451,,,2021/9/26 09:00,MedCity,Why patient control of their own data is the key to health equity,Why patient control of their own data is the key to health equity,"It will take a combination of legislation to protect patient data privacy by governing communication between apps and the power of innovation and the free market, but these apps are coming. And they will put control of health data where it belongs – with patients.",https://medcitynews.com/2021/09/why-patient-control-of-their-own-data-is-the-key-to-health-equity/
452,,,2021/9/26 10:00,MedCity,Study: Rural hospitals that merged or were bought saw death rates drop,Study: Rural hospitals that merged or were bought saw death rates drop,"The mortality rates at rural hospitals for certain conditions, including heart attacks and stroke, decreased in the years following a merger or an acquisition compared with facilities that remained independent, a new study shows. This is a departure from research done on the effects of M&A on urban hospitals. ",https://medcitynews.com/2021/09/study-rural-hospitals-that-merged-or-were-bought-saw-death-rates-drop/
453,,,2021/9/24 09:30,Biotech,"Novartis loses cell, gene leader, digital exec—Chutes & Ladders","Novartis loses cell, gene leader, digital exec—Chutes & Ladders","Novartis loses a cell, gene pipeline leader to MiroBio. The Swiss Big Pharma also lost its chief digital officer. Aerie CEO departs days after flop.",https://www.fiercebiotech.com/biotech/chutes-ladders-novartis-loses-two-leaders-one-to-mirobio-another-to-a-video-game-game
454,,,2021/9/24 08:20,Biotech,Bavarian Nordic gets government support for COVID booster trial,Bavarian Nordic gets government support for COVID booster trial,"Having missed out on the first vaccination phase, Bavarian Nordic is set to receive up to $126 million muscle in on the booster market.",https://www.fiercebiotech.com/biotech/vaccine-boost-bavarian-nordic-gets-government-support-to-join-second-wave-covid-19-jabs
455,,,2021/9/24 08:10,Biotech,Kids suffer serious adverse reactions in AGTC gene therapy trial,Kids suffer serious adverse reactions in AGTC gene therapy trial,Sixty percent of subjects in the small high-dose cohort had suspected unexpected serious adverse reactions after being treated for an eye disease.,https://www.fiercebiotech.com/biotech/kids-suffer-serious-adverse-reactions-agtc-gene-therapy-trial
456,,,2021/9/24 07:00,Biotech,Capricor finds efficacy in older Duchenne patients in phase 2,Capricor finds efficacy in older Duchenne patients in phase 2,Capricor Therapeutics’ Duchenne muscular dystrophy therapy appears to have slowed disease progression in older boys and young men.,https://www.fiercebiotech.com/biotech/capricor-s-cap-1002-duchenne-muscular-dystrophy-phase-2-hope-2-results
457,,,2021/9/24 18:20,MedCity,Cerner joins $135M funding round for Elligo Health Research ,Cerner joins $135M funding round for Elligo Health Research ,"Elligo Health Research uses EHR data, technology and services to expand patient access to clinical trials. It will use the new funds to further invest in its technology platform and purchase research practice management company ClinEdge. ",https://medcitynews.com/2021/09/cerner-joins-135m-funding-round-for-elligo-health-research/
458,,,2021/9/24 16:39,MedCity,"HHS rule bolsters health equity, Brooks-LaSure tells state rulemakers","HHS rule bolsters health equity, Brooks-LaSure tells state rulemakers","New healthcare marketplace policies seek to make the ACA more equitable by investing in low-income and underinsured communities, changing the rules in ways that upset some insurers but delight many state and consumer health advocates.",https://medcitynews.com/2021/09/hhs-rule-bolsters-health-equity-brooks-lasure-tells-state-rulemakers/
459,,,2021/9/24 16:37,MedCity,Retail pharmacies: The key to making clinical trials accessible for everybody?,Retail pharmacies: The key to making clinical trials accessible for everybody?,"Covid-19, if nothing else, has forced the hands of the clinical research community and we have discovered the possibilities for taking giant leaps forward in healthcare by leveraging modern technologies, existing retail infrastructure, and one another.",https://medcitynews.com/2021/09/retail-pharmacies-the-key-to-making-clinical-trials-accessible-for-everybody/
460,,,2021/9/24 16:21,MedCity,Life sciences use of digital twins mirrors its application in other industries,Life sciences use of digital twins mirrors its application in other industries,Life sciences companies are using “digital twins” for everything from drug discovery to manufacturing. A panel of experts at MedCity News’ INVEST Digital Health conference discussed how this capability to run virtual simulations is changing practices now while also shaping the industry for the years to come.,https://medcitynews.com/2021/09/life-sciences-use-of-digital-twins-mirrors-its-application-in-other-industries/
461,,,2021/9/24 16:18,MedCity,Express Scripts takes a crack at vaccine passports,Express Scripts takes a crack at vaccine passports,The company is rolling out an app for users to show proof of vaccination using a QR code. It can automatically pull in vaccine records for people whose health plans use Express Scripts and who got vaccinated at a pharmacy.,https://medcitynews.com/2021/09/express-scripts-takes-a-crack-at-vaccine-passports/
462,,,2021/9/24 15:57,Biotech,Cue Health makes Nasdaq debut with $200M IPO,Cue Health makes Nasdaq debut with $200M IPO,"Right on cue, another diagnostics-focused startup has made the transition to a public company.",https://www.fiercebiotech.com/medtech/cue-health-kicks-off-200m-ipo-to-expand-its-portable-diagnostics-beyond-covid-19
463,,,2021/9/24 12:16,Biotech,FDA stamps Class I label on Cordis angiographic catheter recall,FDA stamps Class I label on Cordis angiographic catheter recall,"A total of 25,000 devices distributed between January 2019 and July 20 of this year are included in the recall.",https://www.fiercebiotech.com/medtech/cordis-issues-class-i-recall-angiographic-catheters-could-leave-metal-pieces-arteries
464,,,2021/9/24 11:37,Biotech,CytoDyn's shareholders have a plan to get leronlimab approved,CytoDyn's shareholders have a plan to get leronlimab approved,"After weeks of very public infighting at CytoDyn, a stockholder group has come forward with a plan to get leronlimab approved in a cancer indication.",https://www.fiercebiotech.com/biotech/cytodyn-leronlimab-shareholder-proposal-for-combination-therapy-partnership-big-pharma
465,,,2021/9/24 11:14,Biotech,Brooklyn ImmunoTherapeutics snags Roivant CMO for same post,Brooklyn ImmunoTherapeutics snags Roivant CMO for same post,"After a yearlong stint at Roivant Sciences, Roger Sidhu, M.D., has left for the CMO post at cell and gene therapy bio Brooklyn ImmunoTherapeutics.",https://www.fiercebiotech.com/biotech/brooklyn-immunotherapeutics-snags-roivant-sciences-cmo-to-lead-same-post
466,,,2021/9/24 10:55,Biotech,"AI improves breast cancer diagnoses by 37%, NYU study finds","AI improves breast cancer diagnoses by 37%, NYU study finds",A group of physicians achieved an average accuracy of 92% when they reviewed more than 600 breast exams—a number that jumped to 96% aided by the AI.,https://www.fiercebiotech.com/medtech/ultrasound-analyzing-ai-improves-breast-cancer-diagnoses-by-37-nyu-study-finds
467,,,2021/9/23 08:45,Biotech,Solid Bio hopes a shred of positive DMD data will spark a rally,Solid Bio hopes a shred of positive DMD data will spark a rally,Solid Bio will present new biopsy results today for three patients who received the troubled gene therapy SGT-001.,https://www.fiercebiotech.com/biotech/solid-bio-new-data-duchenne-muscular-dystrophy-gene-therapy-sgt-001-clinical-hold
468,,,2021/9/23 08:00,Biotech,Garuda bags $72M to advance off-the-shelf stem cell transplants,Garuda bags $72M to advance off-the-shelf stem cell transplants,Garuda wants to treat more than 70 diseases by ending the need for healthcare providers to find matched donor materials or use a patient’s own cells.,https://www.fiercebiotech.com/biotech/garuda-thinks-it-has-cracked-code-to-off-shelf-stem-cell-transplants-and-investors-are
469,,,2021/9/23 07:50,Biotech,AstraZeneca allies with startup to test spin on red-hot modality,AstraZeneca allies with startup to test spin on red-hot modality,AstraZeneca has teamed up with a new British startup that has put a twist on the idea of using nucleic acids to trigger production of a molecule.,https://www.fiercebiotech.com/biotech/astrazeneca-makes-rna-play-teaming-up-startup-to-advance-twist-red-hot-modality
470,,,2021/9/23 07:30,MedCity,Digital: Healthcare’s co-pilot in delivering consumer-oriented care,Digital: Healthcare’s co-pilot in delivering consumer-oriented care,"With other industries digitizing their business processes and providing top-notch consumer experience, the healthcare industry is under pressure to improve its consumer experience. ",https://medcitynews.com/2021/09/digital-healthcares-co-pilot-in-delivering-consumer-oriented-care/
471,,,2021/9/23 05:00,MedCity,"FDA authorizes Pfizer Covid-19 vaccine booster shots, but only for certain groups","FDA authorizes Pfizer Covid-19 vaccine booster shots, but only for certain groups","The FDA has authorized dosing of booster shots of Pfizer and BioNTech’s Covid-19 vaccine. Consistent with the recommendations of an FDA advisory committee, the agency’s amendment to the emergency authorization covers only certain groups at high risk of infection and complications from the virus.",https://medcitynews.com/2021/09/fda-authorizes-pfizer-covid-19-vaccine-booster-shots-but-only-for-certain-groups/
472,,,2021/9/23 15:25,Biotech,NIH vouches for new kidney disease diagnostic not based on race,NIH vouches for new kidney disease diagnostic not based on race,"Following a 1999 study that found, on average, higher levels of creatinine in Black patients, race has been factored into kidney function estimates.",https://www.fiercebiotech.com/medtech/nih-vouches-for-new-kidney-disease-diagnostic-doesn-t-rely-faulty-race-based-calculations
473,,,2021/9/23 14:00,Biotech,Repairing heart damage by transiently turning back the clock,Repairing heart damage by transiently turning back the clock,A Max Planck team proposed that selectively expressing four heart-specific genes could return adult cardiomyocytes to a fetal state.,https://www.fiercebiotech.com/research/transiently-turning-back-clock-adult-heart-cells-to-repair-damage
474,,,2021/9/23 13:39,MedCity,Choosing the best health cloud for your digital transformation priorities,Choosing the best health cloud for your digital transformation priorities,"As healthcare organizations make progress on their way to the digital transformation of healthcare, choosing a health cloud vendor to support and enable that work should not be taken lightly. ",https://medcitynews.com/2021/09/choosing-the-best-health-cloud-for-your-digital-transformation-priorities/
475,,,2021/9/23 12:31,Biotech,Esker Therapeutics snags former Principia CEO in hiring spree,Esker Therapeutics snags former Principia CEO in hiring spree,"He led Principia to a $3.7 billion exit to Sanofi last August. Now, Martin Babler takes the reins at Esker Therapeutics alongside 7 other new leaders.",https://www.fiercebiotech.com/biotech/esker-therapeutics-goes-hiring-spree-snagging-former-principia-ceo-seven-other-leaders
476,,,2021/9/23 11:54,Biotech,Lucid Diagnostics files for $58M IPO to leave the PAVmed nest,Lucid Diagnostics files for $58M IPO to leave the PAVmed nest,"Months after PAVmed said it would spin off Lucid Diagnostics into a public company, the esophageal cancer test-maker’s path forward has become clear.",https://www.fiercebiotech.com/medtech/lucid-diagnostics-prepares-to-leave-pavmed-nest-57m-ipo-filing
477,,,2021/9/23 11:28,Biotech,Eli Lilly-backed GenEdit inks $26M to deliver gene therapies,Eli Lilly-backed GenEdit inks $26M to deliver gene therapies,"GenEdit wants to quash the toxic effects of gene therapy delivery. Now, it has $26 million from Lilly and others to deploy its polymer nanoparticles.",https://www.fiercebiotech.com/biotech/genedit-strikes-eli-lilly-gold-26m-for-gold-nanoparticles-gene-therapy-delivery-system
478,,,2021/9/23 10:23,Biotech,GE drops $1.45B to acquire OR ultrasound provider BK Medical,GE drops $1.45B to acquire OR ultrasound provider BK Medical,"BK Medical provides imaging support during procedures, allowing surgeons to peer inside the body in real time.",https://www.fiercebiotech.com/medtech/ge-healthcare-drops-1-45b-to-acquire-bk-medical-bringing-its-ultrasound-franchise-to-or
479,,,2021/9/23 10:10,Biotech,Automated lab platform Opentrons closes $200M series C,Automated lab platform Opentrons closes $200M series C,The latest round of VC funding will help Opentrons add new robotics and assays to its automated lab platform.,https://www.fiercebiotech.com/medtech/lab-platform-opentrons-closes-200m-series-c-to-build-out-robotics-diagnostics-cell
480,,,2021/9/22 09:30,Biotech,Blocking a 'rogue' inflammatory response during stroke,Blocking a 'rogue' inflammatory response during stroke,Researchers think they've found a way in mice to block an immune pathway that can worsen brain damage after stroke.,https://www.fiercebiotech.com/research/a-protein-blocking-inflammatory-response-improved-stroke-recovery-mice-study-finds
481,,,2021/9/22 08:55,Biotech,Clover's COVID-19 vaccine tames delta in pivotal study,Clover's COVID-19 vaccine tames delta in pivotal study,"The adjuvanted protein vaccine held up against a range of variants in a phase 2/3 trial, teeing Clover up to seek approval this year.",https://www.fiercebiotech.com/biotech/clover-s-covid-19-shot-tames-delta-pivotal-study-delivering-boost-to-global-vaccination
482,,,2021/9/22 07:45,Biotech,FDA objects to Summit's midstudy pooling of pivotal trials,FDA objects to Summit's midstudy pooling of pivotal trials,"Having previously decided to pool subjects in two Clostridium difficile trials, Summit has now revealed the FDA disagrees with its changes.",https://www.fiercebiotech.com/biotech/fda-objects-to-summit-s-midstudy-pooling-pivotal-trials
483,,,2021/9/22 19:40,MedCity,"Google, Microsoft execs: AI should be designed to support, not replace, clinicians","Google, Microsoft execs: AI should be designed to support, not replace, clinicians","As Google and Microsoft compete over their cloud capabilities for healthcare, both companies are touting tools to make clinicians’ lives easier by streamlining documentation or making records searchable.  At MedCity INVEST Digital Health, executives from both companies agreed on one thing: these tools should play a supporting role for clinicians while keeping patients at the center. ",https://medcitynews.com/2021/09/google-microsoft-execs-ai-should-be-designed-to-support-not-replace-clinicians/
484,,,2021/9/22 19:04,MedCity,Spotting and rooting out bias in AI algorithms for healthcare,Spotting and rooting out bias in AI algorithms for healthcare,"Algorithms are everywhere and so are the biases behind them. As algorithms find greater use in healthcare, a panel at MedCity News’ INVEST Digital Health virtual conference addressed how and why algorithms are biased, how that bias affects clinical care, and some possible solutions to bias.",https://medcitynews.com/2021/09/spotting-and-rooting-out-bias-in-ai-algorithms-for-healthcare/
485,,,2021/9/22 18:58,MedCity,Report: 1 in 5 U.S. counties are hospital deserts,Report: 1 in 5 U.S. counties are hospital deserts,"In over 20% of U.S. counties, most people have to drive more than 30 minutes to reach the closest hospital, making them hospital desert areas, according to a recent report. Large swathes of the country are also pharmacy and trauma center deserts. ",https://medcitynews.com/2021/09/report-1-in-5-u-s-counties-are-hospital-deserts/
486,,,2021/9/22 05:00,Biotech,More llama-inspired anti-COVID antibodies could be on the way,More llama-inspired anti-COVID antibodies could be on the way,"British researchers are seeking funding to develop llama-inspired COVID-19 nanobodies, but they could be competing with multiple rivals.",https://www.fiercebiotech.com/research/another-research-group-joins-llama-inspired-covid-19-nanobody-treatment-arena
487,,,2021/9/22 16:05,Biotech,"Castor, Trialbee forge clinical trial enrollment partnership","Castor, Trialbee forge clinical trial enrollment partnership",Castor and Trialbee will integrate their platforms so sponsors can better match patients with clinical trials and increase diversity in studies.,https://www.fiercebiotech.com/cro/castor-trialbee-team-up-for-patient-enrollment-engagement-clinical-trials
488,,,2021/9/22 15:35,Biotech,SAB Biotherapeutics banks $60M more for COVID-19 antibody,SAB Biotherapeutics banks $60M more for COVID-19 antibody,SAB Biotherapeutics has snared another $60.5 million from the U.S. Department of Defense to fund an antibody program to treat COVID-19.,https://www.fiercebiotech.com/biotech/sab-biotherapeutics-banks-60m-more-funding-from-u-s-officials-for-covid-19-antibody
489,,,2021/9/22 15:30,Biotech,"Summit Clinical Research, PathAI partner for NASH trial services","Summit Clinical Research, PathAI partner for NASH trial services",Summit Clinical Research will work with PathAI to support clinical development programs for nonalcoholic fatty liver disease treatments.,https://www.fiercebiotech.com/cro/summit-clinical-research-and-pathai-partner-nash-clinical-trial-services
490,,,2021/9/22 15:29,MedCity,Investors see promise in digital health — the challenge is adoption,Investors see promise in digital health — the challenge is adoption,"VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work. ",https://medcitynews.com/2021/09/investors-see-promise-in-digital-health-the-challenge-is-adoption/
491,,,2021/9/22 15:20,Biotech,Epic success: FDA OKs Abbott's newest replacement mitral valve,Epic success: FDA OKs Abbott's newest replacement mitral valve,"With a green light from the FDA, Abbott is scaling up its replacement mitral and aortic valve portfolio to Epic Plus proportions.",https://www.fiercebiotech.com/medtech/epic-success-fda-approves-abbott-s-upgraded-longer-lasting-replacement-mitral-valve
492,,,2021/9/22 15:14,MedCity,How self-diagnostics can cut healthcare costs and save Lives,How self-diagnostics can cut healthcare costs and save Lives,The call to action is that point-of-care testing needs to move to the home and it needs to be supported by a Medicaid or Medicare billing code to support insurance coverage and payment for the testing.,https://medcitynews.com/2021/09/how-self-diagnostics-can-cut-healthcare-costs-and-save-lives/
493,,,2021/9/22 15:10,Biotech,HealthVerity will supply Janssen with real-world data for R&D,HealthVerity will supply Janssen with real-world data for R&D,HealthVerity will provide Johnson & Johnson's Janssen access to data on 330 million patients in the U.S. to further support clinical trial work.,https://www.fiercebiotech.com/cro/healthverity-partners-j-j-s-janssen-to-provide-real-world-data-for-clinical-trial-r-d-work
494,,,2021/9/22 15:01,MedCity,CMS grants quality reporting exceptions for facilities recovering from Hurricane Ida,CMS grants quality reporting exceptions for facilities recovering from Hurricane Ida,"The agency has granted certain Medicare quality reporting exceptions to healthcare facilities in areas of Louisiana, Mississippi, New York and New Jersey that were battered by Hurricane Ida. By providing the exceptions, CMS aims to enable facilities to direct their resources toward recovery. ",https://medcitynews.com/2021/09/cms-grants-quality-reporting-exceptions-for-facilities-recovering-from-hurricane-ida/
495,,,2021/9/22 15:00,Biotech,Velocity Clinical Research snags 11 sites through 2 acquisitions,Velocity Clinical Research snags 11 sites through 2 acquisitions,"After its own buyout in April, Velocity Clinical Research has now inked two deals for 11 trial sites in South Carolina and California.",https://www.fiercebiotech.com/cro/velocity-clinical-research-acquires-11-sites-through-two-companies-after-april-buyout
496,,,2021/9/22 12:17,Biotech,"Know Labs unveils noninvasive, pocket-sized glucose monitor","Know Labs unveils noninvasive, pocket-sized glucose monitor",In vitro tests have found that the radiofrequency sensor technology measured glucose levels with accuracy comparable to Abbott’s Freestyle Libre CGM.,https://www.fiercebiotech.com/medtech/know-labs-unveils-pocket-sized-glucose-monitor-swaps-fingersticks-for-radiofrequency
497,,,2021/9/22 11:59,Biotech,FDA clears Paige's AI as first program to spot prostate cancer,FDA clears Paige's AI as first program to spot prostate cancer,The software highlights areas of a standard prostate biopsy image most likely to contain cancer and flags them for further review.,https://www.fiercebiotech.com/medtech/fda-clears-paige-s-ai-as-first-program-to-spot-prostate-cancer-amid-tissue-slides
498,,,2021/9/22 11:24,Biotech,Cassava drops interim Alzheimer's data with plenty of caveats,Cassava drops interim Alzheimer's data with plenty of caveats,Cassava Sciences is hoping some interim results will soothe worried investors after the company was accused of manipulating data.,https://www.fiercebiotech.com/biotech/cassava-drops-interim-alzheimer-s-data-plenty-caveats
499,,,2021/9/22 10:31,Biotech,Hexagon nabs $61M for fungi-derived treatments for cancer,Hexagon nabs $61M for fungi-derived treatments for cancer,"Hexagon Bio snags $61 million to bankroll drug discovery, preclinical work on the microbial genome for treating cancer and infectious diseases.",https://www.fiercebiotech.com/biotech/fungi-funding-hexagon-bio-snags-61m-to-test-drugs-from-fungi-for-cancer-infectious-diseases
500,,,2021/9/22 10:25,Biotech,ESMO: Owkin's deep learning AI predicts breast cancer relapse,ESMO: Owkin's deep learning AI predicts breast cancer relapse,"To speed up the race to a 100% survival rate, Owkin's AI model can classify the five-year relapse risk of a patient with early-stage breast cancer.",https://www.fiercebiotech.com/medtech/esmo-owkin-s-deep-learning-ai-predicts-chances-metastatic-breast-cancer-relapse-within-next
501,,,2021/9/22 10:10,Biotech,Striking deals with Blueprint COO Haviland,Striking deals with Blueprint COO Haviland,"Financials are obviously important, but there's more to biotech dealmaking than the cash, according to Blueprint Medicines COO Kate Haviland.",https://www.fiercebiotech.com/biotech/striking-deals-blueprint-coo-kate-haviland
502,,,2021/9/22 10:05,Biotech,Luxturna inventor launches new gene therapy biotech with $19M,Luxturna inventor launches new gene therapy biotech with $19M,"Jean Bennett, inventor of gene therapy Luxturna, is behind another eye gene therapy biotech, Opus Genetics, which now has $19 million for the clinic.",https://www.fiercebiotech.com/biotech/luxturna-inventor-behind-new-eye-gene-therapy-biotech-opus-genetics-snags-19m
503,,,2021/9/21 09:50,Biotech,iPhones may soon automatically assess mental health: report,iPhones may soon automatically assess mental health: report,"Soon, the iPhone may automatically detect mental health issues like depression and cognitive decline—using daily activity data it already collects.",https://www.fiercebiotech.com/medtech/apple-taps-biogen-ucla-to-explore-addition-mental-health-tracking-to-iphone-report
504,,,2021/9/21 09:26,Biotech,Boehringer Ingelheim acquires Abexxa for immuno-oncology assets,Boehringer Ingelheim acquires Abexxa for immuno-oncology assets,"Boehringer Ingelheim seeded Texas biotech Abexxa Biologics in 2016. Now, the German Big Pharma is acquiring the biotech.",https://www.fiercebiotech.com/biotech/boehringer-ingelheim-acquires-abexxa-biologics-for-precision-cancer-drug-pipeline
505,,,2021/9/21 09:00,MedCity,Engaging communities of color is crucial to achieving health equity and cultural proficiency in healthcare,Engaging communities of color is crucial to achieving health equity and cultural proficiency in healthcare,"Reaching out to and connecting with communities of color is a moral imperative.  It’s a business imperative. For the healthcare system, it is no longer an option in an increasingly multicultural society.",https://medcitynews.com/2021/09/engaging-communities-of-color-is-crucial-to-achieving-health-equity-and-cultural-proficiency-in-healthcare/
506,,,2021/9/21 08:20,Biotech,Aerie CEO exits days after downplaying midphase eye disease flop,Aerie CEO exits days after downplaying midphase eye disease flop,"Aerie CEO Vicente Anido has left the company, leaving an interim leader to pursue what he claimed was “a clear path toward approval.”",https://www.fiercebiotech.com/biotech/aerie-ceo-exits-days-after-downplaying-midphase-eye-disease-flop
507,,,2021/9/21 08:00,Biotech,"Oncology, RNA biotech 858 Therapeutics inks $60M series A","Oncology, RNA biotech 858 Therapeutics inks $60M series A",The team behind Quanticel and Jecure is ready for its next venture: launching RNA biotech 858 Therapeutics with a $60 million series A fundraising.,https://www.fiercebiotech.com/biotech/vc-versant-backed-biotech-858-therapeutics-to-develop-oncology-therapeutics-60m-series-a
508,,,2021/9/21 07:45,Biotech,BioMed bets $1.2B to ease U.K. life science capacity crunch,BioMed bets $1.2B to ease U.K. life science capacity crunch,"BioMed is already a major force in the U.K. life sciences property game, with AstraZeneca and Illumina among the companies to occupy its sites.",https://www.fiercebiotech.com/biotech/biomed-bets-1-2b-to-ease-u-k-life-science-capacity-crunch
509,,,2021/9/21 06:30,Biotech,Novartis veteran Barth takes the helm at MiroBio,Novartis veteran Barth takes the helm at MiroBio,"As MiroBio gears up for its first clinical trial, the autoimmune biotech is getting a new CEO: Carolin Barth, M.D.",https://www.fiercebiotech.com/biotech/novartis-veteran-barth-takes-helm-at-autoimmune-biotech-mirobio
510,,,2021/9/21 16:01,Biotech,European watchdog delivers ultimatum to Illumina over Grail deal,European watchdog delivers ultimatum to Illumina over Grail deal,The commission described its actions as an unprecedented step in response to the companies’ defiant move to proceed last month.,https://www.fiercebiotech.com/medtech/european-antitrust-regulators-deliver-ultimatum-to-illumina-over-8b-grail-deal
511,,,2021/9/21 15:30,Biotech,"Abbott's Alinity COVID tests may give false positives, FDA says","Abbott's Alinity COVID tests may give false positives, FDA says",The FDA suggested labs and healthcare providers retest anyone who has recently tested positive with either of the affected assays.,https://www.fiercebiotech.com/medtech/fda-warns-abbott-alinity-pcr-covid-test-results-may-only-be-presumptive-due-to-risk-false
512,,,2021/9/21 01:15,Biotech,Novartis adds 2nd biotech to optogenetics gene therapy portfolio,Novartis adds 2nd biotech to optogenetics gene therapy portfolio,Novartis already bought into optogenetic gene therapy technology last year but will add Arctos Medical to dig deeper into the space.,https://www.fiercebiotech.com/biotech/novartis-optogenetics-arctor-vedere-gene-therapy-eye-disease-blindness
513,,,2021/9/21 12:41,Biotech,Boston Scientific offers up $336M to devour Devoro Medical,Boston Scientific offers up $336M to devour Devoro Medical,"The deal will see Boston Scientific put down about $269 million up front to acquire Devoro, in which it has been a strategic investor since 2019.",https://www.fiercebiotech.com/medtech/boston-scientific-offers-up-336m-to-devour-devoro-medical-and-its-blood-clot-removal-tech
514,,,2021/9/21 12:37,MedCity,"Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer","Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer","The Seagen and Genmab antibody drug conjugate (ADC), named Tivdak, is approved to treat cases of cervical cancer that have returned or spread following treatment with chemotherapy. Tivdak is Seagen’s third ADC; for Genmab, the drug will become its first commercialized product.",https://medcitynews.com/2021/09/seagen-genmab-antibody-drug-conjugate-gets-fda-approval-in-cervical-cancer/
515,,,2021/9/21 12:14,MedCity,How Inheret drives early detection for genetic cancers with its guidelines-based tool,How Inheret drives early detection for genetic cancers with its guidelines-based tool,Inheret CEO and Founder Dr. David F. Keren talks about the origins of the cancer risk detection platform and his mission to identify hereditary diseases early.,https://medcitynews.com/2021/09/inheret-drives-early-detection-for-genetic-cancers/
516,,,2021/9/21 11:10,MedCity,The decision support toolbox to help healthcare providers manage care capacity,The decision support toolbox to help healthcare providers manage care capacity,A look at how SAP’s cloud services are helping healthcare providers respond to public health crisis.,https://medcitynews.com/2021/09/the-decision-support-toolbox-to-help-healthcare-providers-manage-care-capacity/
517,,,2021/9/20 21:35,MedCity,Consumerism is driving a bold new vision for home healthcare,Consumerism is driving a bold new vision for home healthcare,"Consumers want the healthcare industry to meet them where they are, and this shift in patient mindset has expanded the definition of home healthcare and who benefits from it, according to a panel at MedCity INVEST Digital Health conference. ",https://medcitynews.com/2021/09/consumerism-is-driving-a-bold-new-vision-for-home-healthcare/
518,,,2021/9/20 19:03,MedCity,Health apps could face big fines if they don’t disclose privacy breaches ,Health apps could face big fines if they don’t disclose privacy breaches ,"The agency reminded health apps and wearables companies that they must disclose any breach of users’ health information, even if they are not a HIPAA covered entity. Companies that fail to disclose a breach could face thousands of dollars per day in fines.",https://medcitynews.com/2021/09/health-apps-could-face-big-fines-if-they-dont-disclose-privacy-breaches/
519,,,2021/9/20 17:01,MedCity,MySugr founder launches new startup focused on diabetes care,MySugr founder launches new startup focused on diabetes care,"Frank Westermann sold his previous startup, mySugr, to Roche four years ago. Now, he’s starting a new company with the goal of making healthcare providers and diabetes medications more accessible. ",https://medcitynews.com/2021/09/mysugr-founder-launches-new-startup-focused-on-diabetes-care/
520,,,2021/9/20 16:25,MedCity,Biogen and Samsung land FDA approval for biosimilar to blockbuster Roche drug,Biogen and Samsung land FDA approval for biosimilar to blockbuster Roche drug,The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic product have approval to treat three eye conditions that lead to vision loss.,https://medcitynews.com/2021/09/biogen-and-samsung-land-fda-approval-for-biosimilar-to-blockbuster-roche-drug/
521,,,2021/9/20 15:55,Biotech,Abbott joins TAVR market with FDA approval for its Portico valve,Abbott joins TAVR market with FDA approval for its Portico valve,"Previously available in Europe, the Portico valve is designed for severely narrowed aortic heart valves where open-heart surgery may be too risky.",https://www.fiercebiotech.com/medtech/abbott-joins-tavr-market-fda-approval-for-its-portico-heart-valve
522,,,2021/9/20 14:59,MedCity,"Study: Resilience, emotional support key to helping healthcare workers fight stress","Study: Resilience, emotional support key to helping healthcare workers fight stress","Along with daily surveys, a research team from Mount Sinai used Apple Watches to measure how stress impacted healthcare workers’ bodies and pinpointed the characteristics that were associated with lower stress levels over time. ",https://medcitynews.com/2021/09/study-resilience-emotional-support-key-to-helping-healthcare-workers-fight-stress/
523,,,2021/9/20 14:07,Biotech,Medtronic recalls brain aneurysm-blocking Pipeline Flex implant,Medtronic recalls brain aneurysm-blocking Pipeline Flex implant,"Two deaths have been linked to the recall so far, according to the FDA, in addition to 10 serious injuries and 59 reports of device malfunction.",https://www.fiercebiotech.com/medtech/medtronic-recalls-brain-aneurysm-blocking-implant-due-to-potential-breakages-during
524,,,2021/9/20 12:02,Biotech,Illumina Ventures closes $325M genomic startup fund,Illumina Ventures closes $325M genomic startup fund,"The proceeds will be used to support genomics-focused, early-stage startups looking to build new clinical diagnostics and life science research tools.",https://www.fiercebiotech.com/medtech/illumina-ventures-more-than-doubles-its-capital-new-325m-fund
525,,,2021/9/20 11:41,Biotech,"J&J, Mauna Kea launch study of lung cancer biopsy tool","J&J, Mauna Kea launch study of lung cancer biopsy tool","No longer will surgeons be flying blind while biopsying peripheral lung nodules—at least, not if Mauna Kea and J&J have anything to say about it.",https://www.fiercebiotech.com/medtech/johnson-johnson-mauna-kea-launch-study-lung-cancer-biopsy-guidance-tool
526,,,2021/9/20 11:30,Biotech,Syros targets KRAS-mutant cancer with CDK7 inhibitor,Syros targets KRAS-mutant cancer with CDK7 inhibitor,The combination of SY-5609 and gemcitabine showed near-complete tumor inhibition in mice with xenografts of KRAS-G12D pancreatic tumors.,https://www.fiercebiotech.com/research/syros-targets-kras-mutant-cancer-as-cdk7-inhibitor-shows-early-promise
527,,,2021/9/19 09:47,Biotech,ESMO: Mirati pulls away from Amgen in colorectal cancer,ESMO: Mirati pulls away from Amgen in colorectal cancer,"The data put Mirati over the bars it said it needs to clear to potentially seek accelerated approval in colorectal cancer, albeit only by a whisker.",https://www.fiercebiotech.com/biotech/esmo-mirati-pulls-away-from-amgen-colorectal-cancer-updated-data-kras-drug
528,,,2021/9/19 08:12,MedCity,Cala hopes real-world data on essential tremor device will win over payers,Cala hopes real-world data on essential tremor device will win over payers,"The startup, which has a cleared device to reduce tremors using electrical stimulation, recently shared the results of a post-market analysis showing device use and efficacy. ",https://medcitynews.com/2021/09/cala-hopes-real-world-data-on-essential-tremor-device-will-win-over-payers/
529,,,2021/9/17 09:55,Biotech,Medtronic expands Type 1 diabetes reach with infusion tech buy,Medtronic expands Type 1 diabetes reach with infusion tech buy,Medtronic and the Mann Foundation will work together to further develop the technology into a new type of implantable insulin pump.,https://www.fiercebiotech.com/medtech/medtronic-buys-implanted-infusion-pump-tech-to-develop-new-type-1-diabetes-treatment
530,,,2021/9/17 09:30,Biotech,AltruBio snags new CMO with pivot to immunology—Chutes & Ladders,AltruBio snags new CMO with pivot to immunology—Chutes & Ladders,"AltruBio secures new CMO with Sublimity, Ardea, Amgen experience. Walking Fish Therapeutics snags former Five Prime founder. ViaCyte fills CSO spot.",https://www.fiercebiotech.com/biotech/chutes-ladders-altrubio-snags-new-cmo-resume-at-sublimity-ardea-amgen-and-abbott
531,,,2021/9/17 08:52,Biotech,FDA hits pause on Protagonist's blood cancer med,FDA hits pause on Protagonist's blood cancer med,"Protagonist's treatment for a rare, slow-growing blood cancer is under an FDA clinical hold after mice developed skin tumors in a nonclinical study.",https://www.fiercebiotech.com/biotech/fda-hits-pause-protagonist-s-blood-cancer-med-after-mouse-study-turns-up-skin-tumors
532,,,2021/9/17 08:40,Biotech,AstraZeneca taps Dana-Farber's Rahma to lead its GI work,AstraZeneca taps Dana-Farber's Rahma to lead its GI work,AstraZeneca is following suit of many other pharmas and tapping academic and cancer organizations to fill out its oncology research team.,https://www.fiercebiotech.com/biotech/astrazeneca-taps-dana-farber-s-osama-rahma-to-lead-its-gi-oncology-work
533,,,2021/9/17 08:30,Biotech,Elevian snags $40M for stroke recovery trials in early 2023,Elevian snags $40M for stroke recovery trials in early 2023,"Elevian raises $40 million to work on medicines for age-related diseases, including completing phase 1 trials for stroke recovery in early 2023.",https://www.fiercebiotech.com/biotech/elevian-secures-40-million-for-stroke-recovery-and-age-related-diseases
534,,,2021/9/17 08:18,MedCity,"Brain data startup Rune Labs reveals $23M, plans to rev up neuro drug R&D","Brain data startup Rune Labs reveals $23M, plans to rev up neuro drug R&D","Rune Labs developed software that aggregates brain data, providing insights for clinical care and clinical research. Health systems are starting to adopt the technology, and the startup has now raised $22.8 million to grow that part of the business while also expanding use of the technology in drug development.",https://medcitynews.com/2021/09/brain-data-startup-rune-labs-reveals-23m-plans-to-rev-up-neuro-drug-rd/
535,,,2021/9/17 20:15,MedCity,FDA panel backs booster shots in high-risk groups after rejecting broader proposal,FDA panel backs booster shots in high-risk groups after rejecting broader proposal,"An FDA advisory panel voted down a proposal for booster shots of the Pfizer/BioNTech Covid-19 in the general population, opting instead to support third shots in certain high-risk groups, such as the elderly. Panelists want to see more information supporting the need for a booster, as well as data about a heart safety risk the vaccine may pose to young males.",https://medcitynews.com/2021/09/fda-panel-backs-booster-shots-in-high-risk-groups-after-rejecting-broader-proposal/
536,,,2021/9/17 07:30,Biotech,ESMO: Daiichi unveils first early peek at next-gen ADC,ESMO: Daiichi unveils first early peek at next-gen ADC,"Early Friday morning at the European Society of Medical Oncology Congress, we got a glimpse of its fourth ADC, known simply as DS-7300.",https://www.fiercebiotech.com/biotech/esmo-daiichi-unveils-first-early-peek-at-next-gen-adc-as-analysts-see-strong-dataset
537,,,2021/9/17 16:58,MedCity,"Abbott seeks expanded indication, national coverage for CardioMEMS device","Abbott seeks expanded indication, national coverage for CardioMEMS device","With the results of a recent trial, Abbott is seeking an expanded indication from the FDA for its CardioMEMS device, intended to prevent hospitalizations in patients with heart failure.  It’s also hoping to win over national coverage from CMS. ",https://medcitynews.com/2021/09/abbott-seeks-expanded-indication-national-coverage-for-cardiomems-device/
538,,,2021/9/17 14:04,MedCity,CareFirst unveils virtual-first primary care practice,CareFirst unveils virtual-first primary care practice,"The practice, which initially will only be offered to CareFirst BCBS commercial members, provides an array of services, including preventive care, insurance navigation and behavioral and mental health services. Patients will be referred to in-person care with local providers when needed. ",https://medcitynews.com/2021/09/carefirst-unveils-virtual-first-primary-care-practice/
539,,,2021/9/17 14:00,Biotech,Bats' immunity could lead to new treatment options for COVID-19,Bats' immunity could lead to new treatment options for COVID-19,"Bats' ability to fight coronaviruses can be traced to reduced inflammasome signaling, suggesting new strategies for fighting COVID-19, a study said.",https://www.fiercebiotech.com/research/bats-immunity-could-point-to-new-therapeutic-approaches-for-fighting-covid-19
540,,,2021/9/17 11:30,Biotech,Gynesonics nabs FDA OK for uterine fibroid ablation system,Gynesonics nabs FDA OK for uterine fibroid ablation system,The newly cleared version of Gynesonics’ platform can perform ablations 20% smaller than previous iterations.,https://www.fiercebiotech.com/medtech/gynesonics-nabs-fda-clearance-for-updated-ultrasound-powered-ablation-system-to-shrink
541,,,2021/9/17 10:45,Biotech,Hong Kong COVID tester Prenetics sets up $1.7B SPAC deal,Hong Kong COVID tester Prenetics sets up $1.7B SPAC deal,The proceeds will fund Prenetics' global expansion as well as an acquisition strategy aimed at growing its U.S. footprint.,https://www.fiercebiotech.com/medtech/hong-kong-covid-tester-prenetics-sets-up-1-7b-spac-deal
542,,,2021/9/17 10:31,Biotech,Pyxis names ADC Therapeutics vet as CMO,Pyxis names ADC Therapeutics vet as CMO,Industry veteran Jay Feingold will join Pyxis Oncology to lead clinical development of next-gen antibody-drug conjugates.,https://www.fiercebiotech.com/biotech/pyxis-oncology-names-new-chief-medical-officer-to-lead-cancer-adcs-development
543,,,2021/9/17 10:20,Biotech,Everest inks $561M biobucks deal for renal disease treatment,Everest inks $561M biobucks deal for renal disease treatment,Everest Medicines bought into the COVID-19 vaccine and mRNA space earlier this week and will now add a $561 million biobucks deal in renal diseases.,https://www.fiercebiotech.com/biotech/everest-inks-second-deal-week-will-pay-up-to-561m-for-sinovent-sinomab-for-renal-diseases
544,,,2021/9/17 10:10,Biotech,Excision's HIV CRISPR therapy cleared for human studies by FDA,Excision's HIV CRISPR therapy cleared for human studies by FDA,A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing.,https://www.fiercebiotech.com/biotech/excision-hiv-crispr-gene-editing-therapy-cleared-for-human-studies-by-fda
545,,,2021/9/16 09:55,Biotech,Biogen's non-opioid painkiller offers mixed results in phase 2,Biogen's non-opioid painkiller offers mixed results in phase 2,Biogen’s non-opioid pain therapy vixotrigine did not reduce average daily pain as intended during a midstage study.,https://www.fiercebiotech.com/biotech/biogen-s-vixotrigine-fails-phase-2-small-fiber-neuropathy-trial
546,,,2021/9/16 08:50,Biotech,ESMO: Zymeworks lays down marker in fight to unseat Herceptin,ESMO: Zymeworks lays down marker in fight to unseat Herceptin,Zymeworks presented encouraging early data on its HER2‑targeted bispecific antibody—and a showdown with the incumbent Herceptin is up next. ,https://www.fiercebiotech.com/biotech/esmo-zymeworks-lays-down-marker-fight-to-unseat-herceptin
547,,,2021/9/16 18:47,MedCity,"Intermountain Healthcare, SCL Health to merge, creating $14B system","Intermountain Healthcare, SCL Health to merge, creating $14B system","If the merger is approved, the combined health system will operate 33 hospitals and 385 clinics across six states. The merger also represents the joining together of a faith-based organization, SCL Health, and a secular entity, Intermountain. ",https://medcitynews.com/2021/09/intermountain-healthcare-scl-health-to-merge-creating-14b-system/
548,,,2021/9/16 18:42,MedCity,"Racism, sexism and now fraud: Lawsuits pile up at New Jersey ‘AI’ firm","Racism, sexism and now fraud: Lawsuits pile up at New Jersey ‘AI’ firm","A previous investigation by MedCity News found that ElectrifAi was touting an improperly-developed algorithm during the earliest phase of the Covid-19 pandemic, with both the company and CEO defendants in an employment discrimination lawsuit. A year later, lawsuits are piling up as more former employees complain that the company and CEO lied about its AI capabilities and business. ",https://medcitynews.com/2021/09/racism-sexism-and-now-fraud-lawsuits-pile-up-at-new-jersey-ai-firm/
549,,,2021/9/16 18:05,Biotech,"Novartis links cancer drug to improved pain, quality of life","Novartis links cancer drug to improved pain, quality of life","With positive phase 3 primary endpoint data in the bag, Novartis arrived at the ESMO Congress 2021 armed with quality of life and pain data.",https://www.fiercebiotech.com/biotech/esmo-novartis-links-prostate-cancer-drug-to-improved-pain-quality-life-as-regulatory
550,,,2021/9/16 17:37,MedCity,Behavioral health startup Spring Health valued at $2B ,Behavioral health startup Spring Health valued at $2B ,"The company, which offers mental health solutions for employers and health plans, recently closed a $190 million series C round, that included both equity and debt. It also brought on Guardian Life as a strategic investor.",https://medcitynews.com/2021/09/behavioral-health-startup-spring-health-valued-at-2b/
551,,,2021/9/16 14:00,Biotech,The immune connection between mutated genes and cancer,The immune connection between mutated genes and cancer,"More than 100 mutated cancer-suppressor genes work by blocking the immune system from recognizing and destroying tumors, a new study reveals.",https://www.fiercebiotech.com/research/how-do-faulty-genes-drive-cancer-there-s-a-surprising-immune-connection-study-finds
552,,,2021/9/16 13:12,Biotech,First witnesses in Holmes trial outline Theranos' corner-cutting,First witnesses in Holmes trial outline Theranos' corner-cutting,"The first two witnesses took the stand in former Theranos CEO Elizabeth Holmes’ federal fraud trial, both ex-employees of the blood-testing startup.",https://www.fiercebiotech.com/medtech/first-witnesses-elizabeth-holmes-fraud-trial-say-theranos-manipulated-lab-data-inflated
553,,,2021/9/16 13:05,Biotech,"FDA names CIO, shuffles IT, cybersecurity work into new office","FDA names CIO, shuffles IT, cybersecurity work into new office","The FDA has reorganized and elevated its IT, data and cybersecurity efforts into a single, new office that will report directly to the commissioner.",https://www.fiercebiotech.com/medtech/fda-appoints-cio-reorganizes-it-cybersecurity-efforts-into-single-digital-office
554,,,2021/9/16 11:41,Biotech,Vifor doles out $55M upfront to license Travere's asset,Vifor doles out $55M upfront to license Travere's asset,"FDA asked Travere for more data on its kidney drug in May, and now the biotech has a licensing agreement with Vifor worth up to $190 million.",https://www.fiercebiotech.com/biotech/vifor-doles-out-55m-upfront-to-license-travere-s-late-stage-kidney-asset-slated-for
555,,,2021/9/16 10:50,Biotech,FDA clears trial for Intellia's ex vivo cancer candidate,FDA clears trial for Intellia's ex vivo cancer candidate,Intellia can now move forward with early human testing of NTLA-5001 after the FDA cleared an early stage clinical trial.,https://www.fiercebiotech.com/biotech/intellia-ex-vivo-gene-editing-cancer-treatment-ntla-5001-trial-cleared-by-fda
556,,,2021/9/16 10:25,Biotech,"Oxford Nanopore, Oracle form genomic sequencing partnership","Oxford Nanopore, Oracle form genomic sequencing partnership","A week after announcing its intent to debut on the London Stock Exchange, Oxford Nanopore has found an investor to snap up half the shares on offer.",https://www.fiercebiotech.com/medtech/oxford-nanopore-scores-ps150m-investment-genomic-sequencing-cloud-support-from-oracle
557,,,2021/9/16 10:22,Biotech,"China's IASO nets $108M to advance cell therapies, antibodies","China's IASO nets $108M to advance cell therapies, antibodies",IASO Biotherapeutics bagged $108 million to fuel a teeming pipeline of cell therapies and antibodies for cancer and autoimmune disease.,https://www.fiercebiotech.com/biotech/china-s-iaso-nets-108m-to-advance-cell-therapies-antibodies-for-cancer-autoimmune-disease
558,,,2021/9/16 10:15,Biotech,Novo-backed Amolyt Pharma snags $80M for endocrine pipeline,Novo-backed Amolyt Pharma snags $80M for endocrine pipeline,"Amolyt Pharma snags $80 million series B from Novo Holdings and venture groups to advance three programs, including a PeptiDream-licensed asset.",https://www.fiercebiotech.com/biotech/novo-backed-amolyt-pharma-snags-80m-series-b-for-endocrine-pipeline
559,,,2021/9/15 13:49,MedCity,Analysis: Cost of care for unvaccinated Covid patients spikes to $5.7B,Analysis: Cost of care for unvaccinated Covid patients spikes to $5.7B,"The cost of hospital care for unvaccinated Covid-19 patients has more than doubled, jumping from about $2 billion to $5.7 billion over the summer. And this figure may still be lower than the actual cost burden unvaccinated people represent to the healthcare system. ",https://medcitynews.com/2021/09/analysis-cost-of-care-for-unvaccinated-covid-patients-spikes-to-5-7b/
560,,,2021/9/15 13:18,MedCity,"With $100M in new funding, Tia CEO says the ‘tide has turned’ for investing in women’s health","With $100M in new funding, Tia CEO says the ‘tide has turned’ for investing in women’s health","Tia, a concierge clinic combining primary care and OBGYN services, recently raised $100 million in funding. Amid a surge of financing into women’s health startups, CEO Carolyn Witte said investors’ perspectives are changing. ",https://medcitynews.com/2021/09/with-100m-in-new-funding-tia-ceo-says-the-tide-has-turned-for-investing-in-womens-health/
561,,,2021/9/15 13:16,MedCity,"“No Surprises” enforcement left to states, big questions left unanswered in HHS rule","“No Surprises” enforcement left to states, big questions left unanswered in HHS rule","Enforcement of the No Surprises Act is still a work in progress, but CMS is ready to give out As for effort. Whether patients will agree with that grade still remains to be seen.",https://medcitynews.com/2021/09/no-surprises-enforcement-left-to-states-big-questions-left-unanswered-in-hhs-rule/
562,,,2021/9/15 12:22,MedCity,"Theravance’s lead drug fails in Phase 3, triggers a restructuring cutting 75% of staff","Theravance’s lead drug fails in Phase 3, triggers a restructuring cutting 75% of staff","The clinical trial failure of Theravance Biopharma’s most advanced internal program, a drug for a rare blood pressure disorder, is leading to a companywide restructuring. Going forward, the biotech will focus on developing drugs for respiratory disorders.",https://medcitynews.com/2021/09/theravances-lead-drug-fails-in-phase-3-triggers-a-restructuring-cutting-75-of-staff/
563,,,2021/9/14 19:07,MedCity,"CMS wants to repeal breakthrough device coverage rule, dashing med device industry hopes","CMS wants to repeal breakthrough device coverage rule, dashing med device industry hopes","After pushing back the start date twice, CMS now wants to scrap the Trump-era rule, which provides an expedited pathway to Medicare coverage for devices that receive the FDA breakthrough designation. ",https://medcitynews.com/2021/09/cms-wants-to-repeal-breakthrough-device-coverage-rule-dashing-med-device-industry-hopes/
564,,,2021/9/14 17:57,MedCity,Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s,Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s,"Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.",https://medcitynews.com/2021/09/neuro-startup-vanqua-bio-emerges-with-85m-and-a-first-focus-on-parkinsons/
565,,,2021/9/14 17:42,MedCity,Patient care is displaced for good. Can our tech keep up?,Patient care is displaced for good. Can our tech keep up?,"We’ve already broken down the traditional walls of healthcare, and if we invest in the right tools, we can continue shifting to a more streamlined, efficient, and patient-first care model.",https://medcitynews.com/2021/09/patient-care-is-displaced-for-good-can-our-tech-keep-up/
566,,,2021/9/14 15:52,MedCity,"IncludeHealth strikes partnership with Google, Ohio-based health system for virtual PT","IncludeHealth strikes partnership with Google, Ohio-based health system for virtual PT","Cincinnati-based IncludeHealth launched a virtual physical therapy program using pose-estimation models developed by Google. It plans to offer this software to healthcare providers, starting with its largest partner to date, ProMedica Health System.",https://medcitynews.com/2021/09/includehealth-strikes-partnership-with-google-ohio-based-health-system-for-virtual-pt/
567,,,2021/9/14 14:16,MedCity,Highmark partners with Ria Health to offer alcohol use disorder-specific telehealth services,Highmark partners with Ria Health to offer alcohol use disorder-specific telehealth services,"Through the partnership, Highmark members will gain access to a personalized digital program that aims to reduce harmful drinking. The program includes virtual visits, medication-assisted treatment and coaching support. ",https://medcitynews.com/2021/09/highmark-partners-with-ria-health-to-offer-alcohol-use-disorder-specific-telehealth-services/
568,,,2021/9/13 09:00,MedCity,We’re not out of the COVID woods yet. But what we’ve already learned is going to save millions of lives.,We’re not out of the COVID woods yet. But what we’ve already learned is going to save millions of lives.,"Covid-19 exposed serious weaknesses in the American healthcare system, and has taken an unfortunate personal and economic toll on the entire world. But in the end, I do believe that our healthcare system will emerge more accessible, affordable, and effective",https://medcitynews.com/2021/09/were-not-out-of-the-covid-woods-yet-but-what-weve-already-learned-is-going-to-save-millions-of-lives/
569,,,2021/9/13 17:56,MedCity,Evidence lacking for AI-based breast cancer screening  ,Evidence lacking for AI-based breast cancer screening  ,"A review of 12 studies about AI systems used to screen patients for breast cancer found that they lacked evidence to prove that they would work well in a clinical setting. Researchers highlighted concerns about study quality, including the fact that all of the studies were retrospective and many of them had a high risk of bias.",https://medcitynews.com/2021/09/evidence-lacking-for-ai-based-breast-cancer-screening/
570,,,2021/9/13 14:55,MedCity,"New HHS proposed rule requires payers to disclose broker rates, share air ambulance data","New HHS proposed rule requires payers to disclose broker rates, share air ambulance data","HHS wants insurers offering individual and short-term, limited-duration coverage to disclose to members the rates they pay to brokers who help people select health plans. The government also wants to collect air ambulance data to help curb the high and unexpected costs that arise from these services. ",https://medcitynews.com/2021/09/new-hhs-proposed-rule-requires-payers-to-disclose-broker-rates-share-air-ambulance-data/
571,,,2021/9/13 12:09,MedCity,"AbbVie makes another gene therapy move, paying $370M to partner with Regenxbio","AbbVie makes another gene therapy move, paying $370M to partner with Regenxbio","AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.",https://medcitynews.com/2021/09/abbvie-makes-another-gene-therapy-move-paying-370m-to-partner-with-regenxbio/
572,,,2021/9/12 09:20,MedCity,Teladoc adds feature to bring surgical support from afar  ,Teladoc adds feature to bring surgical support from afar  ,"The telehealth giant struck a partnership with Proximie, which uses augmented reality to let clinicians virtually “scrub in” to operating rooms. ",https://medcitynews.com/2021/09/teladoc-adds-feature-to-bring-surgical-support-from-afar/
573,,,2021/9/12 09:00,MedCity,DotCom Therapy snags $13M to expand pediatric teletherapy services,DotCom Therapy snags $13M to expand pediatric teletherapy services,"The company, which partners with health systems and schools to provide virtual therapy services for kids, will use the Series A funds to expand. The round was led by New Capital Partners, with participation from LRVHealth and OSF Ventures. ",https://medcitynews.com/2021/09/dotcom-therapy-snags-13m-to-expand-pediatric-teletherapy-services/
574,,,2021/9/12 09:00,MedCity,The future of healthcare is dependent on securing AI-powered medical devices,The future of healthcare is dependent on securing AI-powered medical devices,"As more connected medical devices are built on AI, cybersecurity risks will increase as well – and it’s more important than ever before for manufacturers to implement advanced security protections in the design phase to ensure the safety of healthcare organizations, providers and patients.",https://medcitynews.com/category/channel/medical-devices-channel/
575,,,2021/9/12 08:08,MedCity,FDA sets expectations for pediatric Covid-19 vaccines; decision could come mid-fall,FDA sets expectations for pediatric Covid-19 vaccines; decision could come mid-fall,"Acknowledging the demand for a Covid-19 vaccine for children, the FDA said it expects regulatory review could take weeks, not months, depending on the timing of a submission from vaccine developers. U.S. health officials told Reuters they expect the Pfizer/BioNTech vaccine will be the first one ready for an FDA submission.",https://medcitynews.com/2021/09/fda-sets-expectations-for-pediatric-covid-19-vaccines-decision-could-come-mid-fall/
576,,,2021/9/10 17:06,MedCity,Digital health companies debate: how much can we scale the human element in mental health?,Digital health companies debate: how much can we scale the human element in mental health?,"Four digital health leaders debated the role of self care apps, coaches and therapists in mental health during a panel at “What’s Next in Health Care?” While some touted the broader reach of self-guided treatments, others noted it was critical to have a therapist available for patients who need it.  ",https://medcitynews.com/2021/09/digital-health-companies-debate-how-important-is-the-human-element-in-mental-health/
577,,,2021/9/9 09:00,MedCity,Developing value-based virtual partnerships: What health plans should know,Developing value-based virtual partnerships: What health plans should know,"Given the growing interest specialty providers are showing in virtual visits, health plans should ensure that their telehealth offerings include consumer access to a wide breadth of specialists.",https://medcitynews.com/2021/09/developing-value-based-virtual-partnerships-what-health-plans-should-know/
578,,,2021/9/9 18:50,MedCity,Justice Department sues Texas to block restrictive abortion law  ,Justice Department sues Texas to block restrictive abortion law  ,The Biden administration has issued a legal challenge to invalidate the controversial Texas law that bans abortions after six weeks of pregnancy claiming that it will strip residents of their constitutional rights. ,https://medcitynews.com/2021/09/justice-department-sues-texas-to-block-restrictive-abortion-law/
579,,,2021/9/9 06:45,MedCity,"Neuroglee looks to Mayo partnership, digital therapeutics to tackle mild cognitive impairment","Neuroglee looks to Mayo partnership, digital therapeutics to tackle mild cognitive impairment",Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment. ,https://medcitynews.com/2021/09/neuroglee-looks-to-mayo-partnership-digital-therapeutics-to-tackle-mild-cognitive-impairment/
580,,,2021/9/9 17:48,MedCity,How tech can help solve the overpayments problem in healthcare RCM,How tech can help solve the overpayments problem in healthcare RCM,"When CMS overpays for services, providers and commercial payers are responsible for paying the agency back, and at times, they are on the hook for millions of dollars. But technology can help healthcare stakeholders catch the mistakes that lead to overpayments, thereby reducing unnecessary costs. ",https://medcitynews.com/2021/09/how-tech-can-help-solve-the-overpayments-problem-in-healthcare-rcm/
581,,,2021/9/9 15:48,MedCity,Cycle-tracking app Flo raises $50M ,Cycle-tracking app Flo raises $50M ,The funding round boosted Flo’s valuation to $800 million. It plans to put the funds toward new technical capabilities and new hires.,https://medcitynews.com/2021/09/cycle-tracking-app-flo-raises-50m/
582,,,2021/9/9 14:00,MedCity,Reducing low-value care starts by understanding its drivers,Reducing low-value care starts by understanding its drivers,"There is no single driver of low-value care — providers, systems, and patients all play a role. But with the right tools, stakeholders can work together to re-align incentives and transform our healthcare delivery system into one that prioritizes value, eliminates waste and leads to better overall patient outcomes.",https://medcitynews.com/2021/09/reducing-low-value-care-starts-by-understanding-its-drivers/
583,,,2021/9/9 10:48,MedCity,Mammoth Bio’s massive $195M financing makes the CRISPR company a unicorn,Mammoth Bio’s massive $195M financing makes the CRISPR company a unicorn,"Mammoth Biosciences is applying CRISPR technology to both diagnostics and therapeutics. With the new financing, CEO Trevor Martin said that the company is looking ahead toward clinical trials and perhaps partnerships with larger companies.",https://medcitynews.com/2021/09/mammoth-bios-massive-195m-financing-makes-the-crispr-company-a-unicorn/
584,,,2021/9/8 19:16,MedCity,Startup A-Alpha Bio sets out to solve a major protein problem facing big pharma,Startup A-Alpha Bio sets out to solve a major protein problem facing big pharma,"A-Alpha Bio’s technology analyzes millions of protein-protein interactions simultaneously, a capability that speeds up drug discovery research. Biotech industry partners are already using the technology and now with $20 million in Series A funding, the startup plans to build machine-learning capabilities to crunch the data produced by all of those protein interactions.",https://medcitynews.com/2021/09/startup-a-alpha-bio-sets-out-to-solve-a-major-protein-problem-facing-big-pharma/
585,,,2021/9/8 18:59,MedCity,"Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation","Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation","The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, like epilepsy, and movement disorders. ",https://medcitynews.com/2021/09/mayo-clinic-google-develop-ai-algorithm-to-enhance-electrical-brain-stimulation/
586,,,2021/9/8 05:39,MedCity,Invitae to buy health records startup Ciitizen for $325M ,Invitae to buy health records startup Ciitizen for $325M ,"Combining the two companies would allow patients to access genetic testing and their health records in one place, and make it easier for Invitae to collect and organize health records. ",https://medcitynews.com/2021/09/invitae-to-buy-health-records-startup-ciitizen-for-325m/
587,,,2021/9/7 09:00,MedCity,"The Post-pandemic future of clinical trials: How recruiting, participating and monitoring are changing","The Post-pandemic future of clinical trials: How recruiting, participating and monitoring are changing","Unleashed from restrictive norms for recruiting and interacting with patients, researchers are finding ways to bring more people into trials by simply making enrollment and participation accessible beyond restraints like geography and availability during “business hours.”",https://medcitynews.com/2021/09/the-post-pandemic-future-of-clinical-trials-how-recruiting-participating-and-monitoring-are-changing/
588,,,2021/9/7 07:30,MedCity,INVEST Digital Health preview: Where does the gush of investment dollars in digital health go?,INVEST Digital Health preview: Where does the gush of investment dollars in digital health go?,"The healthcare conference, held in a virtual format due to Covid-19, brings together innovative investors across the healthcare spectrum, prominent industry players and the most promising digital health startups.",https://medcitynews.com/2021/09/invest-digital-health-preview-where-does-the-gush-of-investment-dollars-in-digital-health-go/
589,,,2021/9/7 18:20,MedCity,Solv raises $45M to build network of same-day appointments ,Solv raises $45M to build network of same-day appointments ,"The startup, founded by several former Trulia executives, builds software to help healthcare providers with administrative tasks, including scheduling, registration and price transparency. ",https://medcitynews.com/2021/09/solv-raises-45m-to-build-network-of-same-day-appointments/
590,,,2021/9/7 17:47,MedCity,Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer,Roche bets $300M on Adaptimmune tech for off-the-shelf cell therapies for cancer,"Roche is partnering with Adaptimmune Therapeutics to develop allogeneic cell therapies based on Adaptimmune’s technology. In addition to these “off-the-shelf” products, the partners will also develop a personalized allogeneic cell therapy designed specifically for a patient’s cancer.",https://medcitynews.com/2021/09/roche-bets-300m-on-adaptimmune-tech-for-off-the-shelf-cell-therapies-for-cancer/
591,,,2021/9/7 16:43,MedCity,"As Delta surges, CMIOs’ focus on plans to provide vaccine booster shots, fight false information","As Delta surges, CMIOs’ focus on plans to provide vaccine booster shots, fight false information","Chief medical information officers are in a unique position to help their organizations fight the Covid-19 pandemic — from setting up IT systems to support Covid testing, care and vaccination to helping fight fast-spreading misinformation.",https://medcitynews.com/2021/09/as-delta-surges-cmios-focus-on-plans-to-provide-vaccine-booster-shots-fight-false-information/
592,,,2021/9/7 14:00,MedCity,America’s provider shortage: Can digital health resuscitate our broken care delivery system?,America’s provider shortage: Can digital health resuscitate our broken care delivery system?,"Ultimately, digital health solutions will be critical to empowering informed connected healthcare consumers to proactively self-manage their care and be part of the solution for combatting the growing providers supply shortage.",https://medcitynews.com/2021/09/americas-provider-shortage-can-digital-health-resuscitate-our-broken-care-delivery-system/
593,,,2021/9/7 13:11,MedCity,Cancer concerns lead FDA to place clinical hold on BioMarin gene therapy,Cancer concerns lead FDA to place clinical hold on BioMarin gene therapy,"A Phase 1/2 study of BioMarin Pharmaceutical’s gene therapy for phenylketonuria has been placed under a clinical hold after interim results from a preclinical study showed that some mice developed liver tumors. Patients did not receive the same high dose that was given to the mice, and no one in the clinical trial has developed cancer.",https://medcitynews.com/2021/09/cancer-concerns-lead-fda-to-place-clinical-hold-on-biomarin-gene-therapy/
594,,,2021/9/6 14:52,MedCity,Startup Modulus embraces AI to design better NK cell therapies for cancer,Startup Modulus embraces AI to design better NK cell therapies for cancer,"Modulus Therapeutics recently emerged from stealth with technology from various disciplines and seed funding that the startup is using to develop better cell therapies. Natural killer cells directed against breast cancer is Modulus’s initial focus, but the startup says its approach can apply to multiple types of immune cells and multiple types of cancer.",https://medcitynews.com/2021/09/startup-modulus-embraces-ai-to-design-better-nk-cell-therapies-for-cancer/
595,,,2021/9/3 09:00,MedCity,7 ways eConsent can help health researchers achieve better participant engagement,7 ways eConsent can help health researchers achieve better participant engagement,Tools like eConsent provides organizations with an efficient and streamlined way to garner consent from study participants. Removing this barrier can help improve engagement and deeper the pool of potential participants.,https://medcitynews.com/2021/09/7-ways-econsent-can-help-health-researchers-achieve-better-participant-engagement/
596,,,2021/9/3 17:57,MedCity,UnitedHealthcare to expand ACA exchange offerings to 7 new states,UnitedHealthcare to expand ACA exchange offerings to 7 new states,"UnitedHealthcare is planning to participate in the ACA insurance exchanges in Alabama, Florida, Georgia, Illinois, Louisiana, Michigan and Texas. This will bring its total ACA marketplace footprint to 18 states. ",https://medcitynews.com/2021/09/unitedhealthcare-to-expand-aca-exchange-offerings-to-7-new-states/
597,,,2021/9/3 15:26,MedCity,"Report: Apple Watch to add blood pressure, thermometer features","Report: Apple Watch to add blood pressure, thermometer features","According to a report by the Wall Street Journal, Apple is planning to add more health features to its watch, including a feature to track blood pressure and a wrist-based thermometer. ",https://medcitynews.com/2021/09/report-apple-watch-to-add-blood-pressure-thermometer-features/
598,,,2021/9/3 14:07,MedCity,"Feds slap UPMC, cardiothoracic surgery chair with billing fraud suit","Feds slap UPMC, cardiothoracic surgery chair with billing fraud suit","The lawsuit alleges that UPMC and the chair of its cardiothoracic surgery department knowing submitted false claims for concurrent surgeries that violated regulations. But, according to UPMC, there is no regulation that prohibits overlapping surgeries or billing for them. ",https://medcitynews.com/2021/09/feds-slap-upmc-cardiothoracic-surgery-chair-with-billing-fraud-suit/
599,,,2021/9/3 14:00,MedCity,10 issues every healthcare leader should be thinking about,10 issues every healthcare leader should be thinking about,"Healthcare organizations demonstrated tremendous vision, innovation and flexibility as they navigated unprecedented challenges brought on by the pandemic. However, the challenges and changes to the healthcare industry will continue long after Covid-19 disappears. ",https://medcitynews.com/2021/09/10-issues-every-healthcare-leader-should-be-thinking-about/
600,,,2021/9/3 13:38,MedCity,25 years of HIPAA: How the groundbreaking statute has kept pace with technology,25 years of HIPAA: How the groundbreaking statute has kept pace with technology,"For HIPAA to remain relevant for the next 25 years, policymakers and healthcare providers will need to remain agile and alert; this groundbreaking legislation will only be effective for as long as it keeps pace with the newest technologies and security challenges.",https://medcitynews.com/2021/09/25-years-of-hipaa-how-the-groundbreaking-statute-has-kept-pace-with-technology/
601,,,2021/9/3 12:46,MedCity,Novartis “one transplant for life” drug flunks test in kidney transplant patients,Novartis “one transplant for life” drug flunks test in kidney transplant patients,"A Novartis drug intended to prevent organ rejection has failed to beat out the standard of care therapy in a Phase 2 study in kidney transplant patients. Other clinical trial failures announced ahead of the Labor Day weekend include a Forte Biosciences atopic dermatitis drug, as well a cancer therapy from Takeda Pharmaceutical.",https://medcitynews.com/2021/09/novartis-one-transplant-for-life-drug-flunks-test-in-kidney-transplant-patients/
602,,,2021/9/2 09:00,MedCity,Collaborative care with a virtual lens: enabling patients and providers to overcome the mental health crisis,Collaborative care with a virtual lens: enabling patients and providers to overcome the mental health crisis,"By establishing a virtual relationship with consulting telepsychiatrists, psychiatric nurse practitioners, and licensed clinical social workers, PCPs and their behavioral care managers have access anytime to the appropriate support for patients’ mental health needs.",https://medcitynews.com/2021/09/collaborative-care-with-a-virtual-lens-enabling-patients-and-providers-to-overcome-the-mental-health-crisis/
603,,,2021/9/2 19:35,MedCity,"Buoyed by Covid-19 tests, Cue files for IPO ","Buoyed by Covid-19 tests, Cue files for IPO ","The San Diego-based company began marketing its first product, a portable Covid-19 test, after receiving an emergency use authorization last year. Now, it’s filing the initial paperwork to go public as it scales up manufacturing. ",https://medcitynews.com/2021/09/buoyed-by-covid-19-tests-cue-files-for-ipo/
604,,,2021/9/2 19:09,MedCity,"Ochsner Health, Bold partner to reduce falls among seniors","Ochsner Health, Bold partner to reduce falls among seniors","Through the partnership, Ochsner Health’s Medicare Advantage patients will gain access to Bold’s platform, which assesses current fitness levels to create a personalized exercise program for users. ",https://medcitynews.com/2021/09/ochsner-health-bold-partner-to-reduce-falls-among-seniors/
605,,,2021/9/2 06:16,MedCity,Impedimed device gets breakthrough designation for kidney failure,Impedimed device gets breakthrough designation for kidney failure,The company’s bioimpedance spectroscopy device would be used to measure how much fluid should be removed from a patient during dialysis. ,https://medcitynews.com/2021/09/impedimed-device-gets-breakthrough-designation-for-kidney-failure/
606,,,2021/9/1 09:01,MedCity,Patient equations will help us work out of the current pandemic and address the next,Patient equations will help us work out of the current pandemic and address the next,"Neutralizing the next threat to public health requires a new mindset, a new development path that uses computers and algorithms working in concert with patients, physicians, and scientists.",https://medcitynews.com/2021/09/patient-equations-will-help-us-work-out-of-the-current-pandemic-and-address-the-next/
607,,,2021/9/1 07:00,MedCity,Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing,Asher Bio’s encouraging early data against rival cancer drug sparks $108M financing,"Five months after raising $55 million to back a new technology and a promising lead cancer immunotherapy, Asher Biotherapeutics has reeled in $108 million more. CEO Craig Gibbs said investors were enticed by encouraging new data suggesting Asher Bio’s lead program is superior to a competitor’s.",https://medcitynews.com/2021/09/asher-bios-encouraging-early-data-against-rival-cancer-drug-sparks-108m-financing/
608,,,2021/9/1 18:53,MedCity,"Akron Children’s, CareSource to launch ACO","Akron Children’s, CareSource to launch ACO","Dubbed the Akron Children’s Health Collaborative, the pediatric ACO will focus on improving care for the approximately 100,000 children in Ohio covered by Medicaid whose benefits are managed by CareSource.",https://medcitynews.com/2021/09/akron-childrens-caresource-to-launch-aco/
609,,,2021/9/1 18:00,MedCity,"Big Health tests if insomnia app can help with anxiety, depression","Big Health tests if insomnia app can help with anxiety, depression",The company recently finished a study showing patients in the U.K. who used both Sleepio’s app and therapy saw improvements in anxiety and depression compared to people who used therapy alone. But the study also had several limitations. ,https://medcitynews.com/2021/09/big-health-tests-if-insomnia-app-can-help-with-anxiety-depression/
610,,,2021/9/1 17:23,MedCity,"FDA cracks down on JAK drug class, calls for new warnings of heart, cancer risks","FDA cracks down on JAK drug class, calls for new warnings of heart, cancer risks","The FDA’s review of a post-marketing study for Pfizer blockbuster anti-inflammatory drug Xeljanz found a higher risk of cardiovascular problems and cancer, and the agency is requiring additional warnings flagging those risks. The updated warnings extend to AbbVie and Eli Lilly medicines in the same drug class.",https://medcitynews.com/2021/09/fda-cracks-down-on-jak-drug-class-calls-for-new-warnings-of-heart-cancer-risks/
611,,,2021/9/1 14:56,MedCity,Report: Medicare trust fund still expected to run out by 2026,Report: Medicare trust fund still expected to run out by 2026,"The latest report from the Medicare Board of Trustees shows that the health insurance trust fund, also known as Medicare Part A, will run out in a mere five years, which is in line with reports released in 2018, 2019 and 2020, indicating that the Covid-19 pandemic has not hastened the fund’s depletion.",https://medcitynews.com/2021/09/report-medicare-trust-fund-still-expected-to-run-out-by-2026/
612,,,2021/9/1 14:00,MedCity,The do’s and don’ts of digital transformation for healthcare CIOs,The do’s and don’ts of digital transformation for healthcare CIOs,"Done right, digital transformation in healthcare drives productivity, satisfaction, quality of care, and reimbursement—but it can be easy to get wrong.",https://medcitynews.com/2021/09/the-dos-and-donts-of-digital-transformation-for-healthcare-cios/
